{"100-1.\n60\u6b72\u5973\u6027\u56e0\u89e3\u8840\u4fbf\u81f3\u6025\u8a3a\uff0c\u7d93\u8f38\u6db2\u6cbb\u7642\u7a69\u5b9a\u751f\u547d\u5fb5\u8c61\u5f8c\u5b89\u6392\u5927\u8178\u93e1\u53ca\u80c3\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u4e26\u7121\u767c\u73fe\u53ef\u7591\u7684\u51fa\u8840\u75c5\u7076\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6b64\u7a2e\u51fa\u8840\u578b\u614b\u7a31\u70baoccult GI bleeding\nB. \u5c0f\u8178\u662f\u6700\u53ef\u80fd\u7684\u75c5\u7076\u4f4d\u7f6e\nC. \u53ef\u4ee5\u662f\u8840\u7ba1\u6027\u75c5\u7076\nD. \u60a3\u8005\u82e5\u6301\u7e8c\u56b4\u91cd\u6027\u51fa\u8840\u53ef\u8003\u616eTc-RBC scan\u6216angiography\nE. \u82e5\u51fa\u8840\u505c\u6b62\u5247\u8003\u616e\u9032\u884cvideo capsule\u6216enteroscopy\u6aa2\u67e5\n": "(A)", "100-2.\n20\u6b72\u7537\u6027\u5065\u5eb7\u6aa2\u67e5\u6642\u767c\u73feBilirubin (total/direct)\u70ba2.0/0.2 mg/dL\uff0c\u5176\u8a3a\u65b7\u53ef\u80fd\u70ba\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.Gilbert's syndrome.\r2.Rotor's syndrome.\r3.glucose-6-phosphate dehydrogenase and pyruvate kinase deficiency.\r4..Dubin-Johnson syndrome.\r5.Crigler-Najjar syndrome.\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 2+3+5\nE. 1+3+5\n": "(E)", "100-3.\n\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u9ad4\u58c1\u8179\u819c(parietal peritoneum)\u767c\u708e\u5f15\u8d77\u7684\u75bc\u75db\u5b9a\u4f4d\u8f03\u81df\u58c1\u8179\u819c(visceral peritoneum)\u767c\u708e\u6e05\u695a\r2.\u9ad4\u58c1\u8179\u819c\u6613\u56e0\u81df\u5668\u62c9\u626f\u64f4\u5f35\u6536\u7e2e\u800c\u5f15\u8d77\u75d9\u6523\u75db\u4e14\u5408\u4f75\u76dc\u6c57\u3001\u5641\u5fc3\u53ca\u5fc3\u8df3\u8b8a\u5316\u7b49\u81ea\u5f8b\u795e\u7d93\u75c7\u72c0\r3.\u89f8\u75db\u4e43\u56e0\u81df\u58c1\u8179\u819c\u800c\u8d77\uff0c\u5177\u7279\u7570\u6027\u53ca\u8f03\u4f73\u4e4b\u5b9a\u4f4d\u4f5c\u7528\r4.\u8178\u7f3a\u8840\u56b4\u91cd\u60a3\u8005\u6709\u6642\u7406\u5b78\u6aa2\u67e5\u5fb5\u5019\u8f15\u5fae\r5.\u80f0\u81df\u708e\u8179\u75db\u5287\u70c8\u5fb5\u5019\u660e\u986f\u6613\u88ab\u8a8d\u70basurgical abdomen\nA. 1+2+3\nB. 1+4+5\nC. 1+3+4\nD. 2+3+4\nE. 2+4+5\n": "(B)", "100-4.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u4f7f\u7528\u975c\u8108\u71df\u990a(parenteral nutrition)\u60a3\u8005\u5e38\u898b\u7684\u4ee3\u8b1d\u6027\u554f\u984c?\nA. Hyponatremia\nB. Hypocalcemia\nC. Hyperphosphatemia\nD. Hypermagnesemia\nE. Azotemia\n": "(D)", "100-5.\n55\u6b72\u7537\u6027\u60a3\u8005\uff0c\u6709\u62bd\u7159\u3001\u559d\u9152\u3001\u559d\u5496\u5561\u7fd2\u6163\uff0c\u4e3b\u8a34\u80c3\u9178\u9006\u6d41\u53ca\u80f8\u53e3\u707c\u71b1\uff0c\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\u7d50\u679c\u5982\u9644\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u670d\u7528\u9223\u96e2\u5b50\u963b\u65b7\u5291(calcium channel blocker)\u53ef\u4f7f\u75c7\u72c0\u7de9\u89e3\nB. \u670d\u7528\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291(proton pump inhibitor)\u53ef\u4f7f\u5df2\u767c\u751f\u7684\u9ecf\u819c\u5316\u751f(metaplasia)\u5b8c\u5168\u6062\u5fa9\u6b63\u5e38\nC. \u6e1b\u91cd\u7121\u6cd5\u4f7f\u75c7\u72c0\u7de9\u89e3\nD. \u5207\u7247\u6aa2\u67e5\u82e5\u6709\u9ecf\u819c\u9ad8\u5ea6\u5316\u751f\u4e0d\u826f(high-grade dysplasia)\uff0c\u5247\u5167\u8996\u93e1\u8ffd\u8e64\u983b\u7387\u70ba\u6bcf\u5e741\u6b21\nE. \u6bcf\u5e74\u767c\u751f\u764c\u75c7\u7684\u6a5f\u6703\u70ba0.5%\n": "(E)", "100-6.\n\u80c3\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(Helicobacter pylori)\u662f\u9020\u6210\u6d88\u5316\u6027\u6f70\u760d\u548c\u80c3\u764c\u7684\u91cd\u8981\u539f\u56e0\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u4e0d\u9069\u7528\u65bc\u9664\u83cc\u6cbb\u7642\uff1f\nA. Lansoprazole\nB. Cephalexin\nC. Bismuth subsalicylate\nD. Clarithromycin\nE. Amoxicillin\n": "(B)", "100-7.\n\u6709\u95dc\u85e5\u7269\u9020\u6210\u80c3\u8178\u9053\u9ecf\u819c\u50b7\u5bb3\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Alendronate\u53ef\u4ee5\u9020\u6210\u98df\u9053\u6f70\u760d\nB. Cyclooxygenase-1(COX-1)\u70ba\u7dad\u6301\u80c3\u8178\u9ecf\u819c\u529f\u80fd\u6240\u5fc5\u9700\nC. Cyclooxygenase-2(COX-2)\u6291\u5236\u5291\u4e0d\u6703\u9020\u6210\u80c3\u6f70\u760d\nD. \u4f4e\u5291\u91cf\u7684aspirin(75~100mg)\u4e5f\u6703\u9020\u6210\u80c3\u6f70\u760d\nE. \u540c\u6642\u4f7f\u7528glucocorticoid\u6703\u589e\u52a0non-steroidal anti-inflammatory drug (NSAID)\u7522\u751f\u6f70\u760d\u7684\u6a5f\u6703\n": "(C)", "100-8.\n30\u6b72\u5973\u6027\u56e0\u6025\u6027\u8179\u75db\u5408\u4f75\u5641\u5fc3\u3001\u5614\u5410\u81f3\u6025\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u6709\u53f3\u4e0b\u8179\u89f8\u75db\uff0c\u9ad4\u6eab37.5\u2103\uff1b\u8840\u6db2\u6aa2\u67e5\u6709\u767d\u8840\u7403\u4e0a\u5347\u73fe\u8c61(13000cells/uL)\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u7d50\u679c\u5982\u9644\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. Fecolith\u662f\u5e38\u898b\u7684\u539f\u56e0\nB. \u5bc4\u751f\u87f2\u9020\u6210\u963b\u585e\u4e5f\u662f\u53ef\u80fd\u7684\u8d77\u56e0\nC. \u53f3\u4e0b\u8179\u75db\u7684\u5973\u6027\u60a3\u8005\u5fc5\u9808\u8207twisted ovarian cyst, endometriosis\u6216corpus luteum rupture\u505a\u9451\u5225\u8a3a\u65b7\nD. Acute mesenteric lymphadenitis\u4e5f\u662f\u53ef\u80fd\u7684\u9451\u5225\u8a3a\u65b7\nE. \u55ae\u7528\u6297\u751f\u7d20\u5373\u53ef\u670980%\u4ee5\u4e0a\u7684\u6cbb\u7642\u6210\u529f\u7387\uff0c\u4e14\u5fa9\u767c\u7387\u8f03\u624b\u8853\u70ba\u4f4e\n": "(E)", "100-9.\n75\u6b72\u5973\u6027\u56e0\u75b2\u5026\u3001\u8d70\u8def\u6c23\u5598\u3001\u982d\u6688\u3001\u4e0b\u8179\u75bc\u75db\u3001\u767c\u71d2\u548c\u9ad4\u91cd\u6e1b\u8f15\u81f3\u6025\u8a3a\uff0c\u8840\u6db2\u6aa2\u67e5Hb:5.0g/dL\uff0c\u5168\u5927\u8178\u93e1\u6aa2\u67e5\u5982\u9644\u5716\uff0c\u8840\u6db2\u57f9\u990a\u9577\u51fa\u7d30\u83cc\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u767c\u73fe\u4f55\u7a2e\u7d30\u83cc\uff1f\nA. Staphylococcus aureus\nB. Clostridium difficile\nC. Streptococcus bovis\nD. Salmonella typhi\nE. E. coli\n": "(C)", "100-10.\n\u52a0\u8b77\u75c5\u623f\u60a3\u8005\u51fa\u73fe\u8179\u7009\u3001\u8840\u4fbf\u548c\u767c\u71d2\u60c5\u5f62\uff0c\u8178\u93e1\u6aa2\u67e5\u7d50\u679c\u5982\u9644\u5716\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u4e0d\u9069\u5408\u7528\u65bc\u6b64\u60a3\u8005\u7684\u6cbb\u7642\uff1f\nA. Metronidazole\nB. Clindamycin\nC. Vancomycin\nD. Teicoplanin\nE. Fusidic acid\n": "(B)", "100-11.\n40\u6b72\u5bb6\u5ead\u4e3b\u5a66\u56e0\u4e0a\u8179\u75db\u3001\u5614\u5410\u81f3\u6025\u8a3a\uff0c\u809d\u751f\u5316\u6aa2\u67e5\u986f\u793aAST:1090 IU/L, ALT:1870 IU/L, Bil(T/D):3.2/1.8 mg/dL, WBC:12500 cells/uL\uff0c\u8179\u90e8\u8d85\u97f3\u6ce2\u548c\u96fb\u8166\u65b7\u5c64\u5982\u5716\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u624b\u8853\u662f\u4e3b\u8981\u7684\u6cbb\u7642\u65b9\u5f0f.\r2.\u53ef\u5148\u7528morphine\u6b62\u75db.\r3.\u5167\u79d1\u6cbb\u7642\u53ef\u4ee5\u4f7f75%\u75c5\u4eba\u7de9\u89e3\u4f46\u4e00\u5e74\u5fa9\u767c\u7387\u670925%\r4.ileus\u548cbiliary-enteric fistula\u662f\u53ef\u80fd\u7684\u4f75\u767c\u75c7\r5.\u624b\u8853\u5f8c\u7684\u4f75\u767c\u75c7\u5305\u62ecbile salt-induced constipation\nA. 1+2+3\nB. 1+3+4\nC. 1+4+5\nD. 2+3+4\nE. 3+4+5\n": "(B)", "100-12.\n52\u6b72\u5973\u59d3\u75c5\u4eba\u56e0\u98df\u9053\u975c\u8108\u66f2\u5f35\u51fa\u8840\u800c\u4f4f\u9662\u3002\u63a2\u8a0e\u5176\u75c5\u56e0\u6642\u767c\u73fe\u5176\u8840\u4e2dBil(T)=1.0 mg/dL (< 1.2)\uff0cAST=100 IU/L (< 31)\uff0cALT=95 IU/L (< 31)\uff0cALP=1200 IU/L (< 220)\uff0cgamma-GT:850 IU/L (< 50)\uff1b\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u4e26\u7121\u809d\u5167\u81bd\u7ba1\u64f4\u5927\u73fe\u8c61\uff0c\u4e5f\u7121\u809d\u5167\u816b\u7624\u3002\u95dc\u65bc\u9019\u4f4d\u75c5\u4eba\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7d0430%\u4e4b\u6b64\u985e\u75c5\u4eba\u6703\u51fa\u73fepruritus\u4e4b\u75c7\u72c0\nB. \u6b64\u7a2e\u75c5\u4eba\u53ef\u80fd\u5408\u4f75sicca syndrome\u53caautoimmune thyroid dysfunction\u7b49\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\nC. \u62bd\u8840\u6aa2\u9a57microsomal antibody\u4f86\u8a3a\u65b7\u6b64\u75c5\u4e4bsensitivity\u53caspecificity \u7686> 95%\nD. UDCA (ursodeoxycholic acid) 12~15 mg/kg (body weight)\u53ef\u5ef6\u7de9\u75c5\u60c5\u4e4b\u60e1\u5316\nE. \u82e5\u4e00\u518d\u51fa\u73fe\u56b4\u91cd\u4e4b\u4f75\u767c\u75c7\uff0c\u61c9\u5b89\u6392\u809d\u81df\u79fb\u690d\n": "(C)", "100-13.\nGastroesophageal reflux disease (GERD) \u8fd1\u5e74\u4f86\u5df2\u662f\u4e00\u7a2e\u5e38\u898b\u7684\u75be\u75c5\uff0c\u4e14\u88ab\u8a8d\u70ba\u53ef\u80fd\u6703\u5c0e\u81f4Barrett esophagus\uff0c\u751a\u81f3\u884d\u751f\u98df\u9053\u764c\u3002\u95dc\u65bcBarrett esophagus\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. Barrett esophagus\u5e38\u898b\u65bc\u6709large hiatal hernia, low lower esophageal pressure\u53caabnormal esophageal motility\u4e4b\u75c5\u4eba\r2. Short-segment Barrett esophagus (< 3 cm) \u8f03long-segment\u8005\u6613\u5c0e\u81f4esophageal adenocarcinoma\r3. \u5927\u591a\u6578\u5c08\u5bb6\u8a8d\u70basymptomatic GERD\u60a3\u8005\u61c9\u63a5\u53d7\u5167\u8996\u93e1\u8ffd\u8e64\u6aa2\u67e5\u81f3\u5c115\u5e74\r4. Barrett esophagus\u75c5\u4eba\u958b\u59cb\u63a5\u53d7\u5167\u8996\u93e1\u7be9\u6aa2\u6642\uff0c\u524d\u5169\u6b21\uff08\u76f8\u9694\u4e00\u5e74\uff09\u7686\u8981\u884cmultiple biopsies\r5. \u4ee5proton pump inhibitors (PPIs) \u6cbb\u7642\u53ef\u4f7f\u7570\u5e38\u4e4b\u98df\u9053\u7c98\u819c\u56de\u5fa9\u6b63\u5e38\uff0c\u9032\u800c\u5ef6\u7de9Barrett esophagus\u4e4b\u60e1\u5316\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 1+3+4\nE. 2+4+5\n": "(D)", "100-14.\n\u4e00\u4f4d40\u6b72\u5973\u6027\u75c5\u4eba\u88ab\u8a3a\u65b7\u6709ulcerative colitis\u5df2\u67096\u5e74\uff0c\u76ee\u524d\u63a5\u53d7azathioprine\u53catopical mesalamine\u6cbb\u7642\uff0c\u75c5\u60c5\u5c1a\u7a69\u5b9a\uff0c\u6bcf\u5929\u6392\u4fbf1~2\u6b21\uff0c\u5927\u4fbf\u6210\u5f62\u3002\u904e\u53bb\u5169\u9031\uff0c\u5979\u56e0\u4e0a\u547c\u5438\u9053\u611f\u67d3\u4f75\u6709\u9ec3\u8272\u81bf\u75f0\u800c\u670d\u7528\u6297\u751f\u7d20\u3002\u4e09\u5929\u524d\uff0c\u5979\u958b\u59cb\u51fa\u73fe\u8179\u90e8\u7d5e\u75db\uff0c\u5927\u4fbf\u6b21\u6578\u589e\u81f3\u6bcf\u59298~10\u6b21\uff0c\u591a\u4e0d\u6210\u5f62\uff0c\u767c\u71d2\u81f338.1\u00b0C\uff0c\u8840\u4e2dWBC\u4e0a\u5347\u81f320,000/uL\uff0c\u6709postural hypotension\u53catachycardia\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8179\u90e8\u6709tenderness\uff0c\u4f46\u7121rebound tenderness\u53camuscle guarding\u3002\u6025\u8a3a\u8655\u91ab\u5e2b\u958b\u59cb\u7d66\u4e88IV fluid\uff0c\u4e26\u63a1\u96c6\u5927\u4fbf\u9001\u6aa2\u3002\u4e0b\u5217\u4f55\u8005\u61c9\u99ac\u4e0a\u63a5\u8457\u53bb\u505a\uff1f\nA. \u7d66\u4e88IV corticosteroid\nB. \u7d66\u4e88cyclosporine\nC. \u7d66\u4e88infliximab (\u4e00\u7a2eanti-TNF-alpha\u85e5\u7269)\nD. \u589e\u52a0azathioprine\u4e4b\u5291\u91cf\nE. \u7d66\u4e88\u53e3\u670dvancomycin\n": "(E)", "100-15.\n\u4e0b\u5217\u95dc\u65bcdiarrhea\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6aa2\u67e5\u5927\u4fbf\u4e2d\u7684fat\u4e43\u662f\u7be9\u6aa2malabsorption\u6700\u4f73\u65b9\u5f0f\nB. Malabsorption\u60a3\u8005\u4e00\u5b9a\u6703\u6709diarrhea\nC. Non-inflammatory chronic watery diarrhea\u4e2d\uff0csecretory diarrhea\u65bcfasting\u5f8c\u6703\u505c\u6b62\nD. Irritable bowel syndrome\u60a3\u8005\u4e4bdiarrhea\u65bcfasting\u5f8c\u6703\u6301\u7e8c\nE. \u5c0dsevere diarrhea\u60a3\u8005\uff0c\u61c9\u5118\u5feb\u7d66\u4e88opiates\u85e5\u7269\u6cbb\u7642\n": "(A)", "100-16.\n\u6162\u6027\uff23\u578b\u809d\u708e\u76ee\u524d\u5df2\u6709\u76f8\u7576\u6709\u6548\u4e4b\u6cbb\u7642\u85e5\u7269\uff0c\u53f0\u7063\u7684\u5065\u4fdd\u5c40\u5728\u7d66\u4ed8\u65b9\u9762\u4ea6\u5927\u5e45\u653e\u5bec\uff0c\u56e0\u6b64\u6709\u6108\u4f86\u6108\u591a\u7684\u75c5\u4eba\u63a5\u53d7\u6cbb\u7642\u3002\u4e0b\u5217\u6709\u95dc\u6162\u6027\uff23\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u76ee\u524d\u4e4b\u4e3b\u6d41\u6cbb\u7642\u65b9\u5f0f\u70bapegylated IFN-alpha2a or IFN-alpha2b\u4f75\u7528ribavirin\r2. \u82e5\u75c5\u4eba\u65bc\u958b\u59cb\u6cbb\u76424\u5468\u5f8c\uff0c\u8840\u4e2dHCV RNA\u5df2\u6e2c\u4e0d\u5230\uff0c\u4e14\u6cbb\u7642\u524d\u4e4bHCV RNA < 400000 IU/mL\uff0c\u7642\u7a0b\u53ea\u898124\u5468\r3. \u75c5\u4eba\u958b\u59cb\u6cbb\u7642\u5f8c12\u5468\uff0c\u8840\u4e2dHCV RNA\u4ecd\u6e2c\u5f97\u5230\uff0c\u4e14\u5176\u91cf\u6e1b\u5c11\u4e0d\u5230100\u500d\uff08\u5982\uff1a\u81ea1000000\u6e1b\u81f310000 IU/mL)\u5373\u61c9\u505c\u6b62\u6cbb\u7642\r4. Ribavirin\u4e4b\u526f\u4f5c\u7528\u5305\u62ec\u6eb6\u8840\r5. \u82e5\u75c5\u4eba\u5df2\u51fa\u73feliver decompensation\uff0c\u61c9\u8d95\u5feb\u65bd\u4ee5\u6cbb\u7642\nA. 1+2+3+4\nB. 1+2+3+5\nC. 2+4+5\nD. 3+4+5\nE. 1+4+5\n": "(A)", "100-17.\n\u6162\u6027\uff22\u578b\u809d\u708e\u4e4b\u6cbb\u7642\u5305\u62ecpegylated IFN-alpha\u53ca\u53e3\u670d\u6297\uff22\u578b\u809d\u708e\u75c5\u6bd2\u85e5\u7269\uff0c\u53f0\u7063\u7684\u5065\u4fdd\u5c40\u5728\u7d66\u4ed8\u65b9\u9762\u5df2\u5927\u5e45\u653e\u5bec\uff0c\u80fd\u63a5\u53d7\u6cbb\u7642\u4e4b\u75c5\u4eba\u5927\u589e\u3002\u4e0b\u5217\u6709\u95dc\u6162\u6027\uff22\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u82e5\u75c5\u4eba\u5df2\u51fa\u73feliver decompensation\uff0c\u61c9\u8d95\u5feb\u63a5\u53d7pegylated IFN-alpha\u4e4b\u6cbb\u7642\r2. HBeAg (+)\u75c5\u4eba\u4e4bALT\u6578\u503c\u6301\u7e8c\u4e0a\u5347\u57281\u500d\u223c2\u500d\u4e4b\u9593\uff0c\u4e14\u8840\u4e2dHBV DNA > 20,000 IU/mL\uff0c\u53ef\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\r3. HBeAg (-)\u75c5\u4eba\u4e4bALT\u6578\u503c\u57283\u500b\u6708\u5167\u81f3\u5c11\u6709\u5169\u6b21\u4e0a\u5347\u81f32\u500d\u4ee5\u4e0a\uff0c\u4e14\u8840\u4e2dHBV DNA > 2,000 IU/mL\uff0c\u53ef\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\r4. \u53e3\u670d\u6297\uff22\u578b\u809d\u708e\u75c5\u6bd2\u85e5\u7269\u4e2d\uff0ctelbivudine\u53ef\u80fd\u5c0e\u81f4myopathy\uff0cadefovir\u53ef\u80fd\u50b7\u814e\r5. HBeAg (+)\u75c5\u4eba\u82e5\u51fa\u73fe\u8840\u4e2dHBeAg seroconversion\u6642\uff0c\u5373\u53ef\u65bc3\u500b\u6708\u5167\u505c\u85e5\nA. 1+2\nB. 3+4\nC. 4+5\nD. 1+2+4\nE. 3+4+5\n": "(B)", "100-18.\n\u4e00\u4f4d35\u6b72\u7537\u6027\u75c5\u4eba\u5230\u91ab\u9662\u5c31\u91ab\uff0c\u4e3b\u8a34\u70ba\u6700\u8fd1\u5e38\u611f\u75b2\u5026\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feALT=200 (< 41) IU/L\uff0cAST=180 (< 37) IU/L\uff0c\u5176\u5b83\u809d\u529f\u80fd\u9805\u76ee\u7686\u5728\u6b63\u5e38\u7bc4\u570d\u5167\uff1bHBsAg (-)\uff0cAnti-HCV (-)\uff0cANA (-)\u3002\u4ed6\u7684\u9ad4\u91cd\u70ba110 \u516c\u65a4\uff0c\u8eab\u9ad8165\u516c\u5206\uff0c\u6c92\u6709\u9157\u9152\u7fd2\u6163\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u50c5\u767c\u73fe\u53f3\u4e0a\u8179\u6709\u8f15\u5fae\u58d3\u75db\u3002\u95dc\u65bc\u9019\u4f4d\u75c5\u4eba\u4e4b\u8a3a\u65b7\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u6b64\u7a2e\u75c5\u4eba\u53ef\u80fd\u6703\u884d\u8b8a\u6210\u809d\u786c\u5316\uff0c\u751a\u81f3\u7522\u751f\u809d\u7d30\u80de\u764c\r2. \u6b64\u7a2e\u75c5\u4eba\u8840\u4e2dAST\u503c\u901a\u5e38\u5927\u65bcALT\u503c\uff0c\u4e14AST\u6578\u503c\u5f88\u5c11\u5927\u65bc250 IU/L\r3. \u6b64\u985e\u809d\u75c5\u4e4b\u4e3b\u8981\u75c5\u7406\u751f\u7406\u7f3a\u9677\u70bainsulin resistance\r4. Lifestyle modification\u70ba\u6700\u4f73\u6cbb\u7642\u65b9\u5f0f\r5. Coronary artery disease\u662f\u6b64\u7a2e\u75c5\u4eba\u6700\u5e38\u898b\u7684\u55ae\u4e00\u6b7b\u56e0\nA. 1+2+3+4\nB. 2+3+4+5\nC. 1+3+4+5\nD. 2+4+5\nE. 2+3\n": "(C)", "100-19.\n\u95dc\u65bc\u98df\u9053\u764c\u4e4b\u5371\u96aa\u56e0\u5b50\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. Barrett esophagus\u70basquamous cell cancer\u4e4b\u5371\u96aa\u56e0\u5b50\r2. Bile reflux\u70baadenocarcinoma\u4e4b\u5371\u96aa\u56e0\u5b50\r3. Cigarette smoking\u70baadenocarcinoma\u4e4b\u5371\u96aa\u56e0\u5b50\r4.  Achalasia\u70basquamous cell carcinoma\u4e4b\u5371\u96aa\u56e0\u5b50\r5. Human papilloma virus (HPV)\u611f\u67d3\u70basquamous cell carcinoma\u4e4b\u5371\u96aa\u56e0\u5b50\nA. 1+2+3\nB. 2+3+4\nC. 1+3+4\nD. 2+4+5\nE. 1+2+5\n": "(D)", "100-20.\n\u95dc\u65bc\u80f0\u81df\u764c\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. Genetic predisposition\u8207\u80f0\u81df\u764c\u4e4b\u767c\u751f\u5bc6\u5207\u76f8\u95dc\r2. 50\u6b72\u4ee5\u5f8c\u624d\u767c\u751f\u7cd6\u5c3f\u75c5\uff0c\u8981\u8a73\u67e5\u80f0\u81df\u764c\u4e4b\u53ef\u80fd\u6027\r3. \u8840\u4e2dCA19-9\u5c0d\u65bc\u80f0\u81df\u764c\u4e4b\u8a3a\u65b7\u5177\u6709\u76f8\u7576\u597d\u7684sensitivity\u53caspecificity\r4. \u82e5\u75c5\u4eba\u767c\u751f\u963b\u585e\u6027\u9ec3\u75b8\uff0c\u81e8\u5e8a\u5224\u65b7\u53ef\u80fd\u662f\u80f0\u81df\u982d\u90e8\u764c\u75c7\uff0c\u4f46multidetector CT with dynamic contrast\u770b\u4e0d\u5230\u816b\u7624\uff0c\u6b64\u6642\u61c9\u8003\u616e\u8840\u7ba1\u651d\u5f71\r5. \u5167\u8996\u93e1\u8d85\u97f3\u6ce2\uff08endoscopic ultrasound\uff09\u5c0d\u76f4\u5f912\u516c\u5206\u4ee5\u4e0b\u80f0\u81df\u764c\u4e4b\u5075\u6e2c\u7387\u53ef\u80fd\u6bd4CT\u70ba\u4f73\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 2+4+5\nE. 1+2+5\n": "(E)", "100-21.\n\u4e00\u4f4d42\u6b72\u75c5\u4eba\u56e0\u4e0a\u8179\u75db\u6c42\u91ab\uff0c\u61f7\u7591\u6709\u80c3\u6f70\u760d\uff0c\u91ab\u5e2b\u70ba\u5176\u5b89\u6392\u5167\u8996\u93e1\u6aa2\u67e5\u3002\u9019\u4f4d\u75c5\u4eba\u5e73\u6642\u5c0d\u91ab\u5b78\u77e5\u8b58\u6709\u6240\u6d89\u7375\uff0c\u77e5\u9053\u80c3\u6f70\u760d\u8207H. pylori \u6709\u5bc6\u5207\u95dc\u4fc2\uff0c\u4e14\u8207\u80c3\u764c\u6709\u95dc\uff0c\u56e0\u6b64\u8acb\u91ab\u5e2b\u8a73\u52a0\u8aaa\u660eH. pylori\u6709\u95dc\u4e4b\u8a3a\u65b7\u53ca\u6cbb\u7642\u72c0\u6cc1\u3002\u82e5\u60a8\u662f\u5176\u4e3b\u6cbb\u91ab\u5e2b\uff0c\u4e0b\u5217\u8aaa\u6cd5\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u62bd\u8840\u6aa2\u9a57H. pylori\u4e4b\u6297\u9ad4\uff08antibody test\uff09\u53c8\u4fbf\u5b9c\u53c8\u6709good negative predictive value\uff0c\u56e0\u6b64\u5c07\u7528\u65bc\u6cbb\u7642\u5f8c\u5224\u65b7H. pylori\u662f\u5426\u5df2\u6839\u9664\r2. Urea breath test\u6709good positive and negative predictive value\uff0c\u65bc\u6cbb\u7642\u5f8c\u4e8c\u5468\u5373\u53ef\u7528\u4f86\u5224\u65b7H. pylori\u662f\u5426\u5df2\u6839\u9664\r3. \u63a5\u53d7H. pylori\u4e4b\u6839\u9664\u6cbb\u7642\u5f8c\uff0c\u6700\u597d\u518d\u505a\u4e00\u6b21\u5167\u8996\u93e1\uff0c\u53d6\u80c3\u7c98\u819c\u884cculture\u4ee5\u78ba\u5b9aH. pylori\u662f\u5426\u5df2\u6839\u9664\r4. Triple therapy (PPI + Clarithromycin + Amoxicillin) \u662f\u76ee\u524d\u6700\u5e38\u7528\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f46\u82e5\u75c5\u4eba\u5c0dPenicillin\u66fe\u6709\u904e\u654f\u73fe\u8c61\uff0c\u61c9\u4ee5Metronidazole\u53d6\u4ee3Amoxicillin\r5.  \u82e5Triple therapy\u6cbb\u7642\u5931\u6557\uff0c\u53ef\u6539\u7528Bismuth-based quadruple therapy 7-14\u5929 (PPI + Bismuth + Metronidazole + Tetracycline) \u6cbb\u7642\nA. 1+2+3\nB. 4+5\nC. 2+3+4\nD. 3+4+5\nE. 1+5\n": "(B)", "100-22.\n\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u6025\u6027\u767c\u4f5c\u4e4b\u5614\u5410\uff0c\u82e5\u4f34\u96a8\u6709\u56b4\u91cd\u4e4b\u8179\u75db\uff0c\u53ef\u80fd\u6709intestinal\u6216gastric obstruction\r2. \u6025\u6027\u767c\u4f5c\u4e4b\u5614\u5410\uff0c\u82e5\u7121\u5408\u4f75\u8179\u75db\uff0c\u53ef\u80fd\u662fdiabetic ketoacidosis\u6240\u9020\u6210\r3.\u6162\u6027\u6301\u7e8c\u6216\u53cd\u8986\u767c\u4f5c\u4e4b\u5614\u5410\uff0c\u82e5\u4f34\u96a8\u6709\u8179\u75db\uff0c\u53ef\u80fd\u662fhypothyroidism\u6240\u9020\u6210\r4. \u6162\u6027\u6301\u7e8c\u6216\u53cd\u8986\u767c\u4f5c\u4e4b\u5614\u5410,\u82e5\u6c92\u6709\u5408\u4f75\u8179\u75db,\u53ef\u80fd\u662f\u8166\u90e8\u9577\u7624\nA. 1+2+3\nB. 2+3+4\nC. 3+4+1\nD. 1+2+4\nE. 1+2+3+4\n": "(D)", "101-1.\n\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u53ef\u80fd\u662f\u4e0a\u8179\u75db(epigastralgia)\u4e4b\u75c5\u56e0\uff1f\nA. Reflux esophagitis\nB. Ruptured aortic aneurysm\nC. Myocardial infarction\nD. Mesenteric lymphadenitis\nE. Peptic ulcer disease\n": "(D)", "101-2.\n\u8179\u6c34\uff08ascites\uff09\u75c5\u56e0\u4e4b\u9451\u5225\u8a3a\u65b7\u6709\u8cf4SAAG (Serum-Ascites Albumin Gradient)\uff0c\u4e0b\u5217\u6709\u95dcSAAG\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\r(1)Nephrotic syndrome > 1.1 g/dL\r(2)Tuberculous peritonitis < 1.1 g/dL\r(3)Cirrhosis > 1.1 g/dL\r(4)Peritoneal carcinomatosis < 1.1 g/dL\r(5)Constrictive pericarditis < 1.1 g/dL\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (1)+(4)+(5)\n": "(B)", "101-3.\n\u4e0b\u5217\u6709\u95dcpancreatic neuroendocrine tumor\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r(1)Glucagonoma\u53ef\u80fd\u5c0e\u81f4\u7cd6\u5c3f\u75c5\r(2)VIPoma (VIP: vasoactive intestinal peptide)\u53ef\u80fd\u5c0e\u81f4peptic ulcers\r(3)Insulinoma\u5e38\u70ba\u60e1\u6027\u816b\u7624\r(4)EUS (endoscopic ultrasound)\u662f\u5075\u6e2c\u9019\u985e\u816b\u7624\u4e4b\u6700\u4f73\u5de5\u5177\r(5) Liver metastasis\u5c0d\u60a3\u8005\u4e4b\u9810\u5f8c\u5f71\u97ff\u751a\u5927\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (2)+(3)+(5)\nE. (1)+(4)+(5)\n": "(E)", "101-4.\n\u4e0b\u5217\u6709\u95dcjaundice\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\uff08\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848\uff09\r(1)Isolated elevation of serum bilirubin,\u3000\u4e14direct bilirubin\u4f5470%\u4ee5\u4e0a\uff0c\u53ef\u80fd\u70baCrigler-Najjar syndrome\r(2)Isolated elevation of serum bilirubin\uff0c\u4e14indirect bilirubin\u4f5470%\u4ee5\u4e0a\uff0c\u53ef\u80fd\u70bahemolysis\r(3)Serum bilirubin \u2191\u2191\uff0cAST\u53caALT \u2191\u2191 \uff0cALP\u7121\u660e\u986f\u4e0a\u5347\uff0c\u53ef\u80fd\u70bahepatic decompensation\r(4)Serum bilirubin \u2191\u2191\uff0cAST\u53caALT \u2191\uff0cALP \u2191\u2191\uff0c Gamma-GT \u2191\u2191 \uff0c\u53ef\u80fd\u70baobstructive jaundice\nA. (1)+(2)\nB. (1)+(2)+(3)\nC. (2)+(3)+(4)\nD. (1)+(3)+(4)\nE. (1)+(4)\n": "(C)", "101-5.\n\u4e0b\u5217\u6709\u95dcgastric polyp\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Adenomatous polyps\u5927\u5c0f\u4e0d\u4e00\uff0cdysplasia\u51fa\u73fe\u6a5f\u7387\u4ea6\u4e0d\u4e00\uff0c\u4f46\u6709\u764c\u5316\u98a8\u96aa\nB. Hyperplastic polyps\u82e5\u540c\u6642\u4f75\u6709H. pylori\u611f\u67d3\uff0c\u65bc\u6839\u9664H. pylori\u5f8c\uff0c\u6b64\u7b49polyps\u53ef\u80fd\u6703\u8b8a\u5c0f\nC. Fundic gland polyps\u591a\u57281~5 mm\u5927\u5c0f\uff0c\u5e38\u70basporadic\u767c\u751f\uff0c\u8207gastric cancer\u5f88\u5c11\u6709\u95dc\u806f\nD. Fundic gland polyps\u767c\u751f\u65bcfamilial adenomatous polyposes\u60a3\u8005\u6642\uff0c\u50c5\u67091% dysplasia\u6a5f\u7387\uff0c\u4e0d\u5fc5\u5b9a\u671f\u8ffd\u8e64\nE. Submucosal lesions\u61c9\u8003\u616e\u4ee5endoscopic ultrasound\u505a\u9451\u5225\u8a3a\u65b7\n": "(D)", "101-6.\n\u4e0b\u5217\u5404\u9805\u95dc\u65bc\u6162\u6027\u809d\u75c5\u4e4b\u75c5\u56e0\u8a3a\u65b7\u7d44\u5408\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Primary biliary cirrhosis---Antimicrosomal antibody\nB. Autoimmune hepatitis---Antinuclear antibody\nC. Fasting transferrin saturation > 60% & elevated serum ferritin---Hemochromatosis\nD. Decreased serum ceruloplasmin & increased urine copper excretion---Wilson disease\nE. Wilson disease---Kayser-Fleischer ring\n": "(A)", "101-7.\n\u6240\u8b02postcholecystectomy syndrome\u662f\u6307\u56e0disorders of extrahepatic bile duct\u800c\u9020\u6210\u53f3\u4e0a\u8179\u75c7\u72c0\u65bc\u8853\u5f8c\u4ecd\u6301\u7e8c\u5b58\u5728\u3002\u4e0b\u5217\u5404\u9805\u75c5\u6cc1\uff0c\u4f55\u8005\u8207postcholecystectomy syndrome\u7121\u95dc\uff1f\nA. Bile salt-induced diarrhea or gastritis\nB. Stenosis or dyskinesia of the sphincter of Oddi\nC. Cystic duct stump syndrome\nD. Retained biliary calculi\nE. Common bile duct dilatation\n": "(E)", "101-8.\n\u4e0b\u5217\u6709\u95dc\u85e5\u7269\u6027\u809d\u50b7\u5bb3\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u85e5\u7269\u5728\u809d\u7d30\u80de\u5167\u4e4b\u4ee3\u8b1d\uff0c\u5206\u70baphase I\u53caphase II reaction\uff0c\u5176\u4e2dphase I reaction\u4e4b\u4e2d\u9593\u7522\u7269\u53ef\u80fd\u6703\u50b7\u5bb3\u809d\u7d30\u80de\nB. Cytochrome p450\u8207phase II reaction\u76f8\u95dc\uff0cglucuronidation\u5247\u8207phase I reaction\u76f8\u95dc\nC. \u85e5\u7269\u50b7\u809d\u4e4b\u6a5f\u8f49\u4e3b\u8981\u5206direct toxicity\u53caidiosyncratic reaction\u5169\u7a2e\nD. \u85e5\u7269\u6027\u809d\u50b7\u5bb3\u4e4b\u8868\u73fe\u5305\u542bhepatotoxicity (hepatocyte necrosis)\u53cacholestasis\nE. \u7b2c\u4e00\u4ee3TZD (Thiozolidinedione)\u767c\u751f\u809d\u50b7\u5bb3\u4e4b\u6a5f\u7387\u8f03\u9ad8\uff0c\u7b2c\u4e8c\u4ee3TZD\u5247\u8f03\u5c11\u898b\n": "(B)", "101-9.\n\u4e0b\u5217\u95dc\u65bcdiverticular disease of the colon\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5927\u8178\u4e4bdiverticulosis\u662f\u4e00\u7a2e\u8001\u5316\u7684\u75be\u75c5\nB. \u8179\u75db\u3001\u767c\u71d2\u53ca\u767d\u8840\u7403\u7570\u5e38\u589e\u591a\u4e43\u662facute uncomplicated diverticulitis\u6700\u5e38\u898b\u4e4b\u8868\u73fe\nC. \u5927\u8178\u93e1\u6aa2(colonoscopy)\u5728\u6025\u6027\u671f\u57f7\u884c\u6700\u6709\u8a3a\u65b7\u6548\u76ca\nD. \u5728\u5973\u6027\u60a3\u8005\uff0c\u6b64\u75c5\u61c9\u8207ovarian cyst, endometriosis\u6216pelvic inflammatory disease\u884c\u9451\u5225\u8a3a\u65b7\nE. uncomplicated\u75c5\u60a3\u61c9\u4ee5\u6297\u751f\u7d20\u6cbb\u7642\u4e4b\n": "(C)", "101-10.\n\u4e0b\u5217\u6709\u95dc\u6025\u6027\u80f0\u81df\u708e\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6025\u6027\u80f0\u81df\u708e\u4e4b\u75c5\u7a0b\u53ef\u5206\u5169\u500bphases\uff0c\u7b2c\u4e00\u500bphase\u4fc2\u767c\u75c5\u5f8c1~2\u9031\u5167\uff0c\u5176\u56b4\u91cd\u5ea6 (severity)\u61c9\u4ee5morphologic findings\u70ba\u4e3b\u8981\u5224\u65b7\u4f9d\u64da\nB. CT Severity Index (CTSI)\u4e4b\u5224\u65b7\u53ca\u8a08\u5206\u5305\u542bunenhanced \u53caenhanced CT\u6240\u898b\nC. \u8840\u4e2damylase level\u7570\u5e38\u5347\u9ad8\u4e5f\u53ef\u898b\u65bcrenal insufficiency\u6216lung cancer\u60a3\u8005\nD. \u82e5\u6709\u4f75\u767chemoperitoneum\uff0c\u5728\u809d\u81cd\u5468\u570d\u53ef\u80fd\u898b\u5230faint blue discoloration\uff0c\u7a31\u70baCullen's sign\nE. \u672c\u5730\u6700\u5e38\u898b\u4e4b\u75c5\u56e0\u70bagallstone \u53caalcoholism\n": "(A)", "101-11.\n\u4e0b\u5217\u6709\u95dc\u75c5\u6bd2\u6027\u809d\u708e\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. E\u578b\u809d\u708e\u75c5\u6bd2\u4e4b\u6f5b\u4f0f\u671f\u7d04\u70ba14~60\u5929 (mean\uff0c5~6\u9031\uff09\nB. D\u578b\u809d\u708e\u4e4b\u50b3\u67d3\u9014\u5f91\u4e3b\u8981\u70bapaid sex\nC. \u6162\u6027\uff22\u578b\u809d\u708e\u60a3\u8005\u8840\u4e2d\u767c\u751f\u81ea\u767c\u6027\uff08spontaneous\uff09HBeAg seroconversion (HBeAg (+) \u8b8a (-)\uff0cAnti-HBe (-) \u8b8a (+)\uff09\uff0c\u662f\u4e00\u500b\u597d\u73fe\u8c61\nD. \u6162\u6027\uff23\u578b\u809d\u708e\u4ee5\u5e72\u64fe\u7d20 + Ribavirin\u6cbb\u7642\u81f3\u5c11\u516d\u500b\u6708\uff0c\u53ef\u80fd\u75ca\u7652\nE. \u76ee\u524d\u53f0\u7063\u4e09\u5341\u6b72\u4ee5\u4e0b\u7684\u5e74\u8f15\u4eba\u7686\u61c9\u63a5\u53d7A\u578b\u809d\u708e\u75ab\u82d7\u63a5\u7a2e\uff0c\u4e00\u500b\u5b8c\u6574\u7684\u7642\u7a0b\u5171\u61c9\u63a5\u53d7\u4e09\u5291\u75ab\u82d7\n": "(E)", "101-12.\n\u6709\u4f4d\u60a3\u8005\u8179\u7009\u8d85\u904e4\u9031\uff0c\u5176\u7279\u5fb5\u70ba\u6c34\u6a23\u6027\u7cde\u4fbf\u4e14\u91cf\u76f8\u7576\u5927\uff0c\u4e26\u6c92\u6709\u8179\u75db\u73fe\u8c61\uff0c\u5373\u4f7f\u7981\u98df\u4ecd\u7136\u8179\u7009\u4e0d\u6b62\uff0c\u7cde\u4fbf\u7684osmotic gap\u6b63\u5e38\uff0c\u5176\u8a3a\u65b7\u53ef\u80fd\u70ba\u4e0b\u5217\u5404\u7a2e\u75be\u75c5\uff0c\u9664\u4e86\uff1a\nA. \u9577\u671f\u98f2\u9152(chronic ethanol ingestion)\nB. \u5927\u8178\u7d68\u6bdb\u817a\u7624(villous adenoma)\nC. \u670d\u7528lactulose\nD. \u611b\u8fea\u751f\u75c5(Addison's disease)\nE. \u80c3\u6ccc\u7d20\u7624(gastrinoma)\n": "(C)", "101-13.\n\u9ad4\u91cd\u7684\u8abf\u63a7\u8207\u9032\u98df\u884c\u70ba\u6709\u95dc\uff0c\u6b63\u5e38\u72c0\u6cc1\u4e0b\u4f55\u8005\u662f\u6e90\u65bc\u80c3\u8178\u9053\u4e14\u53ef\u5f71\u97ff\u9032\u98df\u7684\u8377\u723e\u8499?\r(1)gastrin\r(2)ghrelin\r(3)glucagon\r(4)cholecystokinin\r(5)ciliary neurotrophic factor\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(B)", "101-14.\n50\u6b72\u7537\u6027\u56e0\u4e0a\u8179\u75db\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5(\u57161)\u4e26\u505a\u4e86\u75c5\u7406\u5207\u7247(\u57162)\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u9069\u5408\u505a\u70ba\u6cbb\u7642\u85e5\u7269?\nA. bismuth subcitrate\nB. omeprazole\nC. cephalexin\nD. amoxicillin\nE. clarithromycin\n": "(C)", "101-15.\n60\u6b72\u7537\u6027\u809d\u786c\u5316\u60a3\u8005\uff0c\u56e0\u5410\u8840\u89e3\u9ed1\u4fbf\u81f3\u6025\u8a3a\uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u7d50\u679c\u4e4b\u98df\u9053\u8868\u73fe\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u9069\u7528\u65bc\u6b64\u4f4d\u60a3\u8005\u7684\u8655\u7f6e?\nA. terlipressin\nB. antibiotic\nC. endoscopic variceal ligation\nD. doxazosin\nE. octreotide\n": "(D)", "101-16.\n20\u6b72\u7537\u6027\uff0c\u56e0\u541e\u56a5\u56f0\u96e3\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\uff0c\u5831\u544a\u7d50\u679c\u70ba\u6b63\u5e38\uff0c\u5176\u98df\u9053\u651d\u5f71\u7d50\u679c\u5982\u5716\uff0c\u4e0b\u5217\u6cbb\u7642\u65b9\u5f0f\u53ef\u7de9\u89e3\u5176\u75c7\u72c0\uff0c\u9664\u4e86\uff1a\nA. isosorbide dinitrate\nB. atenolol\nC. nifedipine\nD. endoscopic botulinum toxin injection\nE. endoscopic ballon dilatation\n": "(B)", "101-17.\n22\u6b72\u7537\u6027\uff0c\u56e0\u89e3\u8840\u4fbf\u63a5\u53d7\u5168\u5927\u8178\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u5982\u5716\uff0c\u75c5\u7406\u5207\u7247\u7d50\u679c\u70bagranulomatous inflammation\uff0c\u4e14acid-fast stain\u70ba\u9670\u6027\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u771f\uff1f\r(1)\u62bd\u7159\u53ef\u6e1b\u5c11\u6b64\u75c5\u7684\u767c\u751f\r(2)\u8178\u9053\u5167\u53ad\u6c27\u83cc\uff0c\u4f8b\u5982Bacteroides\uff0c\u53ef\u8a98\u767c\u75c5\u4eba\u7684\u8178\u9053\u767c\u708e\u53cd\u61c9\r(3)\u8d85\u904e50%\u4ee5\u4e0a\u7684\u60a3\u8005\u8840\u4e2dperinuclear antineutrophil cytoplasmic antibodies (PANCAs)\u5448\u73fe\u967d\u6027\u53cd\u61c9\r(4)\u6b64\u75c5\u53ef\u5408\u4f75\u9031\u908a\u95dc\u7bc0\u708e(peripheral arthritis)\u6216\u50f5\u76f4\u6027\u810a\u690e\u708e(ankylosing spondylitis)\r(5)\u53ef\u5408\u4f75\u81bd\u9053\u75be\u75c5\u7684\u767c\u751f\uff0c\u4f8b\u5982primary sclerosing cholangitis\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(E)", "101-18.\n\u500b\u6848\u5065\u5eb7\u6aa2\u67e5\u6642\uff0c\u767c\u73feAST:20 IU/L\uff0cALT:18 IU/L\uff0cALP:95 IU/L\uff0cr-GT:25 IU/L\uff0cbilirubin(total/direct):2.0/0.4 mg/dL\uff0c\u4e14\u8d85\u97f3\u6ce2\u6aa2\u67e5\u6b63\u5e38\uff0c\u500b\u6848\u7528phenobarbital\u5f8cbilirubin\u53ef\u6062\u5fa9\u6b63\u5e38\u3002\u6709\u95dc\u6b64\u500b\u6848\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u6b64\u75c5\u7684\u767c\u751f\u5973\u591a\u65bc\u7537\nB. \u8207\u907a\u50b3\u6709\u95dc\uff0c\u4e14\u70ba\u81ea\u9ad4\u986f\u6027\u907a\u50b3(autosomal dominant)\nC. \u5176bilirubin uridine diphosphate glucuronosyltransferase (UGT) \u9175\u7d20\u6d3b\u6027\u5448\u73fe\u6b63\u5e38\nD. \u5f88\u5c11\u767c\u751f\u6eb6\u8840(hemolysis)\u73fe\u8c61\nE. \u8207UGT1\u57fa\u56e0\u7a81\u8b8a\u6709\u95dc\n": "(E)", "101-19.\n38\u6b72\u7537\u6027\u70baHBsAg(+)\u548cHBeAg(-)\u5e36\u539f\u8005\uff0c\u4f4f\u9662\u524d\u4e00\u9031\u6709\u5026\u6020\u611f\u53ca\u8179\u8139\u73fe\u8c61\uff0c\u63a5\u8457\u51fa\u73fe\u6709\u6df1\u8272\u5c3f\u73fe\u8c61\uff0c\u4f4f\u9662\u6642\u6aa2\u67e5AST:1250 IU/L\u3001ALT:1460 IU/L\uff0cbilirubin (total/direct):11.2/7.1 mg/dL, HBV-DNA:1500000 copies/mL\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8a3a\u65b7\u53ef\u80fd\u70baB\u578b\u809d\u708e\u6025\u6027\u60e1\u5316\nB. \u60a3\u8005\u9ad4\u5167\u75c5\u6bd2\u53ef\u80fd\u5728pre-S region \u7684nucleotide 1896\u8655\u767c\u751fG-->A\u7a81\u8b8a\nC. \u9810\u5f8c\u8f03\u6c92\u6709\u767c\u751f\u7a81\u8b8a\u7684wild-type\u5dee\nD. \u6b64\u578b\u662f\u76ee\u524d\u6b50\u6d32\u6700\u5e38\u898b\u7684B\u578b\u809d\u708e\u767c\u4f5c\u578b\u5f0f\nE. \u7531\u65bc\u79fb\u6c11\u7684\u95dc\u4fc2\uff0c\u76ee\u524d\u7f8e\u570b\u6b64\u578b\u7684\u767c\u751f\u7387\u4e5f\u6709\u589e\u52a0\u7684\u8da8\u52e2\n": "(B)", "101-20.\n45\u6b72\u80a5\u80d6\u7537\u6027\uff0c\u904e\u53bb\u4e00\u5e74\u4f86\u809d\u529f\u80fd\u6301\u7e8c\u7570\u5e38\uff0c\u5176AST/ALT\u5747\u5728\u6b63\u5e38\u503c\u76842\u500d\u81f35\u500d\u6ce2\u52d5\uff0c\u6aa2\u67e5\u767c\u73feHBsAg(-), anti-HCV(+), HCV-RNA: 3500000 copies/mL\uff0c\u75c5\u6bd2\u57fa\u56e0\u578b\u70ba\u7b2c1\u578b,\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r(1)\u500b\u6848\u61c9\u63a5\u53d724\u9031\u7684PEG-IFN\u5408\u4f75ribavirin\u6cbb\u7642,\u6548\u679c\u6700\u597d\r(2)\u500b\u6848\u56e0\u5e74\u9f61\u95dc\u4fc2\uff0c\u6cbb\u7642\u53cd\u61c9\u8f03\u4f73\r(3)\u500b\u6848\u56e0\u75c5\u6bd2\u57fa\u56e0\u578b\u95dc\u4fc2\uff0c\u6cbb\u7642\u53cd\u61c9\u8f03\u5dee\r(4)\u6cbb\u764212\u9031\u6642\u6aa2\u6e2cHCV-RNA\u503c\u6709\u52a9\u65bc\u53cd\u61c9\u7684\u5224\u65b7\r(5)\u500b\u6848\u56e0\u80a5\u80d6\u95dc\u4fc2\uff0c\u6cbb\u7642\u53cd\u61c9\u8f03\u5dee\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "101-21.\n40\u6b72\u5973\u6027\uff0c\u56e0\u6025\u6027\u8179\u75db\u81f3\u6025\u8a3a\u8655\u6c42\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u53f3\u4e0a\u8179\u6709\u660e\u986f\u58d3\u75db\uff0c\u9ad4\u6eab38\u2103\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5AST:1070 IU/L, ALT:1810 IU/L, bilirubin (total/direct) 3.2/1.8 mg/dL\uff0cWBC:12400/\u03bcl\uff0cseg:84%\uff0c\u8d85\u97f3\u6ce2\u53ca\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u5982\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u8a3a\u65b7\u70ba\u6025\u6027\u809d\u708e\nB. \u5e38\u5408\u4f75\u809d\u5167\u81bd\u7ba1\u7d50\u77f3\nC. Morphine\u662f\u6b64\u60a3\u8005\u6b62\u75db\u4e4b\u9996\u9078\nD. \u5167\u79d1\u6cbb\u7642\u70ba\u9996\u9078,\u4e1490%\u4ee5\u4e0a\u60a3\u8005\u5747\u53ef\u5f97\u5230\u75c7\u72c0\u6539\u5584\nE. \u8fd1\u4f86\u4e4b\u8da8\u52e2\u70ba\u5118\u65e9\u624b\u8853\n": "(E)", "101-22.\n37\u6b72\u7537\u6027\u60a3\u8005\uff0c\u4e3b\u8a34\u6162\u6027\u8179\u75db\u4e00\u5e74\u4ee5\u4e0a\uff0c\u6709\u6b62\u75db\u85e5\u4f7f\u7528\u7fd2\u6163\uff0c\u4e14\u6700\u8fd1\u6709\u8179\u7009\u3001\u9ad4\u91cd\u6e1b\u8f15\u73fe\u8c61\uff0c\u8179\u90e8\u8d85\u97f3\u6ce2(\u57161)\u53ca\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u7d50\u679c(\u57162)\uff0c\u6b64\u60a3\u8005\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u7684\u4f75\u767c\u75c7(complication)\uff0c\u9664\u4e86\nA. \u9ec3\u75b8\nB. \u80c3\u8178\u51fa\u8840\nC. \u7dad\u751f\u7d20B1\u5438\u6536\u4e0d\u826f\nD. \u8461\u8404\u7cd6\u8010\u53d7\u7570\u5e38(impaired glucose tolerance)\nE. \u76ae\u4e0b\u8102\u80aa\u58de\u6b7b(subcutaneous fat necrosis)\n": "(C)", "102-1.\n\u4e00\u4f4d50\u6b72\u75c5\u4eba\u81f3\u9580\u8a3a\u5c31\u91ab\uff0c\u81ea\u8a34\u6700\u8fd1\u5065\u6aa2\u4e2d\uff0c\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u4e00\u9846\u809d\u5167\u816b\u7624\uff0c\u4e0d\u77e5\u8a72\u600e\u9ebc\u8fa6\uff0c\u56e0\u6b64\u4ed6\u4f86\u8acb\u6559\u4f60\u7684\u5c08\u696d\u770b\u6cd5\u3002\u4e0b\u5217\u6709\u95dc\u809d\u5167\u816b\u7624\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4e09\u76f8\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff08triphasic CT scan\uff09\u6709\u52a9\u65bc\u809d\u5167\u816b\u7624\u4e4b\u9451\u5225\u8a3a\u65b7\nB. \u809d\u7d30\u80de\u764c\uff08hepatocellular carcinoma\uff09\u5e38\u5408\u4f75\u809d\u786c\u5316\nC. \u809d\u8840\u7ba1\u7624\uff08hemangioma\uff09\u901a\u5e38\u4e0d\u5fc5\u52a0\u4ee5\u8655\u7f6e\nD. \u5c40\u90e8\u7d50\u7bc0\u6027\u589e\u751f\uff08focal nodular hyperplasia, FNH\uff09\u4e4b\u767c\u751f\u8207\u53e3\u670d\u907f\u5b55\u4e38\u6709\u95dc\nE. \u817a\u7624\uff08adenoma\uff09\u53ef\u80fd\u6703\u6709\u816b\u7624\u5167\u51fa\u8840\u4e4b\u98a8\u96aa\n": "(D)", "102-2.\n\u807d\u8aaa50\u6b72\u4ee5\u4e0a\u5c31\u662f\u764c\u75c7\u6613\u767c\u5e74\u9f61\uff0c\u4e00\u4f4d\u75c5\u4eba\u627e\u4f60\u5c31\u91ab\uff0c\u5e0c\u671b\u80fd\u63a5\u53d7\u4e00\u4e9b\u764c\u75c7\u7be9\u6aa2\u63aa\u65bd\u3002\u4e0b\u5217\u5404\u9805\u6709\u95dc\u764c\u75c7\u7be9\u6aa2\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u809d\u7d30\u80de\u764c\uff08hepatocellular carcinoma\uff09\u4e4b\u7be9\u6aa2\u61c9\u5305\u62ec\u8179\u90e8\u8d85\u97f3\u6ce2\u6383\u63cf\u53ca\u62bd\u8840\u6aa2\u9a57\u7532\u7a2e\u80ce\u5152\u86cb\u767d\uff08\u03b1 -fetoprotein\uff09\nB. CA19-9\u53caCEA (carcinoembryonic antigen) \u5169\u7a2e\u816b\u7624\u6a19\u8a18\u52a0\u4e0a\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u80fd\u65e9\u671f\u767c\u73fe\u80f0\u81df\u764c\nC. \u7f8e\u570b\u764c\u75c7\u5b78\u6703\uff08American Cancer Society\uff09\u5efa\u8b7050\u6b72\u4ee5\u4e0a\u7121\u7279\u6b8a\u9ad8\u98a8\u96aa\u56e0\u5b50\u4e4b\u4e00\u822c\u6c11\u773e\uff0c\u6bcf\u5e74\u6aa2\u67e5fecal hemoccult screening\u52a0\u4e0a5\u5e74\u4e00\u6b21sigmoidoscopic examination\nD. \u9577\u671f\u7279\u5225\u559c\u6b61\u9032\u98df\u542b\u6709\u9ad8\u6fc3\u5ea6nitrates\u4e4b\u98df\u7269\u7684\u4eba\uff0c\u61c9\u5b9a\u671f\u63a5\u53d7\u80c3\u90e8\u6aa2\u67e5\uff0c\u5305\u62ecdouble-contrast radiographic examination\u6216\u5167\u8996\u93e1\u6aa2\u67e5\nE. \u540c\u6027\u6200\u7537\u4eba\u6216\u611b\u6ecb\u75c5\u4eba\uff0c\u61c9\u5b9a\u671f\u63a5\u53d7\u809b\u9580\u6307\u8a3a\uff08digital rectal examination\uff09\n": "(B)", "102-3.\n\u4e00\u4f4d\u809d\u786c\u5316\u75c5\u4eba\u5e73\u6642\u8eab\u9ad4\u611f\u5230\u4e0d\u8212\u670d\u6642\uff0c\u5927\u591a\u5148\u627e\u5bb6\u5ead\u91ab\u5e2b\u8655\u7406\u3002\u5982\u679c\u4f60\u662f\u4ed6\u7684\u5bb6\u5ead\u91ab\u5e2b\uff0c\u4e0b\u5217\u5404\u9805\u91ab\u7642\u554f\u984c\u4e4b\u8655\u7f6e\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5176Child's score\u5df2\u81f3B\u7d1a\uff0cprothrombin time (INR)= 1.50\uff0c\u60f3\u8acb\u4f60\u958bVitamin K \u7d66\u4ed6\u6cbb\u7642\nB. \u4ed6\u525b\u56e0\u98df\u9053\u975c\u8108\u66f2\u5f35\u7834\u88c2\u51fa\u8840\u4f4f\u9662\uff0c\u63a5\u53d7variceal band ligation\u8655\u7406\u4e14\u75c5\u60c5\u7a69\u5b9a\u5f8c\u51fa\u9662\u3002\u91ab\u9662\u7684\u4e3b\u6cbb\u91ab\u5e2b\u53eb\u4ed6\u8981\u53e3\u670dpropranolol\uff0c\u6e1b\u5c11\u518d\u5ea6\u51fa\u8840\u4e4b\u6a5f\u7387\u3002\nC. \u62bd\u8840\u6aa2\u9a57\u767c\u73feplatelet count = 72 K/\u03bcL(\u6b63\u5e38 > 150 K) \uff0c\u8207\u809d\u9580\u8108\u9ad8\u58d3 (portal hypertension) \u6709\u95dc\u3002\nD. \u5176\u809d\u786c\u5316\u662f\u56e0\u6162\u6027B\u578b\u809d\u708e\u6240\u9020\u6210\uff0c\u76ee\u524d\u8840\u4e2dALT (alanine aminotransferase)= 89\uff0cAST (aspartate aminotransferase) = 100\uff0cHBV DNA = 100,000 IU/mL\uff0c\u60f3\u8acb\u4f60\u7528interferon \u03b1 \u7d66\u4e88\u6cbb\u7642\uff0c\u4f60\u8a8d\u70ba\u4e0d\u5408\u5b9c\u3002\nE. \u75c5\u4eba\u7f79\u60a3primary biliary cirrhosis\uff0c\u5df2\u6709\u5341\u5e74\u75c5\u53f2\uff0c\u4f60\u8981\u7279\u5225\u6ce8\u610f\u4ed6\u662f\u5426\u6709osteoporosis\u3002\n": "(A)", "102-4.\n\u95dc\u65bc\u809d\u786c\u5316\u4e4b\u4f75\u767c\u75c7\uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u98df\u9053\u975c\u8108\u66f2\u5f35\u7834\u88c2\u51fa\u8840\uff0c\u65bc\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a\u5f8c\u61c9\u5118\u5feb\u65bd\u884cband ligation\u3002\nB. \u82e5\u8179\u90e8\u8139\u5927\u4e14\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8179\u90e8\u6709shifting dullness\uff0c\u61c9\u9650\u5236\u5176\u6bcf\u65e5\u7d0d\u651d\u53d6\u91cf\u4f4e\u65bc2 g\u3002\nC. \u82e5\u6709\u8179\u75db\uff0c\u62bd\u53d6\u8179\u6c34\u6aa2\u9a57\u767c\u73feneutrophils > 250/\u03bcL\uff0c\u61c9\u7acb\u5373\u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u3002\nD. \u82e5\u75c5\u4eba\u884c\u70ba\u7570\u65bc\u5e73\u6642\uff0c\u62bd\u8840\u6aa2\u9a57\u767c\u73feNH3 =100 (\u6b63\u5e38 < 37)\uff0c\u61c9\u512a\u5148\u4ee5neomycin\u6216metronidazole\u7b49\u8178\u9053\u5438\u6536\u751a\u5c11\u4e4b\u6297\u751f\u7d20\u7d66\u4e88\u6cbb\u7642\u3002\nE. \u82e5\u75c5\u4eba\u525b\u5f9e\u809d\u6027\u8166\u75c5\u8b8a (hepatic encephalopathy) \u6062\u5fa9\uff0c\u61c9\u9650\u5236\u5176\u6bcf\u65e5\u86cb\u767d\u8cea\u651d\u53d6\u91cf\uff0c\u5c24\u5176\u662f\u52d5\u7269\u6027\u86cb\u767d\u8cea\u3002\n": "(D)", "102-5.\n\u4e00\u4f4d\u6162\u6027\uff22\u578b\u809d\u708e\u75c5\u4eba\uff0c\u61c9\u9577\u671f\u5b9a\u671f\u63a5\u53d7\u8ffd\u8e64\u6aa2\u67e5\u4ee5\u77ad\u89e3\u4e26\u638c\u63e1\u5176\u75c5\u60c5\u3002\u4e0b\u5217\u5404\u9805\u7d44\u5408\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1) ALT (alanine aminotransferase)\u53caAST (aspartate aminotransferanse) <->\u809d\u767c\u708e\u6307\u6578 (2) albumin <-> \u809d\u6b98\u5b58\u529f\u80fd (3) bilirubin <-> \u809d\u89e3\u6bd2\u529f\u80fd\r\n(4) hemoglobin <-> \u809d\u7e96\u7dad\u5316\u7a0b\u5ea6 (5) AFP (a-fetoprotein) <-> \u81bd\u7ba1\u7d30\u80de\u764c\u816b\u7624\u6a19\u8a18 (6) \u8d85\u97f3\u6ce2\u6aa2\u67e5 <-> \u809d\u7d30\u80de\u764c (7) \u8d85\u97f3\u6ce2\u6aa2\u67e5 <-> \u809d\u786c\u5316 (8) HBV DNA <-> \u809d\u7d30\u80de\u764c\u816b\u7624\u6a19\u8a18\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (1)+(2)+(6)+(7)\nD. (3)+(4)+(6)+(7)\nE. (2)+(4)+(5)+(8)\n": "(C)", "102-6.\n\u5c0d\u65bc\u6162\u6027\uff22\u578b\u809d\u708e\u75c5\u4eba\uff0c\u73fe\u5728\u6709\u5404\u7a2e\u7279\u7570\u6027\u6cbb\u7642\u85e5\u7269\u53ef\u4f9b\u4f7f\u7528\u3002\u9762\u5c0d\u4e0b\u5217\u5404\u7a2e\u81e8\u5e8a\u60c5\u5883\uff0c\u4f55\u8005\u4e0d\u5fc5\u6cbb\u7642\uff1f\nA. HBeAg (+), HBV DNA: 108IU/mL, ALT < 2X ULN (Upper Limits of Normal)\nB. HBeAg (+), HBV DNA: 105IU/mL, ALT > 5X ULN\nC. HBeAg (-), HBV DNA: 106IU/mL, ALT > 2X ULN \u5df2\u8d85\u904e6\u500b\u6708\nD. HBeAg (-), HBV DNA: 30000 IU/mL, ALT < 2X ULN, \u6709\u4ee3\u511f\u6027\u809d\u786c\u5316 (compensated liver cirrhosis)\nE. HBeAg (+), HBV DNA: 106IU/mL, ALT > 5X ULN, Cr (creatinine) = 2.5 mg/dL\n": "(A)", "102-7.\n\u5c0d\u65bc\u6162\u6027C\u578b\u809d\u75c5\u4eba\uff0c\u73fe\u5728\u5df2\u6709\u6210\u529f\u7387\u76f8\u7576\u9ad8\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u4e0b\u5217\u5404\u9805\u76f8\u95dc\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f (1) \u4e3b\u6d41\u7642\u6cd5\u70ba\u6ce8\u5c04\u9577\u6548\u578binterferon \u03b1 (pegylated IFN \u03b1)\u5408\u4f75\u53e3\u670d\u8db3\u91cf\u7684ribavirin (\u81f3\u5c11800 mg/\u5929) (2) anti-HCV (+)\u4e14ALT\u53caAST\u4e0a\u5347\u81f31.5X ULN (Upper Limits of Normal)\u6301\u7e8c\u90546\u500b\u6708\u4ee5\u4e0a\uff0c\u5373\u61c9\u8a72\u63a5\u53d7pegylated IFN \u03b1 + ribavirin\u6cbb\u7642 (3) \u75c5\u4ebaIL-28B SNP (Single Nucleotide Polymorphism) at rs12979860\u5c6cT/T\u8005 (\u6709 T/T\uff0cC/T\uff0cC/C\u4e09\u7a2egenotypes )\uff0c\u6cbb\u7642\u6210\u529f\u7387\u8f03\u9ad8 (4) HCV\u82e5\u70bagenotype 1\u62164\uff0c\u6cbb\u7652\u7387\u905480%\u4ee5\u4e0a (5) \u6cbb\u7642\u524d\u8840\u4e2dHCV RNA level\u4f4e\u65bc800,000\r\nIU/mL\u8005\uff0c\u6cbb\u7652\u7387\u8f03\u9ad8 (6) \u6cbb\u7642\u524d\u809d\u5167\u7e96\u7dad\u5316 (fibrosis)\u6108\u53b2\u5bb3\uff0c\u6cbb\u7652\u7387\u6108\u9ad8\u3002\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(5)+(6)\nC. (2)+(4)+(6)\nD. (2)+(4)+(5)\nE. (1)+(2)+(5)\n": "(E)", "102-8.\n\u6709\u95dc\uff22\u578b\u809d\u708e\u75c5\u6bd2 (HBV) \u6cbb\u7642\u85e5\u7269\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. Interferon \u03b1\u53ef\u80fd\u5c0e\u81f4bone marrow suppression, autoimmune thyroiditis\u53caemotional lability\nB. \u55ae\u7368\u4f7f\u7528lamivudine\uff11\u5e74\uff0cHBV\u5c0d\u5b83\u7522\u751f\u6297\u85e5\u6027\u4e4b\u6a5f\u7387\u53ef\u905430%\nC. \u53ef\u80fd\u7522\u751f\u814e\u6bd2\u6027\u4e4b\u53e3\u670d\u85e5\u7269\u70batelbivudine\nD. \u814e\u529f\u80fd\u7570\u5e38\u6642\uff0c\u61c9\u8abf\u6574\u53e3\u670d\u6297\uff22\u809d\u75c5\u6bd2\u85e5\u7269\u4e4b\u670d\u7528\u5291\u91cf\u3002\nE. Telbivudine\u53ef\u80fd\u5c0e\u81f4asymptomatic creatine kinase elevation\u53caperipheral neuropathy\u3002\n": "(C)", "102-9.\n\u67d0\u4f4d\u75c5\u4eba\u6700\u8fd1\u4e00\u5468\u5fc3\u7aa9\u8655 (epigastric region) \u5e38\u611f\u60b6\u75db\uff0c\u4eca\u5929\u56e0\u75bc\u75db\u7a81\u7136\u52a0\u5287\u800c\u88ab\u9001\u81f3\u6025\u8a3a\u5ba4\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u4e0a\u8179\u90e8\u808c\u8089\u7dca\u7e43 (rigid)\uff0c\u89f8\u8a3a\u6642\u611f\u5230\u76f8\u7576\u786c\uff1b\u7ad9\u7acb\u80f8\u90e8X\u5149\u7167\u76f8\u7d50\u679c\u5982\u5716\u793a\u3002\u4e0b\u5217\u5404\u9805\u81e8\u5e8a\u8a3a\u65b7\uff0c\u4f55\u8005\u6700\u53ef\u80fd\uff1f\nA. Reflux esophagitis\nB. Mallory-Weiss tear\nC. Acute cholecystitis\nD. Perforated peptic ulcer\nE. Myocardial infarction\n": "(D)", "102-10.\n\u4e0b\u5217\u95dc\u65bc\u6d88\u5316\u7cfb\u7d71\u75be\u75c5\u4e4b\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7947\u5c0d\u56fa\u614b\u98df\u7269\u541e\u56a5\u56f0\u96e3\uff0c\u4e14\u6642\u597d\u6642\u58de\uff0c\u6301\u7e8c\u4e00\u5e74\u4ee5\u4e0a\uff0c\u9ad4\u91cd\u672a\u660e\u986f\u6e1b\u8f15\uff0c\u5176\u8a3a\u65b7\u53ef\u80fd\u70baachalasia\nB. Indigestion\u4e4b\u6700\u5e38\u898b\u75c5\u56e0\u70bagastroesophageal reflux\u53cafunctional dyspepsia\nC. \u6703\u5f15\u767c\u5641\u5fc3\u5614\u5410\u4e4b\u85e5\u7269\u5305\u62ec\uff1a\u6297\u751f\u7d20\u3001\u5fc3\u5f8b\u4e0d\u6574\u85e5\u7269\u3001\u964d\u8840\u58d3\u85e5\u7269\u53ca\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\nD. \u5c0d\u65bc\u4e3b\u8a34\u8179\u8139\u7684\u75c5\u4eba\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u4e00\u5b9a\u8981\u78ba\u5b9a\u75c5\u4eba\u662f\u5426\u6709shifting dullness\nE. 90%\u4ee5\u4e0a\u6025\u6027\u8179\u7009\u662f\u50b3\u67d3\u6027\u75c5\u56e0 (infectious agents) \u6240\u81f4\n": "(A)", "102-11.\n\u6839\u9664\u80c3\u5167\u7684\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\uff0c\u53ef\u4ee5\u6e1b\u5c11\u4e0b\u5217\u90a3\u4e9b\u75be\u75c5\u4e4b\u767c\u751f\uff1f\uff08\u61c9\u9078\u51fa\u5168\u90e8\u6b63\u78ba\u7b54\u6848\uff09(1) Gastroesophageal reflux disease (GERD) (2) Esophageal cancer (3) Duodenal ulcer (4) Gastric ulcer (5) Zollinger-Ellison syndrome (6) Gastric mucosa-associated lymphoid tissue (MALT) lymphoma (7) Gastric adenocarcinoma\nA. (1)+(3)+(5)+(7)\nB. (2)+(4)+(6)\nC. (3)+(4)+(6)+(7)\nD. (4)+(5)+(6)\nE. (1)+(3)+(6)+(7)\n": "(C)", "102-12.\n\u6709\u95dc\u9152\u7cbe\u6027\u809d\u75c5(alcoholic liver disease)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f(1)\u7537\u6027\u8f03\u5973\u6027\u6613\u611f\u6027\u9ad8(increased susceptibility) (2)\u71df\u990a\u4e0d\u826f(malnutrition)\u6703\u52a0\u91cd\u75c5\u60c5 (3)\u91cd\u5ea6\u9152\u7cbe\u6027\u809d\u708e(severe alcoholic hepatitis)\u4e0d\u53ef\u4f7f\u7528prednisolone\u6cbb\u7642 (4)\u91cd\u5ea6\u9152\u7cbe\u6027\u809d\u708e\u7528\u6297TNF-\u03b1\u55ae\u682a\u6297\u9ad4\u6cbb\u7642\u6210\u6548\u826f\u597d (5)\u91cd\u5ea6\u9152\u7cbe\u6027\u809d\u708e\u53ef\u8003\u616e\u7528pentoxifylline\u6cbb\u7642\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(B)", "102-13.\n\u6709\u95dc\u611f\u67d3\u6027\u8179\u7009(infectious diarrhea)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1)Yersinia\u611f\u67d3\u53ef\u4fb5\u72af\u672b\u7aef\u8ff4\u8178\uff0c\u800c\u51fa\u73fe\u985e\u4f3c\u6025\u6027\u76f2\u8178\u708e\u73fe\u8c61 (2)Campylobacter\u611f\u67d3\u53ef\u51fa\u73fe\u5408\u4f75\u95dc\u7bc0\u708e\u3001\u5c3f\u9053\u708e\u548c\u7d50\u819c\u708e\u7684\u7684Reiter's syndrome (3)Shigella\u611f\u67d3\u53ef\u5f15\u8d77hemolytic-uremic syndrome (4)\u61f7\u7591\u7d30\u83cc\u611f\u67d3\u6700\u5e38\u4f7f\u7528\u7684empirical treatment\u70baamoxicillin (5)\u61f7\u7591giardiasis\u6700\u5e38\u4f7f\u7528\u7684\u6297\u751f\u7d20\u70bacephalexin\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(2)+(4)\nE. (2)+(3)+(5)\n": "(A)", "102-14.\n60\u6b72\u7537\u6027\u5de5\u4eba\u56e0\u541e\u56a5\u56f0\u96e3\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u5728\u98df\u9053\u4e2d\u6bb5\u767c\u73fe\u75c5\u7076(\u5982\u5716\u793a)\uff0c\u4e0b\u5217\u4f55\u8005\u8207\u6b64\u75c5\u7684\u767c\u751f\u7121\u95dc\uff1f\nA. \u62bd\u7159\nB. \u559d\u9152\nC. \u80c3\u98df\u9053\u9006\u6d41\nD. \u559d\u71b1\u8336\nE. \u98df\u9053\u5f1b\u7de9\u4e0d\u5f35(achalasia)\n": "(C)", "102-15.\n20\u6b72\u5973\u6027\u670d\u7528\u76ae\u819a\u79d1\u7528\u85e5\u5f8c\uff0c\u51fa\u73fe\u541e\u56a5\u75bc\u75db\u53ca\u56f0\u96e3\u73fe\u8c61\uff0c\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\u65bc\u98df\u9053\u767c\u73fe\u5982\u5716\u4e4b\u75c5\u7076\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5f88\u53ef\u80fd\u662f\u670d\u7528doxycycline\nB. \u505c\u6b62\u670d\u7528\u85e5\u7269\u53ef\u80fd\u6539\u5584\nC. \u4ee5\u5f8c\u767c\u751f\u98df\u9053\u764c\u7684\u6a5f\u6703\u589e\u52a0\nD. \u9664\u6297\u751f\u7d20\u5916\uff0cnonsteroidal anti-inflammatory  agents\uff0c\u5982aspirin\u548cindomethacin\u7b49\u4e5f\u53ef\u9020\u6210\u540c\u6a23\u98df\u9053\u50b7\u5bb3\nE. \u670d\u85e5\u6642\u559d\u5927\u91cf\u7684\u6c34\u4e26\u4e14\u63a1\u7ad9\u6216\u5750\u59ff\u53ef\u4ee5\u9810\u9632\u6b64\u75c5\u7684\u767c\u751f\n": "(C)", "102-16.\n70\u6b72\u5973\u6027\u6709\u4e2d\u98a8\u75c5\u53f2\uff0c\u56e0\u89e3\u9ed1\u4fbf\u81f3\u6025\u8a3a\uff0c\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\u6709\u5982\u5716\u4e4b\u75c5\u7076\uff0cbiopsy urease test\u70ba\u9670\u6027\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6700\u9069\u7576\u7684\u7dca\u6025\u8655\u7f6e\uff1f\nA. \u6ce8\u5c04\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291(proton pump inhibitor)\nB. \u6ce8\u5c04\u4e59\u578b\u7d44\u7e54\u80fa\u53d7\u9ad4\u7d50\u6297\u5291(H2 receptor antagonist)\nC. \u5167\u8996\u93e1\u6b62\u8840\u6cbb\u7642\nD. \u5167\u8996\u93e1\u6b62\u8840\u52a0\u4e0a\u6ce8\u5c04\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291\nE. \u624b\u8853\u6cbb\u7642\n": "(D)", "102-17.\n(\u627f\u4e0a\u984c)\u60a3\u8005\u6709\u670d\u7528aspirin\uff0c\u4f4f\u9662\u4e09\u5929\u5f8c\u9806\u5229\u6062\u5fa9\u9032\u98df\uff0c\u51fa\u9662\u5f8c\u8003\u616e\u5fc3\u8840\u7ba1\u53ca\u80c3\u8178\u98a8\u96aa\u7684\u6700\u4f73\u8655\u7f6e\u70ba\uff1f\nA. \u5c07aspirin\u6539\u70baclopidogrel\nB. \u53e3\u670d\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291\u4e26\u5408\u7528aspirin\nC. \u505c\u7528aspirin\uff0c\u4e26\u7d66\u4e88\u53e3\u670d\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291\nD. \u6c38\u4e45\u505c\u7528aspirin\u53ca\u985e\u4f3c\u7684\u6297\u8840\u5c0f\u677f\u85e5\u7269\nE. \u6839\u9664\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\n": "(B)", "102-18.\n45\u6b72\u9157\u9152\u7537\u6027\u56e0\u6162\u6027\u8179\u75db\u53ca\u89e3\u8102\u80aa\u4fbf(steatorrhea)\u63a5\u53d7\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5(\u5982\u5716\u793a)\uff0c\u4e0b\u5217\u4f55\u7a2e\u4f75\u767c\u75c7\u767c\u751f\u7387\u6700\u4f4e\uff1f\nA. \u8461\u8404\u7cd6\u8010\u53d7\u4e0d\u826f(impaired glucose tolerance)\nB. \u7cd6\u5c3f\u75c5\u916e\u9178\u8840\u75c7(diabetic ketoacidosis)\nC. \u80c3\u8178\u51fa\u8840\nD. \u507d\u56ca\u816b(pseudocyst)\nE. \u9ec3\u75b8\n": "(B)", "102-19.\n\u60a3\u8005\u56e0\u5c62\u6b21\u53f3\u4e0a\u8179\u75db\u5408\u4f75\u767c\u71d2\uff0c\u7d93\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u8a3c\u5be6\u6709\u81bd\u7d50\u77f3\uff0c\u8179\u8154\u93e1\u81bd\u56ca\u5207\u9664\u8853(laparoscopic cholecystectomy)\u5f8c\u767c\u73fe\u70ba\u8272\u7d20\u7d50\u77f3(pigment stone)\uff0c\u4e0b\u5217\u4f55\u8005\u8207\u6b64\u7d50\u77f3\u7684\u5f62\u6210\u7121\u95dc\uff1f(1)\u80a5\u80d6(2)\u5973\u6027\u8cc0\u723e\u8499(3)\u85e5\u7269\u4f7f\u7528\uff0c\u5982clofibrate(4)\u809d\u786c\u5316(5)\u60e1\u6027\u8ca7\u8840(pernicious anemia)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(5)\nE. (1)+(2)+(4)\n": "(A)", "102-20.\n\u6709\u95dc\u8178\u963b\u585e(intestinal obstruction)\u7684\u8eab\u9ad4\u8a3a\u5bdf\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u5c0f\u8178\u963b\u585e\u8f03\u5927\u8178\u963b\u585e\u8179\u8139\u60c5\u5f62\u56b4\u91cd\nB. \u963b\u585e\u65e9\u671f\u5e38\u898b38\u5ea6\u4ee5\u4e0a\u7684\u9ad8\u71d2\nC. Strangulating obstruction\u807d\u8a3a\u5e38\u51fa\u73feloud, high-pitched borborygmi\nD. Quiet abdomen\u5373\u53ef\u6392\u9664\u963b\u585e\u4e4b\u53ef\u80fd\u6027\nE. \u767c\u751fclosed-loop strangulating small-bowel obstruction\u6709\u6642\u53ef\u6478\u5230\u8179\u90e8\u816b\u584a\n": "(E)", "102-21.\n30\u6b72\u5973\u6027\u81ea\u5370\u5ea6\u65c5\u904a\u56de\u570b4\u9031\u5f8c\u51fa\u73fe\u8179\u75db\u3001\u8179\u7009\u3001\u9ad4\u91cd\u6e1b\u8f15\uff0c\u5927\u8178\u93e1\u6aa2\u67e5\u767c\u73fe\u6f70\u760d\uff0c\u5f9e\u6f70\u760d\u8655\u7684\u75c5\u7406\u5207\u7247\u7d50\u679c\u5982\u5716\u793a\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u9996\u9078\u6cbb\u7642\uff1f\nA. Ciprofloxacin\nB. Amoxicillin\nC. Metronidazole\nD. Ceftriaxone\nE. Erythromycin\n": "(C)", "102-22.\n22\u6b72\u7537\u6027\u56e0\u8840\u4fbf\u63a5\u53d7\u5927\u8178\u93e1\u6aa2\u67e5\uff0c\u767c\u73fe\u76f4\u8178\u53ca\u4e59\u72c0\u7d50\u8178\u6709\u5982\u5716\u4e4b\u75c5\u7076\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u53ef\u51fa\u73fetoxic megacolon\u4e4b\u4f75\u767c\u75c7\nB. perinuclear anti-neutrophil cytoplasimc antibodies (pANCAs)\u53ef\u4ee5\u5448\u73fe\u967d\u6027\u7d50\u679c\nC. \u76f2\u8178\u5207\u9664\u589e\u52a0\u6b64\u75c5\u7684\u767c\u751f\u7387\nD. \u76ae\u819a\u53ef\u51fa\u73feerythema nodosum\nE. \u76ae\u819a\u53ef\u51fa\u73fepyoderma gangrenosum\n": "(C)", "103-1.\n\u541e\u56a5\u56f0\u96e3(dysphagia)\u53ef\u4f9d\u98df\u7269\u5728\u4e0d\u540c\u90e8\u4f4d\u53d7\u963b\u60c5\u5f62\u5206\u6210\u53e3\u54bd\u578b(oropharyngeal)\u548c\u98df\u9053\u578b(esophageal)\u5169\u5927\u985e\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u9020\u6210\u53e3\u54bd\u578b\u541e\u56a5\u56f0\u96e3\u7684\u539f\u56e0\uff1f\nA. \u5df4\u91d1\u68ee\u75c5(Parkinson's disease)\nB. \u6241\u6843\u817a\u5468\u570d\u81bf\u760d(peritonsillar abscess)\nC. Schatzki's ring\nD. Plummer-Vinson syndrome\nE. Zenker's diverticulum\n": "(C)", "103-2.\n\u6709\u95dc\u5df4\u745e\u7279\u6c0f\u98df\u9053(Barrett's esophagus)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u662f\u98df\u9053\u817a\u764c(esophageal adenocarcinoma)\u7684\u5371\u96aa\u56e0\u5b50\nB. \u6bcf\u5e74\u67095%\u9032\u5c55\u6210\u764c\u75c7\nC. \u4f9d\u9577\u5ea6\u5206\u6210long-segment\u548cshort-segment\uff0c\u81e8\u5e8a\u4e0a\u5f8c\u8005\u8f03\u5e38\u898b\nD. \u53ef\u5c0e\u81f4\u98df\u9053\u6f70\u760d\u53ca\u72f9\u7a84\nE. \u75c5\u7406\u5207\u7247\u6709\u9ad8\u5ea6\u5316\u751f\u4e0d\u826f\u8005(high grade dysplasia)\u670920%\u9032\u5c55\u6210\u764c\u75c7\u6a5f\u6703\n": "(B)", "103-3.\n\u4e00\u4f4d\u4e0a\u8179\u60b6\u75db\u60a3\u8005\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\uff0c\u4e26\u65bc\u80c3\u7ac7\u90e8(antrum)\u5207\u7247\uff0c\u5176\u75c5\u7406\u5982\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u771f\uff1f (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)\u56e0\u70ba\u767c\u708e\u5728\u80c3\u7ac7\u90e8\uff0c\u6240\u4ee5\u53c8\u7a31A\u578b(type A)\u80c3\u708e(2)\u5bb9\u6613\u56e0\u6b64\u800c\u9020\u6210\u9006\u6d41\u6027\u98df\u9053\u708e(3)\u5f97\u5230\u5341\u4e8c\u6307\u8178\u6f70\u760d\u6a5f\u6703\u589e\u52a0(4)\u8207\u80c3\u6dcb\u5df4\u7624\u767c\u751f\u6709\u95dc(5)\u6703\u96a8\u6642\u9593\u589e\u9577\u800c\u9020\u6210\u80c3\u9ecf\u819c\u840e\u7e2e\uff0c\u4e14\u9020\u6210\u8a72\u80c3\u708e\u4e4b\u7d30\u83cc\u91cf\u6703\u56e0\u9ecf\u819c\u840e\u7e2e\u800c\u589e\u52a0\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(C)", "103-4.\n\u627f\u4e0a\u984c\uff0c\u4e0a\u8ff0\u60a3\u8005\u63a5\u53d7\u4e00\u500b\u7642\u7a0b\u7684\u6297\u751f\u7d20\u6cbb\u7642\uff0c\u6cbb\u7642\u5f8c\u505c\u85e54\u9031\uff0c\u6700\u5408\u9069\u7528\u65bc\u78ba\u8a8d\u6cbb\u7642\u6210\u6548\u7684\u6aa2\u67e5\u70ba\u4f55\uff1f\nA. serologic test\nB. urea breath test\nC. endoscopy\nD. histologic examination\nE. endoscopy plus histology\n": "(B)", "103-5.\n\u6709\u95dc\u81bd\u9178(bile acid)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)\u4e3b\u8981\u7531\u98f2\u98df\u800c\u4f86(2)\u809d\u81df\u5408\u6210\u81bd\u9178\u8207\u81bd\u56fa\u9187\u4ee3\u8b1d\u6709\u95dc(3)\u81bd\u9178\u53ef\u65bc\u7a7a\u8178(jejum)\u518d\u5438\u6536\uff0c\u7a31\u70baenterohepatic circulation(4)\u809d\u81df\u5408\u6210\u7684\u81bd\u9178\u6709primary\u53casecondary\u5169\u7a2e\uff0c\u524d\u8005\u4ee5lithocholic acid\u53cachenodeoxycholic acid\u70ba\u4e3b(5)\u81bd\u9178\u7684enterohepatic circulation\u7570\u5e38\u53ef\u5c0e\u81f4\u8179\u7009\uff0c\u751a\u81f3steatorrhea\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(D)", "103-6.\n\u4e00\u4f4d\u6162\u6027\u8179\u7009\u60a3\u8005\uff0c\u5448\u73fe\u6c34\u816b\uff0c\u4f4e\u86cb\u767d\u8840\u75c7(albumin: 2.1g/dL\u3001globulin: 1.8g/dL)\uff0c\u8840\u6db2\u7684AST/ALT/PT/PTT/BUN/Cr\u53ca\u5c3f\u6db2\u6aa2\u67e5\u7686\u6b63\u5e38\u3002\u63a5\u53d7\u5c0f\u8178\u5167\u8996\u93e1\u5408\u4f75\u5207\u7247\u6aa2\u67e5\uff0c\u5207\u7247\u7d44\u7e54\u67d3\u8272\u7d50\u679c\u5982\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4f4e\u86cb\u767d\u8840\u75c7\u8207\u8178\u9053\u904e\u5ea6\u6d41\u5931\u86cb\u767d\u6709\u95dc\nB. \u9664\u4e86\u4f4e\u86cb\u767d\u5916\uff0c\u6b64\u500b\u6848\u4e4b\u5468\u908a\u8840\u6db2\u6dcb\u5df4\u7403\u6578\u76ee\u4e5f\u53ef\u80fd\u6e1b\u5c11\nC. \u53ef\u7528\u03b11-antitrypsin clearance\u5354\u52a9\u78ba\u8a8d\u86cb\u767d\u6d41\u5931\nD. \u8102\u80aa\u6027\u8179\u7009\u5728\u6b64\u7a2e\u75c5\u4eba\u4e5f\u5e38\u767c\u751f\nE. \u6cbb\u7642\u4e0a\u9664\u4e86low fat diet\u5916\uff0c\u61c9\u88dc\u5145long-chain fatty acids\n": "(E)", "103-7.\n23\u6b72\u7537\u6027\u56e0\u5c62\u6b21\u4e0d\u660e\u539f\u56e0\u8179\u75db\u81f3\u6025\u8a3a\uff0c\u5176\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u7d50\u679c\u5982\u5716\uff0c\u5168\u5927\u8178\u93e1\u6aa2\u67e5\u767c\u73fe\u53f3\u5074\u7d50\u8178\u53ca\u672b\u7aef\u8ff4\u8178\u6709\u6f70\u760d\uff0c\u5207\u7247\u75c5\u7406\u70bagranulomatous inflammation\uff0c\u7cde\u4fbf\u6aa2\u67e5\u53ca\u5404\u9805\u57f9\u990a\u4e26\u7121\u7d30\u83cc\u548c\u7d50\u6838\u83cc\u611f\u67d3\u3002\u6709\u95dc\u6b64\u60a3\u8005\u4e4b\u6cbb\u7642\u4f55\u8005\u932f\u8aa4\uff1f\nA. 5-ASA\u4e2d\u7684sulfasalazine\u53ef\u65bc\u80c3\u3001\u8ff4\u8178\u3001\u7d50\u8178\u91cb\u653e\u53ca\u4f5c\u7528\uff0c\u6700\u9069\u5408\u4f5c\u7b2c\u4e00\u7dda\u6cbb\u7642\nB. \u985e\u56fa\u9187\u53ef\u4f7f60~70%\u60a3\u8005\u5f97\u5230\u7de9\u89e3\nC. \u8655\u65b9metronidazole\u6216ciprofloxacin\u5c0d\u6b64\u4f4d\u60a3\u8005\u80fd\u767c\u63ee\u6709\u76ca\u6548\u679c\nD. azathioprine\u53ef\u7528\u65bc\u7dad\u6301\u7de9\u89e3\u6642\u7684\u6cbb\u7642\nE. \u5c0d\u514d\u75ab\u6291\u5236\u85e5\u7269\u7121\u6548\u8005\u53ef\u8003\u616e\u7528anti-TNF antibody\u6cbb\u7642\n": "(A)", "103-8.\n\u6709\u95dc\u5927\u8178\u76f4\u8178\u764c(colorectal cancer)\u7be9\u6aa2(screening)\u7b56\u7565\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1)\u4e0d\u8ad6\u7537\u5973\uff0c50\u6b72\u4ee5\u4e0a\u5373\u5fc5\u9700\u7be9\u6aa2(2)\u67091\u500b\u5c0f\u65bc1\u516c\u5206\u7684\u7ba1\u72c0\u817a\u7624(tubular adenoma)\u8005\uff0c\u61c9\u57281\u5e74\u5f8c\u91cd\u505a\u5927\u8178\u93e1(3)1\u7d1a\u8840\u89aa\u6709\u5927\u8178\u764c\u75c5\u53f2\u8005\uff0c\u7be9\u6aa2\u5e74\u9f61\u70ba50\u6b72(4)\u76ee\u524d\u53f0\u7063\u662f\u4f7f\u7528\u7cde\u4fbf\u6f5b\u8840\u514d\u75ab\u53cd\u61c9\u6cd5\u505a\u7be9\u6aa2(5)\u6709\u907a\u50b3\u6027\u5927\u8178\u764c\u75c7\u5019\u7fa4(hereditary nonpolyposis colorectal cancer)\u5bb6\u65cf\u53f2\u8005\u53ef\u65bc30\u6b72\u5373\u958b\u59cb\u7be9\u6aa2\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(2)+(4)\nE. (1)+(4)+(5)\n": "(E)", "103-9.\n40\u6b72\u5973\u6027\u5065\u5eb7\u4e00\u5411\u826f\u597d\uff0c\u53c3\u52a0\u516c\u53f8\u5065\u5eb7\u6aa2\u67e5\uff0c\u8d85\u97f3\u6ce2\u767c\u73fe\u81bd\u56ca\u6709\u5982\u5716\u4e4b\u7570\u5e38\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u56e0\u70ba\u7121\u75c7\u72c0\uff0c\u53ef\u63a1\u8ffd\u8e64\u7b56\u7565\nB. \u5feb\u901f\u6e1b\u91cd\u662f\u9020\u6210\u6b64\u7570\u5e38\u53ef\u80fd\u539f\u56e0\u4e4b\u4e00\nC. \u81bd\u56ca\u8815\u52d5\u5feb\u901f(gallbladder hypermotility)\u4e5f\u6703\u9020\u6210\u6b64\u7570\u5e38\nD. \u6b64\u7570\u5e38\u8207\u907a\u50b3\u56e0\u5b50\u4e5f\u6709\u95dc\nE. \u6162\u6027\u81bd\u9053\u611f\u67d3\u4e5f\u662f\u53ef\u80fd\u75c5\u56e0\n": "(C)", "103-10.\n\u627f\u4e0a\u984c\uff0c\u4e0a\u8ff0\u60a3\u8005\u56e0\u6025\u6027\u8179\u75db\u3001\u767c\u71d2\u81f3\u6025\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u9ec3\u75b8\uff0c\u8179\u90e8\u8d85\u97f3\u6ce2\u5448\u73fe\u81bd\u7ba1\u64f4\u5f35\uff0c\u8840\u6db2\u57f9\u990a\u6709\u845b\u862d\u6c0f\u9670\u6027\u83cc\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u55ae\u7528\u6297\u751f\u7d20\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\nB. ERCP with endoscopic sphincteromy\u517c\u5177\u8a3a\u65b7\u53ca\u6cbb\u7642\u6548\u679c\nC. laparoscopic cholecystectomy\u70ba\u6700\u4f73\u6cbb\u7642\u65b9\u5f0f\nD. \u6709\u53ef\u80fd\u4f75\u767c\u6025\u6027\u80f0\u81df\u708e\nE. \u7121\u60e1\u6027\u816b\u7624\u72c0\u6cc1\u4e0b\uff0c\u81bd\u7d05\u7d20(bilirubin)\u5f88\u5c11\u8d85\u904e20mg/dL\n": "(C)", "103-11.\n\u60a3\u8005\u56e0\u4e0a\u8179\u75db\u3001\u9ad4\u91cd\u6e1b\u8f15\u3001\u9ec3\u75b8\u63a5\u53d7\u5982\u5716(A\u3001B)\u4e4b\u6aa2\u67e5\u3002\u4e0b\u5217\u4f55\u8005\u8207\u6b64\u75be\u75c5\u7684\u767c\u751f\u8f03\u7121\u95dc\u806f\uff1f\nA. \u80a5\u80d6\nB. \u62bd\u7159\nC. \u7cd6\u5c3f\u75c5\nD. \u5496\u5561\nE. \u6162\u6027\u80f0\u81df\u708e\n": "(D)", "103-12.\n\u4e00\u4f4d60\u6b72\u5973\u6027\u75c5\u60a3\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u4e3b\u8a34\u70ba\u7a81\u7136\u611f\u5230\u56b4\u91cd\u8179\u75db\uff0c\u75bc\u75db\u6307\u6578\u9054\u5230\u4e5d\u5206\uff08\u6eff\u5206\u5341\u5206\uff09\u3002\u75c5\u4eba\u6c92\u767c\u71d2\u3002\u91ab\u5e2b\u5728\u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u767c\u73fe\u5176\u8179\u90e8\u6478\u8d77\u4f86\u4e26\u4e0d\u786c\uff0c\u50c5\u6709\u8f15\u5ea6\u58d3\u75db\uff0c\u4f46\u4e26\u7121\u56fa\u5b9a\u90e8\u4f4d\uff0c\u5176\u8840\u58d3\u6b63\u5e38\u3002\u4ed6\u81ea\u8ff0\u904e\u53bb\u6709\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u73fe\u8c61\u3002\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u8207\u6b64\u75c5\u4eba\u5bc6\u5207\u76f8\u95dc\uff0c\u9664\u4e86\uff1a\nA. \u61c9\u6e2c\u767d\u8840\u7403\u6578\u76ee\u3001\u8840\u6db2\u9178\u9e7c\u5ea6\u3001\u53ca\u8840\u6e05 lactate \u6578\u503c\nB. \u61c9\u8d95\u5feb\u5b89\u6392\u50b3\u7d71\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u56e0\u5176\u8f03\u65b9\u4fbf\u4e14\u8a3a\u65b7\u6548\u76ca\u8f03\u9ad8\nC. CT angiography \u5c0d\u8a3a\u65b7\u6709\u6975\u5927\u52a9\u76ca\nD. \u50b3\u7d71 angiography \u662f\u9ec3\u91d1\u8a3a\u65b7\u4e4b\u4f9d\u64da\nE. \u7acb\u5373\u5b89\u6392 ECG\uff0c\u5fc5\u8981\u6642\u4e5f\u8981\u5b89\u6392 24 hr Holter monitor recording\n": "(B)", "103-13.\n\u4e00\u4f4d50\u6b72\u7537\u6027\u56e0\u76ae\u819a\u6cdb\u9ec3\u4f4f\u9662\u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aBilirubin (T) : 8.5 mg/dL (\u22661.0), Bilirubin (D) : 7.0 mg/dL (\u2266 0.2), ALT : 70 (\u2266 41), AST : 80 (\u2266 31), ALP : 380 (\u2266104), GGT : 500 (\u2266 52)\u3002\u4ed6\u6700\u8fd1\u6c92\u6709\u8179\u75db\u72c0\u6cc1\uff0c\u98df\u617e\u5c1a\u4f73\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u5169\u5074\u809d\u5167\u81bd\u7ba1\uff0c\u8fd1\u809d\u9580\u5340\u4e4b\u7e3d\u81bd\u7ba1\u53ca\u4e3b\u80f0\u7ba1\u7686\u8139\u5927\u3002\u6253\u986f\u5f71\u5291\u4e4b\u96fb\u8166\u65b7\u5c64\u651d\u5f71 (contrat-enhanced spiral CT) \u4ea6\u6709\u540c\u6a23\u767c\u73fe\uff0c\u4f46\u672a\u770b\u5230\u4efb\u4f55\u816b\u7624\u3002\u4e0b\u5217\u5404\u9805\u9032\u4e00\u6b65\u4e4b\u6aa2\u67e5\uff0c\u4f55\u8005\u6700\u6709\u6548\u76ca\uff1f\nA. \u8840\u6e05CA 199\u6aa2\u6e2c\nB. \u78c1\u632f\u9020\u5f71 (MRI)\nC. \u5167\u8996\u93e1\u8d85\u97f3\u6ce2 (EUS)\nD. \u6b63\u5b50\u6383\u7784\u96fb\u8166\u65b7\u5c64 (PET-CT)\nE. 99mTc HIDA scan\n": "(C)", "103-14.\n\u4f60\u7684\u75c5\u4eba\u61f7\u5b55\u5df226\u5468\uff0c\u56e0\u8fd1\u671f\u76ae\u819a\u767c\u7662\uff0c\u751a\u81f3\u7662\u5230\u5f71\u97ff\u7761\u7720\u800c\u4f86\u6c42\u91ab\u3002\u5979\u7947\u6709\u670d\u7528vitamin \u53cafolic acid\uff0c\u672a\u670d\u7528\u4efb\u4f55\u85e5\u7269\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u76ae\u819a\u6709\u6293\u75d5\uff0c\u6c92\u6709petechiae\u6216ecchymoses\u3002\u75c5\u4eba\u610f\u8b58\u6e05\u695a\uff0c\u751f\u547d\u5fb5\u8c61\u6b63\u5e38\uff0c\u6c92\u6709\u767c\u71d2\u3002\u6709mildly icteric sclera\u3002\u8179\u90e8\u6572\u8a3a\u7121shifting dullness\u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aHb=12.0 (\u226710.8); WBC=4800 (\u22674000), platelet=280K (\u2267130K), PT (INR)=1.1 (0.8-1.1), Bilirubin (T)=3.8 mg/dL (\u22661.0), Bilirubin (D)=3.2 mg/dL (\u22660.3), ALT=38 (\u2266 41), AST=29 (\u226631), ALP (Alkaline phosphatase)=330 (\u2266104), GGT=400 (\u226652),\rAlbumin=3.5 g/dL (\u22673.5)\u3002\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5b50\u5bae\u53ca\u80ce\u5152\u6b63\u5e38\u3002\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4e0b\u5217\u90a3\u4e00\u9805\uff1f\nA. HELLP (Hemolysis, Elevated Liver enzymes, and Low Platelets) syndrome\nB. Acute fatty liver of pregnancy\nC. Intrahepatic cholestasis of pregnancy\nD. Hyperemesis gravidarum\nE. Drug-induced liver injury\n": "(C)", "103-15.\n\u4e0b\u5217\u5404\u9805\u4f55\u8005\u53ef\u80fd\u662f\u809d\u786c\u5316\u7684\u4f75\u767c\u75c7\uff1f\uff08\u8acb\u9078\u51fa\u5168\u90e8\u53ef\u80fd\u7b54\u6848\uff09(1) Esophageal varices (2) Spontaneous bacterial peritonitis (3) Hepatic encephalopathy (4) Hepatic failure (5) Hepatorenal syndrome (6) Hepatopulmonary syndrome (7) Portopulmonary hypertension (8) Hepatoovary syndrome\nA. (1)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(4)+(5)\nC. (1)+(2)+(3)+(4)+(5)+(6)\nD. (1)+(2)+(3)+(4)+(5)+(6)+(7)\nE. \u6bcf\u9805\u7686\u53ef\u80fd\u3002\n": "(D)", "103-16.\n\u4e00\u4f4d55 \u6b72\u5973\u6027\u75c5\u4eba\u4f4f\u9662\u4e4b\u4e3b\u8a34\u70ba\u8179\u75db\u5169\u5929\uff0c\u5c0f\u4fbf\u8b8a\u5c11\u3002\u904e\u53bb\u75c5\u53f2\u4e0d\u6e05\u695a\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73femildly icteric sclera\u53cashifting dullness with tenderness of abdomen\u3002\u624b\u81c2\u67092\u8655ecchymoses\u3002\u9ad4\u6eab38\u2103 \uff08\u8033\u6eab\uff09\uff0cB.P.=100/60 mmHg, P.R.=90/min, regular. \u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aAlbumin=2.5 g/dL (\u2267 3.5), Bilirubin (T)=3.8 mg/dL (\u22661), ALT=70 (\u2266 41), AST=80 (\u226631), ALP=380 (\u2266104), GGT=600 (\u226652), Cr=3.0 mg/dL (\u22661.3), PT=17\" (\u226611\")\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u809d\u786c\u5316\u3001\u813e\u816b\u5927\u53ca\u8179\u6c34\u3002\u6709\u95dc\u672c\u75c5\u4eba\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(1)\u61c9\u5118\u5feb\u62bd\u8179\u6c34\u9001\u9a57\u767d\u8840\u7403\u7e3d\u6578\u53ca\u5206\u985e\r(2)\u61c9\u5118\u5feb\u6e2c\u91cfFeNa (fractional excretion of sodium) (3)\u670d\u7528UDCA (ursodeoxycholic acid)\u5c0d\u5176\u75c5\u60c5\u6709\u5e6b\u52a9 (4)\u61c9\u5118\u5feb\u4ee5\u4f4e\u5291\u91cfDopamin\u6cbb\u7642\u4e4b (5)\u6ce8\u5c04Albumin\u5c0d\u5176\u75c5\u60c5\u6709\u5e6b\u52a9 (6)Spironolactone (aldosterone inhibitor)\u53cafurosemide (loop diruetics)\u4e4b\u4f7f\u7528\u4e0d\u5fc5\u8003\u616e\uff08\u8acb\u9078\u51fa\u5168\u90e8\u6b63\u78ba\u7b54\u6848\uff09\nA. (1)+(2)+(3)+(4)+(5)+(6)\nB. (1)+(2)+(4)+(5)\nC. (1)+(3)+(5)+(6)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(5)\n": "(E)", "103-17.\n54\u6b72\u5973\u6027\u81f3\u9580\u8a3a\u505a\u5065\u5eb7\u8aee\u8a62\u3002\u5979\u6bcd\u89aa\u572872\u6b72\u7f79\u60a3\u5927\u8178\u764c\u3002\u5979\u76ee\u524d\u5df2\u505c\u7d93\uff0c\u7121\u4efb\u4f55\u4e0d\u9069\u3002\u8eab\u9ad4\u8a3a\u5bdf\u7121\u7570\u5e38\uff0c\u4e00\u822c\u6aa2\u9a57\uff08\u5305\u542bCEA\u6578\u503c\uff09\u4e4b\u7d50\u679c\u7686\u6b63\u5e38\uff0c\u5927\u8178\u93e1\u6aa2\u67e5\u7121polyp\u53cacancer\u3002\u5979\u5e0c\u671b\u80fd\u670d\u7528\u4e00\u4e9b\u85e5\u7269\u4f86\u9810\u9632\u5927\u8178\u764c\u4e4b\u767c\u751f\u3002\u8acb\u554f\u4e0b\u5217\u5404\u7a2e\u85e5\u7269\uff0c\u4f55\u8005\u5df2\u88ab\u8b49\u5be6\u6709\u6548\u4e14\u88ab\u61c9\u7528\u65bc\u6c11\u773e\uff1f\nA. Aspirin\nB. Celecoxib\nC. Estrogen-replacement therapy\nD. Vitmin D\nE. \u4ee5\u4e0a\u7686\u975e\n": "(E)", "103-18.\n\u5abd\u5abd\u5e36\u845719\u6b72\u5973\u5152\u81f3\u9580\u8a3a\u5c31\u91ab\uff0c\u5979\u81ea\u5df1\u53ca\u5169\u4f4d\u5e74\u7d00\u8f03\u5927\u7684\u5b69\u5b50\u7686\u70baB\u578b\u809d\u708e\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\u3002\u9019\u500b\u5973\u5152\u51fa\u751f\u6642\u63a5\u53d7\u904eB\u578b\u809d\u708e\u75ab\u82d7\u6ce8\u5c04\uff0c\u76ee\u524d\u6aa2\u9a57\u7d50\u679c\u70ba\uff1aHBsAg (+), Anti-HBs (-), Anti-HBc (+), HBeAg (+), Anti-HBe (-), ALT: 22 (\u226641), AST: 25 (\u226631), Bilirubin (T) = 2.5 mg/dL (\u22661.0), Bilirubin (D)=0.3 mg/dL (\u22660.2), Albumin=4.5 g/dL (\u22663.5), PT (INR)=1.05 (0.8-1.2)\u3002\u4e0b\u5217\u4f55\u8005\u662f\u76ee\u524d\u6700\u5408\u9069\u4e4b\u8655\u7f6e\uff1f\nA. \u518d\u8ffd\u52a0B\u809d\u75ab\u82d7\u6ce8\u5c04\nB. \u99ac\u4e0a\u505a\u809d\u5207\u7247 (liver biopsy)\u77ad\u89e3\u75c5\u60c5\nC. \u5118\u901f\u4ee5\u53e3\u670dB\u578b\u809d\u708e\u75c5\u6bd2\u6291\u5236\u85e5\u7269\uff0c\u5982\uff1aentecavir \u6216tenofovir\uff0c\u6cbb\u7642\nD. \u5118\u901f\u5efa\u8b70\u63a5\u53d7 alpha interferon\u6cbb\u7642\nE. \u5b9a\u671f\uff08\u4e8c\u223c\u4e09\u500b\u6708\u4e00\u6b21\uff09\u8ffd\u8e64\u8840\u6e05ALT\u53caAST\u5373\u53ef\n": "(E)", "103-19.\n\u4e00\u4f4d\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\u62bd\u8840\u6aa2\u9a57\u4e4b\u7d50\u679c\u70ba\uff1aALT=53 (\u226641), AST=48 (\u226631), HCV RNA=380,000 IU/mL\u3002Hb=15 (\u226713), WBC=5,000 (\u22674,000), Platelet=110,000 (\u2267130,000)\u3002\u75c5\u4eba\u904e\u53bb\u6c92\u6709\u7532\u72c0\u817a\u75be\u75c5\uff0c\u4e5f\u6c92\u6709depression\u3002\u809d\u5207\u7247\u767c\u73fe\u6162\u6027\u767c\u708e\u4f75\u6709fibrosis\uff0c\u7121\u660e\u986fcirrhosis\u3002\u4e0b\u5217\u4f55\u8005\u662f\u76ee\u524d\u6700\u5408\u5b9c\u4e4b\u8655\u7f6e\uff1f\nA. \u672a\u4f86\u6bcf\u5e74\u63a5\u53d7\u4e00\u6b21\u809d\u5207\u7247\u6aa2\u67e5\uff0c\u8ffd\u8e64\u5176fibrosis\u9032\u884c\u72c0\u6cc1\uff0c\u6c7a\u5b9a\u6cbb\u7642\u6642\u6a5f\u3002\nB. \u672a\u4f86\u6bcf6\u500b\u6708\u6aa2\u67e5\u4e00\u6b21\u8840\u4e2dHCV RNA viral load\uff0c\u6c7a\u5b9a\u6cbb\u7642\u6642\u6a5f\u3002\nC. \u672a\u4f86\u6bcf2\u500b\u6708\u6aa2\u67e5\u4e00\u6b21\u8840\u4e2dALT\u53caAST\uff0c\u6c7a\u5b9a\u6cbb\u7642\u6642\u6a5f\u3002\nD. \u672a\u4f86\u6bcf3\u500b\u6708\u6aa2\u67e5\u4e00\u6b21complete blood count\uff0c\u6c7a\u5b9a\u6cbb\u7642\u6642\u6a5f\u3002\nE. \u7a4d\u6975\u5efa\u8b70\u75c5\u4eba\u958b\u59cb\u63a5\u53d7interfron-based therapy\u3002\n": "(E)", "103-20.\n\u4e0b\u5217\u6709\u95dc\u5614\u5410\u4e4b\u75c5\u56e0\u63a8\u6e2c\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5614\u5410\u7269\u4e3b\u8981\u70ba\u672a\u6d88\u5316\u4e4b\u98df\u7269\uff0c\u53ef\u80fd\u6709achalasia\nB. \u5614\u5410\u7269\u542b\u6709\u81bd\u6c41\uff0c\u4e0d\u53ef\u80fd\u70bagastric obstruction\nC. \u5614\u5410\u7269\u5e36\u6709\u7cde\u5473\uff0c\u53ef\u80fd\u6709distal intestinal or colonic obstruction\nD. \u5614\u5410\u901a\u5e38\u767c\u751f\u65bc\u98ef\u5f8c1\u5c0f\u6642\u5167\uff0c\u53ef\u80fd\u70bapyloric stenosis\nE. \u5614\u5410\u5f8c\u8179\u75db\u6d88\u5931\uff0c\u8868\u793a\u53ef\u80fd\u70baacute pancreatitis\n": "(E)", "103-21.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u6025\u6027\u5fc3\u7aa9\u75db\u800c\u88ab\u9001\u81f3\u6025\u8a3a\u5ba4\u3002\u5fc3\u7aa9\u75db\u6703\u5ef6\u4f38\u81f3\u80cc\u90e8\u3002\u75c5\u4eba\u56e0\u96e3\u53d7\u800c\u986f\u5f97\u7126\u8e81\u4e0d\u5b89\uff0c\u547c\u5438\u6025\u4fc3\u3002\u8eab\u9ad4\u8a3a\u5bdf\u986f\u793a\uff1a\u9ad4\u6eab 39.1\u2103\uff0c\u8840\u58d3 150/90 mmHg\uff0c\u8108\u6476 104/\u5206\uff0c\u898f\u5f8b\uff0c\u547c\u5438\u901f\u7387 24/\u5206\u3002\u5de6\u4e0b\u80ba\u547c\u5438\u97f3\u8f03\u5f31\u3002\u5fc3\u7aa9\u8655\u6709\u8f15\u5fae\u58d3\u75db\u3002\u4ed6\u6700\u8fd1\u6c92\u6709\u4f7f\u7528\u65b0\u85e5\u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aHb=15.0 (\u226713), WBC=16,300 (> 4,000, < 10,000), Amylase=20,000, Lipase=8,000, BUN=68 (\u226624), Cr=2.4 (\u22661.0)\u3002\u6253\u986f\u5f71\u5291\u4e4bCT (contrast-enhanced CT)\u986f\u793a\u80f0\u81df\u5468\u906d\u6709\u6c34\u816b\uff0c\u7121\u7d44\u7e54\u58de\u6b7b\u3001\u4ea6\u7121\u8179\u6c34\u3002\u4e0b\u5217\u5404\u9805\uff0c\u4f55\u8005\u6700\u80fd\u53cd\u6620\u51fa\u672c\u75c5\u4eba\u75c5\u60c5\u4e4b\u56b4\u91cd\u5ea6\uff1f\nA. \u9ad4\u6eab (39.1\u2103)\nB. Amylase \u53ca Lipase serum level\nC. \u80f0\u81df\u5468\u906d\u6c34\u816b\nD. BUN\u6578\u503c\nE. \u5fc3\u7aa9\u75db\u4e14\u5ef6\u4f38\u81f3\u80cc\u9762\n": "(D)", "103-22.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u95dc\u7bc0\u708e\u800c\u9700\u4f7f\u7528NSAIDs\u85e5\u7269\u6cbb\u7642\uff0c\u75c5\u4eba\u5f88\u6015\u6703\u6709\u80c3\u8178\u526f\u4f5c\u7528\u3002\u4e0b\u5217\u5404\u9805\u6709\u95dc\u9810\u9632NSAID-induced gastrointestinal (GI) injury\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Standard-dose proton pump inhibitors (PPI) \u70ba\u9996\u9078\u85e5\u7269\nB. Misoprostol (synthetic prostaglandin E1 analogue) \u4ea6\u53ef\u8003\u616e\u4f7f\u7528\uff0c\u4f46\u5291\u91cf\u4e0d\u5b9c\u904e\u9ad8\u4ee5\u6e1b\u5c11\u8179\u7009\u4e4b\u526f\u4f5c\u7528\nC. High-dose H2 blockers \u6548\u679c\u8207PPI \u6216 Misoprostol \u76f8\u4f3c\uff0c\u6545\u53ef\u505a\u70ba\u66ff\u4ee3\u85e5\u7269\nD. \u82e5\u75c5\u4eba\u5c6clow GI risk \u4e14 low cardiovascular (CV) risk \u8005\uff0c\u4f7f\u7528\u4f4e\u5291\u91cf\u55ae\u4e00\u7a2e NSAID \u6642\u4e0d\u9700\u9810\u9632\u5176\u53ef\u80fd\u7522\u751f\u4e4b GI \u53ca CV toxicity\nE. Enteric-coated NSAIDs \u53ca Aspirin\u7121\u6cd5\u6709\u6548\u9810\u9632\u5176 GI injury\n": "(C)", "104-1.\n\u60a3\u8005\u4e3b\u8a34\u70ba\u541e\u56a5\u56f0\u96e3(dysphagia)\uff0c\u800c\u4e14\u4e00\u958b\u59cb\u767c\u751f\u5373\u5305\u62ec\u56fa\u9ad4(solid)\u548c\u6d41\u8cea(liquid)\u98df\u7269\u7686\u6709\u554f\u984c\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u53ef\u80fd\u662f\u6b64\u4f4d\u60a3\u8005\u541e\u56a5\u56f0\u96e3\u7684\u539f\u56e0\uff1f\nA. achalasia\nB. scleroderma\nC. gastroesophageal reflux disease with weak peristalsis\nD. Schatzki ring\nE. diffuse esophageal spasm\n": "(D)", "104-2.\n\u75c5\u60a3\u4e3b\u8a34\u8179\u70093\u500b\u6708\uff0c\u7cde\u4fbf\u6aa2\u67e5\u986f\u793a\u7121\u767d\u8840\u7403\u3001\u8102\u80aa\u5247\u70ba\u967d\u6027\u3002\u4e0b\u5217\u4f55\u8005\u6700\u6709\u53ef\u80fd\u662f\u9020\u6210\u6b64\u4f4d\u60a3\u8005\u8179\u7009\u7684\u75c5\u56e0\uff1f\nA. \u5927\u8178\u6fc0\u71e5\u75c7(irritable bowel syndrome)\nB. \u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032(hyperthyroidism)\nC. \u5927\u8178\u7d68\u6bdb\u6027\u817a\u7624(villous adenoma)\nD. \u611b\u8fea\u751f\u6c0f\u75c5(Addison's disease)\nE. \u7d30\u83cc\u904e\u5ea6\u589e\u751f(bacterial overgrowth)\n": "(E)", "104-3.\n\u60a3\u8005\u5728\u5634\u5507\u6709\u9ed1\u8272\u7684\u8272\u7d20\u6c88\u6fb1(\u5982\u5716)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8178\u80c3\u9053\u5bb9\u6613\u6709\u606f\u8089\u767c\u751f\nB. \u606f\u8089\u7684\u75c5\u7406\u578b\u614b\u70ba\u817a\u7624(adenoma)\nC. \u70ba\u81ea\u9ad4\u986f\u6027\u907a\u50b3(autosomal dominant)\nD. \u767c\u751f\u5375\u5de2\u816b\u7624\u6a5f\u6703\u589e\u52a0\nE. \u767c\u751f\u80f0\u81df\u816b\u7624\u6a5f\u6703\u589e\u52a0\n": "(B)", "104-4.\n\u8001\u5e74\u60a3\u8005\u4e3b\u8a34\u70ba\u670d\u7528\u85e5\u7269\u5f8c\uff0c\u6709\u6025\u6027\u767c\u4f5c\u7684\u80f8\u75db\u5408\u4f75\u541e\u56a5\u75bc\u75db(odynophagia)\uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u5728\u98df\u9053\u767c\u73fe\u5982\u5716\u7684\u8b8a\u5316(\u5982\u5716)\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8d77\u56e0\u65bc\u4e0d\u826f\u7684\u670d\u85e5\u7fd2\u6163\nB. \u6700\u5bb9\u6613\u767c\u751f\u65bc\u98df\u9053\u4e0b\u7aef\nC. \u670d\u7528nonsteroidal anti-inflammatory drugs\u662f\u53ef\u80fd\u7684\u75c5\u56e0\nD. \u670d\u7528bisphosphonates\u4e5f\u53ef\u4ee5\u9020\u6210\nE. \u53ef\u4ee5\u8655\u65b9antisecretory medications\n": "(B)", "104-5.\n\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(Helicobacter pylori)\u662f\u9020\u6210\u6162\u6027\u80c3\u708e\uff0c\u6d88\u5316\u6027\u6f70\u760d\u548c\u80c3\u764c\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u4e0b\u5217\u4f55\u9805\u85e5\u7269\u4e0d\u9069\u5408\u7528\u65bc\u9664\u83cc\u7684\u5408\u4f75\u6cbb\u7642\uff1f\nA. omeprazole\nB. bismuth subsalicylate\nC. erythromycin\nD. metronidazole\nE. amoxicillin\n": "(C)", "104-6.\n\u6709\u95dc\u81bd\u9178(bile acid)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1)\u98f2\u98df\u6210\u5206\u4e2d\u4e0d\u542b\u81bd\u9178(2)\u8178\u5b50\u5408\u6210\u7684\u81bd\u9178\u70ba\u521d\u7d1a\u81bd\u9178(primary bile acid) (3)\u7d93\u7531\u8178\u5b50\u5438\u6536\u7684\u81bd\u9178\u6703\u56de\u5230\u809d\u81df\uff0c\u6b64\u904e\u7a0b\u6709\u554f\u984c\u6703\u5c0e\u81f4steatorrhea (4)cholestyramine\u53ef\u7528\u65bcbile acid diarrhea (5)deoxycholic acid\u548clithocholic acid\u70ba\u521d\u7d1a\u81bd\u9178\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(D)", "104-7.\n\u767c\u708e\u6027\u5927\u8178\u75be\u75c5(inflammatory bowel disease)\u5305\u62ec\u514b\u9686\u6c0f\u75c7(Crohn's disease\u7c21\u7a31CD)\u548c\u6f70\u760d\u6027\u8178\u708e(ulcerative colitis\u7c21\u7a31UC)\uff0c\u5bb9\u6613\u6709\u8178\u9053\u4ee5\u5916\u7684\u8868\u73fe(extraintestinal manifestation)\u3002\u4e0b\u5217\u4f55\u7a2e\u8178\u9053\u5916\u8868\u73fe\u8f03\u5e38\u898b\u65bcCD\uff1f(1)pyoderma gangrenosum (2)ankylosing spondylitis (3)primary sclerosing cholangitis (4)episcleritis (5)peripheral arthritis\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (2)+(4)+(5)\nE. (1)+(3)+(4)\n": "(D)", "104-8.\n\u6025\u6027\u80f0\u81df\u708e\u7684\u56b4\u91cd\u5ea6\u5224\u65b7\u5c0d\u60a3\u8005\u8655\u7f6e\u548c\u9810\u5f8c\u76f8\u7576\u91cd\u8981\uff0c\u904e\u53bb\u7684Ranson's sign(\u22673)\u548cAPACHE II score (\u22678)\u7531\u65bc\u8f03\u7e41\u7463\uff0c\u76ee\u524d\u6709\u7528bedside index severity\u53d6\u800c\u4ee3\u4e4b\u7684\u8da8\u52e2\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bcbedside index severity of acute pancreatitis (BISAP)\uff1f\nA. age>60years\nB. SIRS\nC. pleural effusion\nD. creatinine>2.0mg/dL\nE. impaired mental status\n": "(D)", "104-9.\n\u85e5\u7269\u5f15\u8d77\u7684\u809d\u81df\u50b7\u5bb3(drug-induced hepatic injury)\uff0c\u53cd\u61c9\u6709direct\u53caidiosyncratic\u5169\u7a2e\uff0c\u4e0b\u5217\u85e5\u7269\u4f55\u8005\u5c6c\u65bcidiosyncratic\u53cd\u61c9\uff1f(1)oral contraceptive agents (2)acetaminophen (3)halothane (4)isoniazid (5)chlorpromazine\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "104-10.\n\u6709\u95dc\u80c3\u5206\u6ccc(gastric secretion)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u57fa\u790e\u80c3\u9178\u5206\u6ccc\u91cf\u5728\u65e9\u4e0a\u6700\u9ad8\nB. \u9664\u80c3\u9178\u5916\uff0c\u80c3\u53ef\u5206\u6cccpepsinogen\nC. \u9435\u8cea\u548cB12\u7684\u5438\u6536\u8207\u80c3\u5206\u6ccc\u6709\u95dc\nD. somatostatin\u53ef\u6291\u5236\u80c3\u9178\u5206\u6ccc\nE. parietal cell\u4e0a\u6709histamine, gastrin\u548cacetylcholine\u53d7\u9ad4\n": "(A)", "104-11.\n\u9577\u671f\u9157\u9152\u7684\u60a3\u8005\u56e0\u89e3\u9ed1\u4fbf\u3001\u5410\u8840\u5230\u6025\u8a3a\u8655\uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u7d50\u679c(\u5982\u5716)\uff0c\u4e0b\u5217\u4f55\u7a2e\u8655\u7f6e\u4e0d\u9069\u5408\u6025\u6027\u51fa\u8840\u7684\u63a7\u5236\uff1f\nA. octreotide\nB. propranolol\nC. injection therapy(sclerotherapy)\nD. transjugular intrahepatic portosystemic shunt\nE. somatostatin\n": "(B)", "104-12.\n\u4fbf\u79d8\uff08constipation\uff09\u53ef\u80fd\u767c\u751f\u65bc\u4e0b\u5217\u60c5\u6cc1\uff0c\u4f55\u8005\u9664\u5916\uff1f\r\u0010\nA. Hypothyroidism\nB. \u670d\u7528Bismuth\nC. Hypocalcemia\nD. \u670d\u7528calcium channel blockers\nE. \u670d\u7528opiates\n": "(C)", "104-13.\n\u5927\u8178\u7684diverticular diseases\u5728\u4e2d\u8001\u5e74\u4eba\u76f8\u7576\u5e38\u898b\uff0c\u4e0b\u5217\u76f8\u95dc\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Diverticulitis\u4e4b\u5178\u578b\u75c7\u72c0\u5305\u62ec\uff1a\u5de6\u6216\u53f3\u4e0b\u8179\u75db\u3001\u767c\u71d2\u53caleukocytosis\nB. \u7528\u4f86\u6cbb\u7642diverticulitis\u4e4b\u6297\u751f\u7d20\u61c9\u5305\u62ec\u5c0d\u6297aerobic gram-negative \u53cagram-positive\u7d30\u83cc\nC. Diverticulitis\u6025\u6027\u767c\u4f5c\u671f\u4e0d\u5b9c\u505a\u5167\u8996\u93e1\u6aa2\u67e5\nD. \u82e5\u8a3a\u65b7\u4e0d\u662f\u5f88\u78ba\u5b9a\uff0cabdominopelvic CT\u662f\u9996\u9078\u6aa2\u67e5\u5de5\u5177\nE. Diverticula of colon \u662f\u8840\u4fbf\u7684\u5e38\u898b\u75c5\u56e0\u4e4b\u4e00\n": "(B)", "104-14.\n\u4e00\u4f4d72\u6b72\u7537\u6027\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u4e3b\u8a34\u70ba\u904e\u53bb\u4e8c\u5468\u6709\u5fc3\u7aa9\u75db\uff0c6\u5c0f\u6642\u524d\u6709\u5410\u51fa\u5496\u5561\u8272\u7269\u8cea\u3002\u4ed6\u904e\u53bb\u66fe\u63a5\u53d7\u624b\u8853\u63db\u904emitral valve\uff0c\u4e5f\u66fe\u6709\u904etransient ischemic attack\uff0c\u73fe\u5728\u4e00\u76f4\u670d\u7528warfarin\u3002\u904e\u53bb\u7121\u809d\u75c5\u53f2\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8840\u58d3\u70ba170/88 mmHg\uff0c\u7121\u59ff\u52e2\u6027\u4f4e\u8840\u58d3\uff0c\u5fc3\u8df3\u70ba92/\u5206\uff0c\u547c\u5438\u901f\u738717/\u5206\uff0c\u9ad4\u6eab\u6b63\u5e38\uff0c\u8179\u90e8\u6aa2\u67e5\u5728\u5fc3\u7aa9\u8655\u6709\u8f15\u5fae\u58d3\u75db\u3002\u62bd\u8840\u6aa2\u67e5INR=2.3 (0.8-1.2), Hb : 13 g/dL (\u2267 13.2), Albumin: 3.8 (\u2267 3.7) g/dL, Bilirubin (total): 0.9 (\u2266 1.0) mg/dL, AST: 31U/L (\u2266 31), ALT: 25U/L (\u2266 41)\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u8feb\u5207\u5408\u5b9c\u4e4b\u8655\u7f6e\uff1f\nA. \u8f38\u6ce8Fresh frozen plasma\nB. \u8f38\u6ce8Vitamin K\nC. \u8f38\u6ce8Platelet\nD. \u7d66\u4e88\u9810\u9632\u6027\u6297\u751f\u7d20\nE. \u5b89\u6392\u5167\u8996\u93e1\u6aa2\u67e5\n": "(E)", "104-15.\n\u4e00\u4f4d60\u6b72\u5973\u6027\u75c5\u4eba\u81ea\u8ff0\u8fd12\u500b\u6708\u6709\u9010\u6f38\u52a0\u91cd\u7684\u6d3b\u52d5\u6027\u6c23\u4fc3\uff08progressive exertional dyspnea\uff09\uff0c\u5979\u4e26\u7121\u80f8\u75db\u6216\u5fc3\u60b8\u7b49\u73fe\u8c61\uff0c\u975c\u6b62\u6216\u7761\u89ba\u6642\u4ea6\u7121\u6c23\u4fc3\u60c5\u6cc1\u3002\u8eab\u9ad4\u8a3a\u5bdf\u50c5\u5728\u80f8\u524d\u767c\u73fespider angiomata\uff0c\u5176\u5b83\u7121\u7570\u5e38\u767c\u73fe\u3002\u62bd\u8840\u6aa2\u9a57\u767c\u73fe\uff1aPaO2=62 mmHg\uff0coxygen saturation 90%\uff0cAST=110 (\u2266 31)\uff0cALT=130 (\u2266 41)\uff0cAlb=3.5 (\u2267 3.7) g/dL\uff0cBil(T)=0.9 (\u2266 1) mg/dL\uff0cINR=0.95 (0.8-1.2)\uff0cWBC=4500 (\u2267 3500)\uff0cPlatelet=103K ( > 140K)\uff0cHBsAg (-)\uff0cAntiHCV (+)\u3002\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u7686\u6b63\u5e38\u3002\u4e0b\u5217\u4f55\u7a2e\u8a3a\u65b7\u6700\u53ef\u80fd\uff1f\nA. Hepatopulmonary syndrome\nB. Portopulmonary hypertension\nC. Ischemic heart disease\nD. Decompensated liver cirrhosis\nE. Idiopathic portal hypertension\n": "(A)", "104-16.\n\u4e00\u4f4d\u809d\u786c\u5316\u75c5\u4eba\u6700\u8fd1\u767c\u751f\u809d\u6027\u8166\u75c5\u8b8a\uff08hepatic encephalopathy\uff09\u3002\u4f4f\u9662\u5f8c\u4e26\u672a\u767c\u73fe\u6709\u8178\u80c3\u9053\u51fa\u8840\u3001\u611f\u67d3\u53ca\u4f4e\u8840\u9240\u7b49\u75c5\u60c5\uff0c\u4ed6\u5728\u5bb6\u4e2d\u6bcf\u5929\u65bc\u670d\u7528lactulose\u4e0b\u89e3\u4fbf\u7d044\u6b21\uff0c\u751f\u75c5\u524d\u4ea6\u7121\u9032\u98df\u904e\u591a\u86cb\u767d\u8cea\u3002\u589e\u52a0\u4e0b\u5217\u4f55\u8005\u7d66\u75c5\u4eba\u670d\u7528\uff0c\u6709\u52a9\u65bc\u9810\u9632\u672a\u4f86\u518d\u767c\u751f\u809d\u6027\u8166\u75c5\u8b8a\u4e14\u4e0d\u6703\u6709\u660e\u986f\u53ef\u9810\u671f\u4e4b\u526f\u4f5c\u7528\uff1f\nA. Dulcolax\nB. Neomycin\nC. Metronidazole\nD. Rifaximin\nE. Anticholinergic drug\n": "(D)", "104-17.\n\u4e0b\u5217\u95dc\u65bcacute intestinal obstruction\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\r(1) \u521d\u671f\u5e38\u6709\u9663\u767c\u6027cramping mid-abdominal pain\r(2) Strangulation\u767c\u751f\u6642\uff0c\u8179\u75db\u8f03\u6703\u56fa\u5b9a\u65bc\u67d0\u4e00\u90e8\u4f4d\uff0c\u4e14\u8b8a\u6210\u6301\u7e8c\u6027\uff0c\u4e5f\u8f03\u4e0d\u6703cramping\r(3) Colon obstruction\u4e4b\u8179\u75db\u8f03\u4e0d\u56b4\u91cd\r(4) \u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u8179\u90e8\u8139\u6c23\u8d8a\u53b2\u5bb3\uff0c\u8868\u793a\u5176\u963b\u585e\u90e8\u4f4d\u8f03\u53ef\u80fd\u5728\u8fd1\u7aef\u5c0f\u8178\u8655\r(5) \u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u807d\u4e0d\u5230bowel sound\uff0c\u53ef\u6392\u9664acute intestinal obstruction\u4e4b\u53ef\u80fd\u6027\r(6) \u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u807d\u4e0d\u5230bowel sound\uff0c\u8868\u793a\u4e00\u5b9a\u662f\u767c\u751fadynamic (paralytic) ileus\r(7) Barium meal study\u662f\u5224\u65b7\u963b\u585e\u90e8\u4f4d\u4e4b\u6700\u597d\u65b9\u5f0f\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (2)+(3)+(6)+(7)\nD. (3)+(4)+(5)+(6)\nE. (4)+(5)+(6)+(7)\n": "(E)", "104-18.\n\u4e0b\u5217\u95dc\u65bcAcute Appendicitis\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r(1) \u5178\u578b\u4e4b\u8179\u75db\u662f\u7531periumbilical/epigastric region\u79fb\u884c\u81f3right lower quadrant of abdomen\r(2) \u5e38\u6709bowel habit change\r(3) \u5e38\u6709anorexia\r(4) \u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u5728\u53f3\u4e0b\u8179\u6c92\u6709\u767c\u73fetenderness\uff0c\u5373\u53ef\u6392\u9664acute appendicitis\u4e4b\u8a3a\u65b7\r(5) psoas/obturator sign\u5c0d\u5224\u65b7acute appendicitis\u4e4b\u6709\u7121\u6975\u5177\u50f9\u503c\r(6) \u4f7f\u7528CT with contrast agent enhancement\u8a3a\u65b7acute appendicitis\u4e4b\u6e96\u78ba\u7387\uff08accuracy\uff09\u76f8\u7576\u9ad8\uff0c\u53ef\u905490%\nA. (1)+(2)+(3)\nB. (2)+(3)+(5)\nC. (1)+(3)+(6)\nD. (3)+(4)+(5)\nE. (4)+(5)+(6)\n": "(C)", "104-19.\n\u4e0b\u5217\u95dc\u65bc\u809d\u81df\u5c40\u9650\u6027\u75c5\u7076\uff08focal lesion\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r(1) \u5927\u7684cyst\u82e5\u6709wall irregularity\uff0c\u61c9\u8003\u616e\u5207\u9664\u4e4b\r(2)  Focal Nodular Hyperplasia (FNH)\u6709malignant potential\uff0c\u6545\u61c9\u5207\u9664\u4e4b\r(3) \u76f4\u5f915\u516c\u5206\u4ee5\u4e0a\u7684adenoma\u53ef\u80fd\u6703spontaneous rupture\u6216\u6f14\u8b8a\u6210\u60e1\u6027\u816b\u7624\uff0c\u6545\u61c9\u5207\u9664\u4e4b\r(4) \u63a5\u89f8ameba\u81f3\u958b\u59cb\u6709liver abscess\u4e4b\u81e8\u5e8a\u75c7\u72c0\uff0c\u5176\u6f5b\u4f0f\u671f\u7d042-4 weeks\r(5) \u63a5\u53d7CT scan\u6aa2\u67e5\uff0c\u6ce8\u5c04\u986f\u5f71\u5291\u5f8c\uff0c\u5728\u8840\u7ba1\u7624\u6703\u6709\u6240\u8b02 \"fill-in\"\u73fe\u8c61\uff0c\u5373\u662f\u986f\u5f71\u5291\u6703\u96a8\u6642\u9593\u5f9e\u8840\u7ba1\u7624\u4e4b\u5468\u908a\u5411\u5176\u4e2d\u592e\u6ef2\u5165\u3002\nA. (3)+(4)+(5)\nB. (2)+(3)+(4)\nC. (1)+(2)+(3)\nD. (2)+(3)+(5)\nE. (1)+(3)+(5)\n": "(E)", "104-20.\n\u76ee\u524d\u5df2\u6709\uff21\u578b\u809d\u708e\u53ca\uff22\u578b\u809d\u708e\u75ab\u82d7\uff0c\u5e74\u8f15\u4e00\u4ee3\u4e4b\u570b\u4eba\u61c9\u63a5\u53d7\u4e4b\u3002\u4e0b\u5217\u76f8\u95dc\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u82e5\u6bcd\u89aa\u70baHBeAg (-)\u4e4b\uff22\u578b\u809d\u708e\u5e36\u539f\u8005\uff0c\u5176\u65b0\u751f\u5152\u61c9\u65bc24\u5c0f\u6642\u5167\u63a5\u53d7HBIG (hepatitis B immune globulin) \u6ce8\u5c04\uff0c\u4e26\u65bc\u4e00\u5468\u5167\u5b8c\u6210\u7b2c\u4e00\u5291\uff22\u578b\u809d\u708e\u75ab\u82d7\u6ce8\u5c04\nB. \u76ee\u524d\u4e4b\uff22\u578b\u809d\u708e\u75ab\u82d7\uff0c\u61c9\u65bc\u516d\u500b\u6708\u5167\u5b8c\u6210\u4e09\u5291\u6ce8\u5c04\nC. \u76ee\u524d\u4e4b\uff21\u578b\u809d\u708e\u75ab\u82d7\uff0c\u61c9\u65bc\u516d\u500b\u6708\u223c\u4e00\u5e74\u5167\u5b8c\u6210\u5169\u5291\u6ce8\u5c04\nD. \u5b8c\u6210\u4e09\u5291\u6ce8\u5c04\u4e14\u7522\u751fanti-HBs\u5f8c\uff0c60%\u4ee5\u4e0a\u53ef\u6301\u7e8c\u7dad\u6301\u5177\u4fdd\u8b77\u6027\u4e4b\u6fc3\u5ea6\u81f3\u5c1110\u5e74\nE. \u5b8c\u6210\u4e8c\u5291\u6ce8\u5c04\u4e14\u7522\u751fanti-HAV\u5f8c\uff0c\u61c9\u53ef\u6301\u7e8c\u7dad\u6301\u5177\u4fdd\u8b77\u6027\u4e4b\u6fc3\u5ea6\u81f3\u5c1120\u5e74\n": "(A)", "104-21.\n\u5728\u65e5\u5e38\u91ab\u7642\u4e4b\u60c5\u6cc1\u4e0b\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6700\u4e0d\u6703\u7522\u751f\u809d\u81df\u50b7\u5bb3\uff1f\nA. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u6fc3\u5ea6\u7684allopurinol\nB. \u9000\u71d2\u6642\u4f7f\u7528acetaminophen\uff08\u9152\u7cbe\u6210\u766e\u8005\u9664\u5916\uff09\nC. \u6cbb\u7642\u7d50\u6838\u75c5\u4e4bisoniazid\nD. \u6cbb\u7642\u8db3\u766c\u4e4bketoconazole\u985e\u85e5\u7269\nE. \u964d\u4f4e\u8840\u4e2d\u81bd\u56fa\u9187\u4e4bstatin\u985e\u85e5\u7269\n": "(B)", "104-22.\n\u4e00\u4f4d45\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u53f3\u4e0a\u8179\u75db\u53ca\u76ae\u819a\u7662\u800c\u5c31\u91ab\uff0c\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aALT=60U/L (\u226641)\uff0cAST=70U/L (\u226631)\uff0cALP=700 (\u2266104)\uff0cr-GT=450U/L (\u226650)\uff0cBil(T)=1.2mg/dL\uff0cBil(D)=0.8mg/dL\u3002\u4f4f\u9662\u5f8c\u63a5\u53d7\u78c1\u632f\u9020\u5f71\u53ca\u81bd\u80f0\u7ba1\u651d\u5f71\uff08MRCP, magnetic resonance cholangio pancreatography\uff09\u767c\u73fe\u809d\u5167\u81bd\u7ba1\u6709\u5206\u5e03\u4e0d\u4e00\u4e4b\u72f9\u7a84\u53ca\u64f4\u5927\u73fe\u8c61\uff08segmental stricture with saccular dilatation\uff09\u3002\u75c5\u4eba\u63a5\u53d7\u809d\u5207\u7247\uff0c\u5176\u7d44\u7e54\u986f\u73feportal tract expansion with ductular proliferation and lymphocytic\rinfiltration\uff0c\u6b64\u75c5\u4eba\u4e4b\u8a3a\u65b7\u56e0\u800c\u5df2\u7d93\u78ba\u7acb\u3002\u95dc\u65bc\u672c\u75c5\u4eba\u4e4b\u75c5\u60c5\uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5e38\u5408\u4f75\u6709\u6162\u6027\u767c\u708e\u6027\u8178\u9053\u75be\u75c5\uff08inflammatory bowel disease\uff09\nB. \u61c9\u96a8\u6642\u6ce8\u610f\u5176\u662f\u5426\u4f75\u767ccholangiocarcinoma\nC. \u9ad8\u5291\u91cf (25 mg/Kg/d) UDCA (ursodeoxycholic acid) \u80fd\u6709\u6548\u63a7\u5236\u5176\u75c5\u60c5\nD. \u82e5\u75c5\u60c5\u60e1\u5316\uff0c\u53ef\u8003\u616e\u809d\u81df\u79fb\u690d\nE. MRCP\u7528\u65bc\u8a3a\u65b7\u6b64\u7b49\u75c5\u4eba\uff0c\u5176\u6e96\u78ba\u7387\u53ef\u905490%\n": "(C)", "105-1.\n25\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u541e\u56a5\u56f0\u96e3\u3001\u80f8\u75db\u53ca\u9ad4\u91cd\u6e1b\u8f15\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u70ba\u6b63\u5e38\u3002\u500b\u6848\u9032\u4e00\u6b65\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u651d\u5f71\u7d50\u679c\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\u8a3a\u65b7\uff1f\nA. \u98df\u9053\u5ee3\u6cdb\u6027\u75d9\u6523(diffuse esophageal spasm)\nB. \u80c3\u98df\u9053\u9006\u6d41\u6027\u75be\u75c5(gastroesophageal reflux disease)\nC. \u98df\u9053\u5f1b\u7de9\u4e0d\u80fd(achalasia)\nD. \u55dc\u4f0a\u7d05\u6027\u98df\u9053\u708e(eosinophilic esophagitis)\nE. \u98df\u9053\u764c(esophageal cancer)\n": "(C)", "105-2.\n60\u6b72\u7537\u6027\u56e0\u80c3\u9178\u9006\u6d41\u3001\u80f8\u53e3\u707c\u71b1\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u767c\u73fe\u98df\u9053\u6709\u5982\u5716\u4e4b\u8b8a\u5316\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u9020\u6210\u6b64\u98df\u9053\u75c5\u8b8a\u4e4b\u4fc3\u767c\u56e0\u5b50\uff1f\nA. acid\nB. pepsin\nC. bile\nD. pancreatic ezyme\nE. Helicobacter pylori infection\n": "(E)", "105-3.\n\u9664\u4e86\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u611f\u67d3\u5916\uff0c\u85e5\u7269\u4e5f\u662f\u9020\u6210\u6d88\u5316\u6027\u6f70\u760d\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u8f03\u4e0d\u6703\u9020\u6210\u6f70\u760d\uff1f\nA. bisphosphonate\nB. clopidogrel\nC. potassium chloride\nD. acetaminophen\nE. chemotherapeutic agent\n": "(D)", "105-4.\n65\u6b72\u7537\u6027\u60a3\u800525\u5e74\u524d\u56e0\u80c3\u51fa\u8840\u63a5\u53d7\u5716\u793a\u4e4b\u624b\u8853\uff0c\u51fa\u73fe\u98ef\u5f8c\u8179\u75db\u3001\u8179\u8139\u3001\u8179\u7009\uff0c\u540c\u6642\u6709\u8102\u80aa\u53ca\u7dad\u751f\u7d20B12\u5438\u6536\u4e0d\u826f\uff0c\u9019\u4e9b\u75c7\u72c0\u5728\u4f7f\u7528\u6297\u751f\u7d20\u5f8c\u5f97\u5230\u6539\u5584\uff0c\u8a66\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. recurrent ulceration\nB. afferent loop syndrome\nC. postvagotomy diarrhea\nD. bile reflux gastropathy\nE. remnant gastric cancer\n": "(B)", "105-5.\n\u6709\u95dc\u81bd\u9178(bile acids)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r\n1. \u98f2\u98df\u4e2d\u6c92\u6709\uff0c\u5176\u4e3b\u8981\u4f86\u6e90\u662f\u809d\u81df\u5408\u6210\r\n2. lithocholic acid\u5c6c\u521d\u7d1a\u81bd\u9178(primary bile acid)\r\n3. \u6b21\u7d1a\u81bd\u9178(secondary bile acid)\u4f8b\u5982deoxycholic acid\u4e4b\u7522\u751f\u662f\u7531\u65bc\u5927\u8178\u5167\u7d30\u83cc\u9175\u7d20\u5206\u89e3\u521d\u7d1a\u81bd\u9178\u800c\u4f86\r\n4. \u81bd\u9178\u7570\u5e38\u6703\u9020\u6210\u6bd4\u8102\u80aa\u9178\u7570\u5e38\u66f4\u56b4\u91cd\u7684\u8102\u80aa\u8179\u7009(steatorrhea)\r\n5. \u81bd\u9178\u5f15\u8d77\u4e4b\u8179\u7009\u5c0d\u4f4e\u8102\u98f2\u98df\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\nA. 1+2+3\nB. 1+3+4\nC. 1+3+5\nD. 2+4+5\nE. 2+3+5\n": "(C)", "105-6.\n20\u6b72\u7537\u6027\u56e0\u53cd\u8986\u6027\u8179\u75db\u4f4f\u9662\uff0c\u5c0f\u8178\u651d\u5f71\u6aa2\u67e5\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. irritable bowel syndrome\nB. celiac sprue\nC. jejunal diverticulosis\nD. Crohn's disease\nE. Whipple's disease\n": "(D)", "105-7.\n\u6709\u95dc\u767c\u708e\u6027\u5927\u8178\u75be\u75c5(inflammatory bowel disease)\u4e2d\u6f70\u760d\u6027\u8178\u708e(ulcerative colitis)\u548c\u514b\u9686\u6c0f\u75c5(Crohn's disease)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\r\n1. \u62bd\u7159\u6703\u589e\u52a0\u6f70\u760d\u6027\u8178\u708e\u7684\u767c\u751f\r\n2. \u76f2\u8178\u5207\u9664\u624b\u8853(appendectomy)\u53ef\u4ee5\u6e1b\u5c11\u6f70\u760d\u6027\u8178\u708e\u7684\u767c\u751f\r\n3. \u4f7f\u7528\u53e3\u670d\u907f\u5b55\u85e5(oral contraceptive)\u6703\u589e\u52a0\u514b\u9686\u6c0f\u75c5\u767c\u751f\r\n4. \u9664\u4e8615-30\u6b72\u5916\uff0c\u5169\u8005\u572860-80\u6b72\u6709\u53e6\u4e00\u597d\u767c\u9ad8\u5cf0\r\n5. \u514b\u9686\u6c0f\u75c5\u5973\u6027\u767c\u751f\u6a5f\u6703\u9ad8\u65bc\u7537\u6027\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 1+4+5\nE. 2+4+5\n": "(B)", "105-8.\n60\u6b72\u7537\u6027\u4e00\u5e74\u524d\u63a5\u53d7\u5927\u8178\u93e1\u6aa2\u67e5\u5728\u4e59\u72c0\u7d50\u8178\u767c\u73fe\u4e00\u4e9b\u61a9\u5ba4(diverticulum)\u3002\u56e0\u70ba\u5de6\u4e0b\u8179\u75bc\u75db\u3001\u767c\u71d2\u81f3\u6025\u8a3a\u8655\uff0c\u8840\u6db2\u6aa2\u67e5WBC: 15000 /\u03bcL\uff0cSeg: 88%\uff0c\u4e14\u8179\u90e8\u53ca\u9aa8\u76c6\u8154\u96fb\u8166\u65b7\u5c64\u4e26\u7121\u6e38\u96e2\u7a7a\u6c23\u6216\u81bf\u760d\u3002\u4e0b\u5217\u4f55\u9805\u8655\u65b9\u8f03\u4e0d\u9069\u5408\u6b64\u60a3\u8005\u7684\u6cbb\u7642\uff1f\nA. penicillin / clavulanic acid\nB. cephalexin\nC. ciprofloxacin / metronidazole\nD. piperacillin\nE. trimethoprim / sulfamethoxazole\n": "(B)", "105-9.\n\u6709\u95dc\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(Helicobacter pylori)\u6aa2\u6e2c\uff0c\u4f55\u8005\u6b63\u78ba?\r\n1. \u547c\u6c23\u6e2c\u8a66(urea breath test)\u654f\u611f\u5ea6\u6700\u9ad8\r\n2. \u7cde\u4fbf\u6297\u539f\u6e2c\u8a66(stool antigen)\u50f9\u683c\u6700\u6602\u8cb4\r\n3. \u8840\u6e05\u6e2c\u8a66\u53ef\u7528\u65bc\u6bba\u83cc\u5f8c\u7684\u65e9\u671f\u8ffd\u8e64\r\n4. \u670d\u7528bismuth\u6216proton pump inhibitor\u6703\u4f7f\u5feb\u901f\u5c3f\u7d20\u9175\u7d20\u6e2c\u8a66(rapid urease test)\u5448\u73fe\u507d\u9670\u6027\u7d50\u679c\r\n5. \u4e8c\u6b21\u4ee5\u4e0a\u6bba\u83cc\u5931\u6557\u5f8c\u53ef\u8003\u616e\u7d30\u83cc\u57f9\u990a\u6e2c\u6297\u85e5\u6027\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 1+4+5\nE. 2+4+5\n": "(D)", "105-10.\n\u6025\u6027\u80f0\u81df\u708e\u572824\u5c0f\u6642\u5167\u6709\u6240\u8b02\u7684bedside index of severity in acute pancreatitis\uff0c\u7c21\u7a31BISAP\uff0c\u4f86\u5354\u52a9\u56b4\u91cd\u5ea6\u7684\u5224\u5b9a\u3002\u4e0b\u5217\u4f55\u9805\u4e0d\u5c6c\u65bcBISAP\uff1f\nA. BUN>22mg/dL\nB. impaired mental status\nC. hemoconcentration\nD. age>60years\nE. pleural effusion\n": "(C)", "105-11.\n\u81bd\u7d50\u77f3\u6709\u81bd\u56fa\u9187\u7d50\u77f3(cholesterol stone)\u548c\u8272\u7d20\u7d50\u77f3(pigment stone)\u5169\u7a2e\uff0c\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u8272\u7d20\u7d50\u77f3\u4e4b\u4fc3\u767c\u56e0\u5b50(predisposing factors)\uff1f\nA. \u8001\u5e74\u4eba\nB. \u61f7\u5b55\nC. \u9152\u7cbe\u6027\u809d\u786c\u5316\nD. \u60e1\u6027\u8ca7\u8840(pernicious anemia)\nE. \u6162\u6027\u6eb6\u8840(chronic hemolysis)\n": "(B)", "105-12.\n\u4e0b\u5217\u4f55\u9805\u6aa2\u6e2c\u4e3b\u8981\u7528\u65bcprimary biliary cirrhosis\uff1f\nA. antinuclear antibody\nB. anti-smooth-muscle antibody\nC. antimitochondrial antibody\nD. C3/C4\nE. IgG4\n": "(C)", "105-13.\n\u809d\u7d30\u80de\u764c\uff08hepatocellular carcinoma, HCC\uff09\u540d\u5217\u570b\u4eba\u764c\u75c7\u5341\u5927\u6b7b\u56e0\u524d\u8305\uff0c\u5176\u9810\u9632\u53ca\u6cbb\u7642\u5c0d\u570b\u4eba\u5065\u5eb7\u5f71\u97ff\u751a\u5927\u3002\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7f79\u60a3HCC\u7684\u75c5\u4eba\uff0c\u5176\u8840\u4e2dalpha-fetoprotein (AFP) \u90fd\u6703\u7570\u5e38\u4e0a\u5347\nB. \u5b9a\u671f\u5c0d\u9ad8\u5371\u96aa\u7fa4\u6aa2\u9a57\u8840\u4e2dAFP\u6578\u503c\u662f\u5fc5\u8981\u7684\nC. \u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u662f\u767c\u73feHCC\u4e4b\u5229\u5668\nD. \u809d\u786c\u5316\u60a3\u8005\u662fHCC\u6700\u9ad8\u5371\u96aa\u7fa4\nE. \u65e9\u671f\u63a7\u5236\u6162\u6027\uff22\u578b\u809d\u708e\u4e4b\u75c5\u60c5\u6709\u52a9\u65bc\u9810\u9632HCC\u4e4b\u767c\u751f\n": "(A)", "105-14.\n\u4e00\u4f4d\u6162\u6027\u809d\u708e\u60a3\u8005\uff0c\u5b9a\u671f\u63a5\u53d7\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u6700\u8fd1\u4e00\u6b21\u88ab\u544a\u77e5\u809d\u5167\u7591\u4f3c\u6709\u4e00\u500b\u816b\u7624\uff0c\u60f3\u5fb5\u8a62\u60a8\u7684\u770b\u6cd5\u3002\u4e0b\u5217\u6709\u95dc\u809d\u5167\u816b\u7624\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\r\n1. \u809d\u5167\u8840\u7ba1\u7624\uff08hemangioma\uff09\u6709\u60e1\u5316\u4e4b\u53ef\u80fd\uff0c\u6700\u597d\u4e88\u4ee5\u8655\u7406\r\n2. \u809d\u5167\u6c34\u6ce1\uff08cyst\uff09\u901a\u5e38\u4e0d\u9700\u8655\u7406\r\n3. \u817a\u7624\uff08adenoma\uff09\u4e0d\u5177hormone responsiveness\r\n4. \u5c40\u90e8\u7d50\u7bc0\u589e\u751f\uff08focal nodular hyperplasia\uff09\u82e5\u5927\u65bc5\u516c\u5206\uff0c\u4e14\u60a3\u8005\u70ba\u5e74\u8f15\u5973\u751f\uff0c\u672a\u4f86\u53ef\u80fd\u6703\u61f7\u5b55\uff0c\u6700\u597d\u4e88\u4ee5\u5207\u9664\r\n5. \u809d\u7d30\u80de\u764c\uff08hepatocellular carcinoma\uff09\u5927\u591a\u70bahypervascular\r\n6. \u8f49\u79fb\u6027\u809d\u764c\uff08metastatic liver cancer\uff09\u5927\u591a\u70bahypovascular\r\n7. \u809d\u5167\u81bd\u7ba1\u764c\uff08cholangiocarcinoma\uff09\u9810\u5f8c\u76f8\u7576\u4e0d\u932f\nA. 3+4+5+6\nB. 1+4+5+6\nC. 2+4+5+6\nD. 2+3+6+7\nE. 1+3+4+7\n": "(E)", "105-15.\n\u4e0b\u5217\u6709\u95dcNSAID (Nonsteroidal Anti-inflammatory Drugs)-induced gastrointestinal complications\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. NSAID\u6703\u6291\u5236prostaglandin synthesis\uff0c\u56e0\u6b64\u53ef\u7528misoprostol\u6cbb\u7642\nB. H. pylori\u611f\u67d3\u8207NSAID-induced\u80c3\u90e8\u6f70\u760d\u6beb\u7121\u95dc\u806f\nC. \u66fe\u6709\u80c3\u6f70\u760d\u51fa\u8840\u65e2\u5f80\u75c5\u53f2\u8005\u5c6c\u65bc\u9ad8\u5371\u96aa\u7fa4\nD. 65\u6b72\u4ee5\u4e0a\u8001\u5e74\u75c5\u4eba\u4f7f\u7528\u9ad8\u5291\u91cfNSAIDs\uff0c\u4ea6\u6709\u8f03\u9ad8\u98a8\u96aa\u6703\u767c\u751f\u6b64\u7b49\u4f75\u767c\u75c7\nE. \u6a19\u6e96\u5291\u91cfproton pump inhibitors (PPIs)\u70ba\u9810\u9632\u6b64\u7b49\u4f75\u767c\u75c7\u4e4b\u9996\u9078\n": "(B)", "105-16.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u76ae\u819a\u767c\u7662\u800c\u5c31\u91ab\uff0c\u62bd\u8840\u6aa2\u9a57\u4e4b\u7d50\u679c\u5982\u4e0b\uff1aALT=105 U/L (<41), AST=100U/L (<37), ALP (alkaline phosphatase)=700 U/L (<104), GGT (gamma-glutamyl transpeptidase)=500 U/L (<50), Bilirubin (total)=1.0 mg/dL  (<1.0)\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \uff22\u578b\u809d\u708e\u4e4b\u53ef\u80fd\u6027\u5f88\u4f4e (hepatitis B)\nB. \uff23\u578b\u809d\u708e\u4e4b\u53ef\u80fd\u6027\u5f88\u4f4e (hepatitis C)\nC. \u85e5\u7269\u6027\u809d\u708e\u4e4b\u53ef\u80fd\u6027\u5f88\u4f4e (drug-induced hepatitis)\nD. \u81bd\u6c41\u9b31\u7a4d\u6027\u809d\u75c5\u4e4b\u53ef\u80fd\u6027\u5f88\u9ad8 (cholestatic liver disease)\nE. Wilson's disease\u4e4b\u53ef\u80fd\u6027\u5f88\u9ad8\n": "(D)", "105-17.\n\u6709\u95dc\u81bd\u56ca\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u7121\u75c7\u72c0\u4e4b\u81bd\u56ca\u7d50\u77f3\u60a3\u8005\uff0c\u4ecd\u61c9\u5118\u65e9\u4e88\u4ee5\u65bd\u884c\u81bd\u56ca\u5207\u9664\nB. \u9ad4\u5916\u9707\u6ce2\u788e\u77f3\u8853\uff08extracorporeal shock wave lithotripsy\uff09\u50c5\u9069\u7528\u65bc\u6cbb\u7642\u5c11\u8a31\u75c5\u4eba\nC. \u76f4\u5f91\u5c0f\u65bc0.5\u516c\u5206\u4e4b\u591a\u767c\u6027\u81bd\u56ca\u606f\u8089\uff0c\u61c9\u52a0\u4ee5\u5207\u9664\nD. \u6709\u76f4\u5f91\u5927\u65bc3\u516c\u5206\u4e4b\u81bd\u56ca\u7d50\u77f3\u60a3\u8005\uff0c\u82e5\u7121\u75c7\u72c0\uff0c\u4e0d\u5fc5\u8003\u616e\u81bd\u56ca\u5207\u9664\nE. Cholechochal cyst\u4e26\u975e\u767c\u751f\u81bd\u56ca\u764c\u4e4b\u9ad8\u98a8\u96aa\u56e0\u5b50\n": "(B)", "105-18.\n\u4e0b\u5217\u6709\u95dcgastroesophageal reflux disease (GERD)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Asthma\u53ef\u80fd\u662f GERD \u7684 extraesophageal syndrome\u4e4b\u4e00\nB. \u904e\u5ea6\u80a5\u80d6\u4e4bGERD\u60a3\u8005\uff0c\u6e1b\u80a5\u6709\u52a9\u65bc\u6539\u5584\u5176GERD\u4e4b\u75c7\u72c0\nC. \u82e5GERD\u5df2\u6210\u6162\u6027\u72c0\u6cc1\uff0c\u9577\u671f\u4f7f\u7528\u4f4e\u5291\u91cfproton pump inbihitors (PPIs) \u901a\u5e38\u9700\u8981\nD. \u52a0\u4e0ametoclopramide\uff08\u5982\uff1aPrimperan\u7b49\uff09\u901a\u5e38\u6709\u52a9\u65bc\u5f37\u5316GERD\u4e4b\u6cbb\u7642\nE. Barrett's esophagus\u4e4b\u75c5\u4eba\u61c9\u5b9a\u671f\u63a5\u53d7\u5167\u8996\u93e1\u6aa2\u67e5\n": "(D)", "105-19.\n\u4e00\u4f4d50\u6b72\u7537\u6027\u4e4b\u5065\u6aa2\u4e2d\u6709\u95dc\u809d\u708e\u75c5\u6bd2\u6a19\u8a18\u4e4b\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aHBsAg (-), Anti-HBs (-), Anti-HBc (+), Anti-HCV (+)\u3002\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\r\n1. \u4ecd\u53ef\u80fd\u662f\uff22\u578b\u809d\u708e\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\r\n2. \u672a\u66fe\u63a5\u89f8\u904e\uff22\u578b\u809d\u708e\u75c5\u6bd2\r\n3. \u61c9\u5118\u5feb\u63a5\u53d7\uff22\u578b\u809d\u708e\u75ab\u82d7\u6ce8\u5c04\r\n4. \u904e\u53bb\u53ef\u80fd\u66fe\u6709Anti-HBs (+)\uff0c\u76ee\u524d\u6fc3\u5ea6\u5df2\u964d\u4f4e\u81f3\u6e2c\u4e0d\u5230\r\n5. \u66fe\u611f\u67d3\u904e\uff23\u578b\u809d\u708e\u75c5\u6bd2\r\n6. \uff23\u578b\u809d\u708e\u53ef\u80fd\u5df2\u75ca\u7652\nA. 1+2+4+5\nB. 2+3+5+6\nC. 1+4+5+6\nD. 3+4+5+6\nE. 2+3+4+5\n": "(C)", "105-20.\n\u95dc\u65bcIBD (inflammatory bowel disease)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Ulcerative colitis \u60a3\u8005\u8f03\u5e38\u6709proctitis\nB. Ulcerative colitis\u60a3\u8005\u4e4b\u75c7\u72c0\u8f03\u70baacute onset, Crohn disease\u60a3\u8005\u5247\u8f03\u5e38indolent onset\nC. Ulcerative colitis\u60a3\u8005\u8f03\u5e38\u6709enterocutaneous fistula\nD. Crohn disease\u60a3\u8005\u8f03\u5e38\u6709perianal abscess\nE. \u5169\u8005\u4e4b\u767c\u751f\u7686\u53ef\u80fd\u6d89\u53cagenetic predisposition, immune dysregulation\u53caenvironmental triggers\n": "(C)", "105-21.\n\u76ee\u524d\u5c0d\u6162\u6027\uff23\u578b\u809d\u708e\u60a3\u8005\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4ee5\u5e72\u64fe\u7d20\uff08interferon)\u70ba\u57fa\u790e\u4e4b\u6cbb\u7642\u5df2\u975e\u512a\u5148\u65b9\u5f0f\nB. \u53e3\u670d\u4e0d\u542b\u5e72\u64fe\u7d20\u4e4b\u65b0\u85e5\uff08direct acting antiviral agents, DAA\uff09\u4e4b\u6cbb\u7652\u7387\u5927\u591a\u53ef\u9054\u4e5d\u6210\u4ee5\u4e0a\nC. DAA\u4e4b\u7642\u7a0b\u591a\u572812-24\u9031\nD. DAA\u4e4b\u526f\u4f5c\u7528\u8f03\u5c11\u4e14\u8f15\u5fae\uff0c\u75c5\u4eba\u4e4b\u9806\u5f9e\u6027\u9ad8\nE. DAA\u8207\u5176\u5b83\u85e5\u7269\u5f88\u5c11\u6709drug interaction\n": "(E)", "105-22.\n\u76ee\u524d\u5c0d\u6162\u6027\uff22\u578b\u809d\u708e\u60a3\u8005\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\r\n1. Pegylated interferon (PEG-interferon) alpha-2\u03b1\u5df2\u4e0d\u5efa\u8b70\u4f7f\u7528\r\n2. Tenofovir\u53caEntecavir\u662f\u5169\u7a2e\u88ab\u63a8\u85a6\u512a\u5148\u4f7f\u7528\u4e4b\u53e3\u670d\u6297\uff22\u809d\u75c5\u6bd2\u85e5\u7269\r\n3. Tenofovir\u53caEntecavir\u4e4b\u4f7f\u7528\u4e0d\u9700\u56e0\u814e\u529f\u80fd\u72c0\u6cc1\u800c\u8abf\u6574\u5291\u91cf\r\n4. \u5c0dTenofovir\u53caEntecavir\u4e4b\u6297\u85e5\u6027\uff22\u809d\u75c5\u6bd2\u51fa\u73fe\u7387\u6975\u4f4e\r\n5. \u5931\u4ee3\u511f\u6027\uff08decompensated\uff09\u809d\u75c5\u60a3\u8005\u61c9\u5118\u901f\u4f7f\u7528PEG-interferon\r\n6. \u82e5\u75c5\u4eba\u5c0dEntecavir\u7522\u751f\u6297\u85e5\u6027\uff0c\u53ef\u6539\u7528Tenofovir\nA. 1+2+3+4\nB. 1+2+5+6\nC. 2+4+6\nD. 3+4+5\nE. 1+3+5\n": "(E)", "106-1.\n\u4e00\u4f4d\u75c5\u4eba\u88ab\u5bb6\u5c6c\u9001\u81f3\u6025\u8a3a\u5ba4\uff0c\u81ea\u8a34\u4e0a\u8179\u4e2d\u592e\u75bc\u75db\u5df2\u67093\u5929\uff0c\u5e73\u8eba\u6703\u66f4\u75db\uff0c\u4f34\u6709\u5614\u5410\u73fe\u8c61\u3002\u95dc\u65bc\u9019\u4f4d\u75c5\u4eba\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u62bd\u8840\u6aa2\u9a57 Liapse \u8f03\u5177\u8a3a\u65b7\u6027\nB. \u82e5\u8840\u4e2d Amylase \u6b63\u5e38,\u5373\u53ef\u6392\u9664\u6025\u6027\u80f0\u81df\u708e\u4e4b\u53ef\u80fd\u6027\nC. \u61c9\u6ce8\u610f\u5176\u8840\u4e2d triglyceride \u662f\u5426\u8d85\u904e1000 mg/dL\nD. \u61c9\u6ce8\u610f\u5176\u8170\u90e8\u662f\u5426\u6709 Turner's sign\nE. \u61c9\u8a62\u554f\u5176\u76ee\u524d\u662f\u5426\u6709\u670d\u7528 Furosemide, Hydrochlorothiazide, 6-Mercaptopurine/azathioprine \u7b49\u85e5\u7269\n": "(B)", "106-2.\n\u6709\u95dc Macroamylasemia\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u9019\u662f\u7531\u65bc amylase multimers \u7121\u6cd5\u7531\u8840\u4e2d\u6392\u81f3\u5c3f\u4e2d\u6240\u81f4\nB. \u8840\u4e2d amylase \u6fc3\u5ea6\u6703\u7570\u5e38\u4e0a\u5347\nC. \u8840\u4e2d Lipase \u901a\u5e38\u4e5f\u6703\u7570\u5e38\u5347\u9ad8\nD. Macroamylase \u53ef\u7528 chromatography \u5075\u6e2c\u51fa\u4f86\nE. \u75c5\u4eba\u901a\u5e38\u6c92\u6709\u8179\u75db\n": "(C)", "106-3.\n\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6025\u6027\u8179\u7009( < 2\u9031) \u75c5\u4eba\u82e5\u6709bloody stool \u6216\u767c\u71d2 >38.5 C \u6642\uff0c\u61c9\u8a73\u67e5\u5176\u539f\u56e0\nB. \u6700\u8fd1\u670d\u7528\u6297\u751f\u7d20\u800c\u5c0e\u81f4\u6025\u6027\u8179\u7009\uff0c\u4e0d\u5fc5\u9032\u4e00\u6b65\u8a73\u67e5\u75c5\u56e0\nC. Osmotic diarrhea \u75c5\u4eba\u4e4b\u5927\u4fbf\u91cf\u901a\u5e38\u5927\u65bc 1L/\u5929\uff0c\u7981\u98df\u5373\u6703\u505c\u6b62\u8179\u7009\nD. Secretory diarrhea \u75c5\u4eba\u4e4b\u5927\u4fbf\u91cf\u901a\u5e38\u5c0f\u65bc 1L/\u5929\uff0c\u5373\u4fbf\u7981\u98df\u4ecd\u6703\u51fa\u73fe\u8179\u7009\nE. Small intestinal bacterial overgrowth \u8f03\u5c11\u767c\u751f\u65bcintestinal motility\u7570\u5e38(dysmotility) \u4e4b\u75c5\u4eba\uff0c\u5982\uff1aautonomic neuropathy\n": "(A)", "106-4.\n\u6709\u95dcC\u578b\u809d\u708e\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1)\u7d93\u7531\u9ad4\u6db2\u50b3\u67d3\uff1b(2)\u6025\u6027C\u578b\u809d\u708e\u591a\u6578\u6c92\u75c7\u72c0\uff0c\u4e0d\u6613\u5bdf\u89ba\uff1b(3)\u76ee\u524d\u5df2\u6709\u75ab\u82d7\u53ef\u4f9b\u9810\u9632\uff1b(4)\u5065\u5eb7\u6210\u5e74\u4eba\u7f79\u60a3\u6025\u6027C\u578b\u809d\u708e\uff0c\u82e5\u672a\u6cbb\u7642\uff0c\u7d0420% \u6703\u8b8a\u6210\u6162\u6027\u809d\u708e\uff1b(5)\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\uff0c\u82e5\u672a\u6cbb\u7642\uff0c20-30\u5e74\u5f8c\u7d04\u670920-30% \u6703\u6f14\u8b8a\u6210\u809d\u786c\u5316\uff1b(6)\u76ee\u524d\u809d\u764c\u75c5\u4eba\u4e4b\u75c5\u56e0\u70ba\u6162\u6027C\u578b\u809d\u708e\u4e4b\u6bd4\u4f8b\u6108\u4f86\u6108\u9ad8\uff1b(7)\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\u4e4b\u81e8\u5e8a\u75c5\u72c0\u50c5\u4fb7\u9650\u5728\u809d\u81df\nA. (1)+(2)+(3)+(4)\nB. (2)+(4)+(5)+(7)\nC. (3)+(5)+(6)+(7)\nD. (1)+(2)+(5)+(6)\nE. (4)+(5)+(6)+(7)\n": "(D)", "106-5.\n\u6709\u95dc\u6162\u6027C\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f(1)\u9577\u6548\u578b\u5e72\u64fe\u7d20 (PEG IFN) \u4f75\u7528Ribavirin \u76ee\u524d\u4ecd\u662f\u6cbb\u7642\u4e3b\u6d41\uff0c\u7279\u5225\u662f\u5728C\u809d\u75c5\u6bd2\u57fa\u56e0\u578b\u7b2c\u4e00\u578b\u60a3\u8005\uff1b(2)\u9577\u6548\u578b\u5e72\u64fe\u7d20 (PEG IFN) \u4f75\u7528Ribavirin\u4e4b\u526f\u4f5c\u7528\u5305\u62ec\uff1a\u985e\u4f3c\u6d41\u611f\u4e4b\u75c7\u72c0\uff0c\u767d\u8840\u7403 (\u4e2d\u6027\u7403) \u964d\u4f4e\u3001\u8ca7\u8840\uff1b(3)\u9577\u6548\u578b\u5e72\u64fe\u7d20 (PEG IFN) \u4f75\u7528Ribavirin\u4e4b\u526f\u4f5c\u7528\u4e0d\u5305\u62ec\uff1a\u81ea\u9ad4\u514d\u75ab\u75be\u75c5 (\u5c24\u5176\u662f\u7532\u72c0\u817a\u708e)\u3001\u6182\u9b31\uff1b(4)\u514d\u5e72\u64fe\u7d20\u5168\u53e3\u670dC\u809d\u85e5\u7269\u985e (Direct Acting Antiviral Agents, DAAs)\r\u4e4b\u526f\u4f5c\u7528\u8f03\u5c11\u4e14\u8f15\u5fae\uff0c\u5305\u62ec\uff1a\u5026\u6020\u3001\u982d\u75db\u3001\u76ae\u819a\u708e\u3001\u7761\u7720\u969c\u7919\uff1b(5)DAAs\u5c0dC\u809d\u75c5\u6bd2\u57fa\u56e0\u578b\u7b2c\u4e8c\u578b\u60a3\u8005\u4e4b\u6cbb\u7652\u7387\u53ef\u9054\u4e5d\u6210\u4e94\u4ee5\u4e0a\uff1b(6)\u6bcf\u4e00\u7a2eDAA\u7686\u53ef\u7528\u65bc\u809d\u529f\u80fd\u5df2\u5931\u4ee3\u511f\u4e4b\u809d\u786c\u5316\u75c5\u4eba(decompensated cirrhotic patients)\uff1b(7)DAAs\u4e4b\u4f7f\u7528\u9700\u7279\u5225\u6ce8\u610f\u85e5\u7269\u4ea4\u4e92\u4f5c\u7528(Drug-Drug Interactions)\nA. (7)+(6)+(5)+(3)\nB. (1)+(3)+(4)+(7)\nC. (1)+(3)+(5)+(6)\nD. (2)+(4)+(6)+(7)\nE. (3)+(4)+(6)+(7)\n": "(C)", "106-6.\n\u95dc\u65bc\u6025\u6027\u809d\u708e\u53ef\u80fd\u75c5\u56e0\u4e4b\u8a3a\u65b7\uff0c\u4e0b\u5217\u7d44\u5408\u4f55\u8005\u6b63\u78ba\uff1f(1)A\u578b\u809d\u708e\uff1aIgG Anti-HAV\uff1b(2)B\u578b\u809d\u708e\uff1aHBsAg, HBV DNA\uff1b(3)C\u578b\u809d\u708e\uff1aAnti-HCV\uff0c HCV RNA\uff1b(4)Wilson's disease: ferritin, transferrin saturation\uff1b(5)Autoimmune hepatitis: Antinuclear antibody (ANA), smooth muscle antibody\uff1b(6)Primary biliary cirrhosis: Mitochondrial antibody\nA. (1)+(3)+(5)+(6)\nB. (2)+(3)+(4)+(5)\nC. (3)+(4)+(5)+(6)\nD. (2)+(3)+(5)+(6)\nE. (1)+(2)+(3)+(5)\n": "(D)", "106-7.\n\u4e00\u4f4d\u6162\u6027B\u578b\u809d\u708e\u5973\u6027\u60a3\u8005\uff0c\u56e0\u75c5\u60c5\u6240\u9700\u670d\u7528 Entecavir (Baraclude) \u6cbb\u7642\u5df2\u6709\u5169\u5e74\u4e4b\u4e45\uff0c\u5176ALT\u53caAST\u4e5f\u4e00\u76f4\u7dad\u6301\u5728\u6b63\u5e38\u7bc4\u570d\u5167\u3002\u4f46\u662f\u6700\u8fd1\u4e00\u6b21\u6aa2\u9a57\u767c\u73feALT=100 (<41) U/L, AST=70 (< 31) U/L, HBV viral load: undetectable, Anti-HCV (+); HCV RNA: undetectable, Anti-HDV (-)\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6b64\u75c5\u4eba\u9ad4\u5167\u4e4bB\u578b\u809d\u708e\u75c5\u6bd2\u5c0d entecavir \u5df2\u7522\u751f\u6297\u85e5\u6027\nB. \u6b64\u75c5\u4eba\u4e0d\u662fC\u578b\u809d\u708e\u75c5\u6bd2 (HCV) superinfection\nC. \u6b64\u75c5\u4eba\u4e0d\u662fD\u578b\u809d\u708e\u75c5\u6bd2 (HDV) superinfection\nD. \u61c9\u52a0\u9a57 IgM Anti-HAV\nE. \u61c9\u52a0\u9a57 Antinuclear antibody (ANA)\u53caSmooth muscle antibody\n": "(A)", "106-8.\n\u6709\u95dc\u6162\u6027B\u578b\u809d\u708e\u7279\u7570\u6027\u6cbb\u7642 (PEG Interferon\u53ca\u53e3\u670d\u6297B\u809d\u75c5\u6bd2\u85e5\u7269) \u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f(1)HBeAg (+) \u60a3\u8005\uff0c\u7121\u809d\u786c\u5316\uff0cULN < ALT < 2X ULN (upper limit of normal range)\uff0c\u61c9\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff1b(2)HBeAg (-) \u60a3\u8005\uff0c\u82e5 HBV DNA \u2267 2000 IU/mL\uff0c\u4e14\u534a\u5e74\u5167\u6709\u5169\u6b21 ALT > 2X ULN (\u5f7c\u6b64\u9593\u96943\u500b\u6708\u4ee5\u4e0a)\uff0c\u61c9\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff1b(3)\u809d\u786c\u5316\u60a3\u8005\uff0c\u82e5HBV DNA  \u2267 10000 IU/mL\uff0c\u61c9\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff1b(4)\u809d\u786c\u5316\u60a3\u8005\uff0c\u5df2\u5931\u53bb\u4ee3\u511f(decompensated liver cirrhosis)\uff0c\u4e0d\u8ad6HBV\rDNA\u6aa2\u6e2c\u7d50\u679c\u70ba\u4f55\uff0c\u61c9\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff1b(5)\u5e74\u8f15\u751f\u80b2\u5e74\u9f61\u4e4b\u60a3\u8005\uff0c\u512a\u5148\u8003\u616e\u53e3\u670d\u6297B\u809d\u75c5\u6bd2\u85e5\u7269\uff1b(6)\u82e5\u6709\u6025\u6027\u767c\u4f5c\u75c5\u60c5\uff0c\u4e14Bilirubin (T)=10.5 (< 1.0), PT=17.5 (< 11), \u61c9\u5118\u901f\u7d66\u4e88PEG Interferon\u6cbb\u7642\nA. (1)+(3)+(5)\nB. (2)+(3)+(4)+(6)\nC. (3)+(4)+(5)\nD. (2)+(3)+(5)+(6)\nE. (1)+(4)+(5)+(6)\n": "(E)", "106-9.\n\u809d\u786c\u5316\u5df2\u6709\u591a\u5e74\u7684\u75c5\u4eba\u6700\u8fd1\u5e38\u56e0\u809d\u6027\u8166\u75c5\u8b8a\u4f4f\u9662\u3002\u5176\u809d\u81df\u6b98\u5b58\u529f\u80fd (liver reserve) \u4e26\u7121\u660e\u986f\u60e1\u5316\uff1b\u4f4f\u9662\u4e2d\u4ea6\u67e5\u4e0d\u51fa\u5404\u7a2e\u8a98\u56e0 (precipitating factor)\u3002\u4ed6\u4e00\u76f4\u56fa\u5b9a\u559d lactulose \u6bcf\u59293\u6b21\uff0c\u6bcf\u6b2120 ml\uff0c\u4e00\u5929\u67093~4\u6b21\u5927\u4fbf\uff1b\u6bcf\u5929\u98df\u7528\u7684\u86cb\u767d\u8cea\u4ea6\u9069\u4e2d\u3002\u52a0\u7528\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\uff0c\u4f55\u8005\u6709\u52a9\u65bc\u6e1b\u5c11\u809d\u6027\u8166\u75c5\u8b8a\u767c\u751f\u4e4b\u983b\u7387\u4e14\u4e0d\u6703\u6709\u660e\u986f\u526f\u4f5c\u7528\uff1f\nA. Rifaximin\nB. Metronidazole\nC. Neomycin\nD. Ciprofloxain\nE. Dulcocax\n": "(A)", "106-10.\n\u95dc\u65bc Ischemic Bowel Disease \u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\r(1)Ischemic colitis \u901a\u5e38\u4e0d\u6703\u4fb5\u72afrectum\uff1b(2)Ischemic colitis \u5e38\u4fb5\u72af\u53f3\u908a\u5927\u8178\uff1b(3)Systemic Lupus Erythematosis \u75c5\u4eba\u53ef\u80fd\u7f79\u60a3ischemic colitis\uff1b(4)Chronic mesenteric ischemia\u0013\u75c5\u4eba\u4e4b\u8179\u75db\u901a\u5e38\u8207\u9032\u98df\u7121\u95dc\uff1b(5)Chronic mesenteric ischemia \u53c8\u7a31intestinal angina\uff1b(6)Acute mesenteric ischemia \u5e38\u767c\u751f\u65bc\u4e2d\u8001\u5e74\u4eba( > 50\u6b72)\uff1b(7)SMA (superior mesenteric artery) embolus \u5c0e\u81f4\u7684acute mesenteric ischemia \u75c5\u4eba\uff0c\u767c\u75c5\u671f\u9593\u5176plain abdomen \u90fd\u4e0d\u6703\u6709\u4efb\u4f55\u7570\u5e38\u8868\u73fe\u3002\nA. (1)+(2)+(4)\nB. (2)+(3)+(6)\nC. (3)+(5)+(7)\nD. (2)+(4)+(7)\nE. (1)+(5)+(6)\n": "(D)", "106-11.\n\u95dc\u65bc obscure gastrointestinal bleeding \u4e4b\u78ba\u8a3a\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u61c9\u518d\u4ee5 colonoscopy\u53caesophagogastroduodenoscopy \u6392\u9664\u5e38\u898b\u7684\u51fa\u8840\u75c5\u7076\nB. Technetium-99m (Tc-99m) labeled nuclear scan \u7528\u65bc\u5075\u6e2c actively bleeding lesions\u5f88\u6709\u7528\uff0c\u53ea\u8981\u51fa\u8840\u91cf\u9054 0.1-0.5 mL/min \u5373\u53ef\uff0c\u4e5f\u80fd\u5224\u65b7\u70ba\u4f55\u7a2e\u75c5\u7076\u53ca\u5176\u89e3\u5256\u4f4d\u7f6e\u3002\nC. Angiography (celiac & mesenteric arteries) \u50c5\u80fd\u7528\u65bc active overt bleeding ( \u9700 > 1 mL/min) \u4e4b\u75c5\u4eba\uff0c\u9664\u4e86\u8a3a\u65b7\uff0c\u4e5f\u80fd\u63d0\u4f9barterial embolization \u6cbb\u7642\u3002\nD. Small-bowel barium study with enteroclysis \u73fe\u5728\u8f03\u5c11\u88ab\u7528\u70ba\u7b2c\u4e00\u7dda\u8a3a\u65b7\u5de5\u5177\nE. Single- and Double-Balloon Enterscopy\u4e0d\u9069\u7528\u65bc\u6709 radiation enteritis, severe ulceration \u53ca recent bowel surgery \u4e4b\u75c5\u4eba\n": "(B)", "106-12.\n28\u6b72\u7537\u6027\u75c5\u60a3\u56e0\u70ba\u541e\u56a5\u56f0\u96e3(dysphagia)\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u651d\u5f71\u6aa2\uff0c\u7d50\u679c\u5982\u5716\u3002\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\uff1f(1)\u53ea\u6709\u5c0d\u56fa\u614b\u98df\u7269\u6703\u6709\u541e\u56a5\u56f0\u96e3\u73fe\u8c61\uff1b(2)\u6b64\u75c5\u7684\u7522\u751f\u53ef\u80fd\u8207\u907a\u50b3\u6613\u611f\u6027(genetic susceptibility)\u52a0\u4e0a\u7b2c\u4e00\u578bHerpes simplex virus\u611f\u67d3\uff1b(3)\u98df\u9053\u6aa2\u58d3\u6e2c\u8a66(manometry)\u70ba\u6b64\u75c5\u6700\u654f\u611f\u7684\u6aa2\u67e5\uff1b(4)\u5f97\u5230\u98df\u9053\u764c\u7684\u6a5f\u7387\u548c\u4e00\u822c\u4eba\u76f8\u540c\uff1b(5)\u4ee5Calcium channel blocker\u6cbb\u7642\u6548\u679c\u826f\u597d\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(4)+(5)\nD. (2)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "106-13.\n\u60a3\u8005\u56e0\u4e0a\u8179\u60b6\u75db\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\uff0c\u767c\u73fe\u5341\u4e8c\u6307\u8178\u6f70\u760d\uff0c\u80c3\u93e1\u5207\u7247\u5feb\u901f\u5c3f\u7d20\ufffdC\u6aa2\u67e5(rapid urease test)\u5448\u73fe\u967d\u6027\uff0c\u75c5\u60a3\u4e26\u672a\u670d\u7528\u6d88\u708e\u6b62\u75db\u5291\uff0c\u4f46\u5c0d\u76e4\u5c3c\u897f\u6797(penicillin)\u904e\u654f\u3002\u7d93\u670d\u752814\u5929omeprazole\u3001metronidazole\u53caclarithromycin\u5f8c\uff0c\u63a5\u53d7\u5c3f\u7d20\u547c\u5438\u6e2c\u8a66(urea breath test)\u7d50\u679c\u967d\u6027\uff0c\u9664\u4e86\u518d\u5ea6\u7d66\u4e88\u8cea\u5b50\u5e6b\u6d66\u6291\u5291(proton pump inhibitor)\u5916\uff0c\u4e0b\u5217\u4f55\u9805\u8655\u65b9\u6700\u9069\u5408\u6b64\u4f4d\u60a3\u8005\uff1f\nA. amoxicilin\u548clevofloxacin\nB. bismuth subsalicylate, metronidazole\u548ctetracycline\nC. clarithromycin\u548camoxicillin\nD. clarithromycin\u548cmetronidazole\nE. trimethoprim-sulfamethoxazole\u548cerythromycin\n": "(B)", "106-14.\n\u6709\u95dc\u81bd\u9178(bile acid)\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u662f\uff1f(1)\u81bd\u9178\u4e3b\u8981\u7531\u809d\u81df\u5408\u6210\u800c\u4f86\uff0c\u81b3\u98df(diet)\u4e2d\u4e26\u7121\u81bd\u9178\u6210\u4efd\uff1b(2)\u6b21\u7d1a(secodary)\u81bd\u9178\u5305\u62ecchenodeoxycholic acid\u548clithocholic acid\u5169\u7a2e\uff1b(3)\u81bd\u9178\u5206\u6ccc\u81f3\u8178\u9053\u5f8c\u4e3b\u8981\u5728\u5927\u8178\u518d\u5438\u6536\uff1b(4)\u6162\u6027\u809d\u75c5\uff0c\u5982\u539f\u767c\u6027\u81bd\u9053\u809d\u786c\u5316(primary biliary cirrhosis)\uff0c\u53ef\u56e0\u70ba\u81bd\u9178\u5408\u6210\u53ca\u5206\u6ccc\u7570\u5e38\u9020\u6210\u8102\u80aa\u6027\u8179\u7009(steatorrhea)\uff1b(5)\u81bd\u9178\u5408\u6210\u4e3b\u8981\u53d7\u81bd\u56fa\u9187degradation\u9175\u7d207\u03b1-hydroxylase\u8abf\u63a7\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(4)+(5)\nD. (2)+(3)+(4)\nE. (2)+(3)+(5)\n": "(C)", "106-15.\n20\u6b72\u7537\u6027\uff0c\u8179\u7009\u8d85\u904e1\u500b\u6708\uff0c\u5927\u4fbf\u5e36\u9ecf\u6db2\u53ca\u8840\u6db2\uff0c\u4e14\u51fa\u73fe\u95dc\u7bc0\u75bc\u75db\u73fe\u8c61\uff0c\u6709\u76ae\u819a\u75c5\u7076(\u5982\u5716)\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1f\nA. \u5927\u8178\u6fc0\u71e5\u75c7(irritable bowel syndrome)\nB. \u670d\u7528\u6297\u751f\u7d20\u5f15\u8d77\u4e4b\u8178\u708e\nC. \u6162\u6027\u80f0\u81df\u708e\nD. \u5c0f\u8178\u5bc4\u751f\u87f2\u611f\u67d3\uff0c\u5982Giardia\nE. \u514b\u9686\u6c0f\u75c7(Crohn's disease)\n": "(E)", "106-16.\n34\u6b72\u5973\u6027\u56e0\u6301\u7e8c\u6027\u4e0a\u8179\u75db\u53cd\u5c04\u81f3\u80cc\u90e8\u3001\u5641\u5fc3\u3001\u5614\u54105\u5929\uff0c\u8a3a\u65b7\u70ba\u9152\u7cbe\u76f8\u95dc\u80f0\u81df\u708e\u800c\u4f4f\u9662\u63a5\u53d7\u9032\u4e00\u6b65\u8a55\u4f30\u3002\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab38.2\u2103\uff0c\u8840\u58d3132/84mmHg\u3001\u8108\u640f101/min\u3001\u547c\u543820/min\u3001\u978f\u819c\u7121\u9ec3\u81bd\u3001\u8179\u90e8\u7030\u6f2b\u6027\u58d3\u75db\u4e14\u8178\u97f3\u70bahypoactive\u3002\u8840\u6db2\u6aa2\u67e5WBC:15400/\u03bcL\u3001AST:189U/L\u3001ALT:151U/L\u3001Bilirubin(total):1.1mg/dL\u3001amylase:388U/L\u3001lipase:924U/L\u3002\u96fb\u8166\u65b7\u5c64\u986f\u793a\u80f0\u81df\u7030\u6f2b\u6027\u6c34\u816b\uff0c\u4e14\u6709peripancreatic fluid collection\uff0c\u4f46\u7121\u58de\u6b7b\u73fe\u8c61\u3002\u6700\u9069\u5408\u7684\u4e0b\u4e00\u6b65\u6cbb\u7642\u70ba\u4f55\uff1f\nA. enteral nutrition by nasojejunal feeding tube\nB. intravenous imipenem\nC. pancreatic debridemet\nD. parenteral nutrition\nE. oral metronidazole\n": "(A)", "106-17.\n68\u6b72\u7537\u6027\u6709\u9157\u9152\u75c5\u53f2\uff0c\u56e0\u9593\u6b47\u6027\u8179\u75db\u5408\u4f75\u8179\u70097\u500b\u6708\u81f3\u6025\u8a3a\uff0c\u75c5\u60a3\u4e26\u672a\u670d\u7528\u4efb\u4f55\u85e5\u7269\u3002\u8eab\u9ad4\u6aa2\u67e5\u4e26\u7121\u767c\u71d2\uff0cBP:108/72mmHg\u3001\u8108\u640f:80/min\u3001\u547c\u543816/min\uff0c\u809a\u5b50\u4e26\u7121\u58d3\u75db\u4e5f\u672a\u6709\u8179\u8139\u3002\u8840\u6db2\u6aa2\u67e5AST:155U/L\u3001ALT:88U/L\u3001ALP:96U/L\u3001Bilirubin(total):1.1mg/dL\u3001amylase:65U/L\u3001lipase:70U/L\u3002\u7cde\u4fbf\u6aa2\u67e5\u6709\u8102\u80aa\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\u6cbb\u7642\uff1f\nA. fiber\nB. cholestyramine\nC. loperamide\nD. pancreatic enzyme\nE. ciprofloxacin\n": "(D)", "106-18.\n81\u6b72\u5a66\u5973\u67093\u500b\u6708\u8179\u75db\u53ca\u80cc\u75db\uff0c\u5408\u4f75\u98df\u617e\u4e0d\u632f\u53ca\u9ad4\u91cd\u6e1b\u8f1511\u516c\u65a4\uff0c\u6700\u8fd12\u9031\u51fa\u73fe\u9ec3\u75b8\u53ca\u76ae\u819a\u6414\u7662\u3002\u8840\u6db2\u6aa2\u67e5WBC:13200/\u03bcL\u3001Bilirubin(total):12.4mg/dL\u3001ALP:784U/L\u3001CA19-9:822U/L\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u65bc\u80f0\u81df\u982d\u67093.2\u516c\u5206\u816b\u7624\u5408\u4f75\u80f0\u7ba1\u548c\u81bd\u7ba1\u64f4\u5f35\u53ca\u809d\u81df\u591a\u9846\u816b\u7624\uff0c\u5167\u8996\u93e1\u8d85\u97f3\u6ce2\u5408\u4f75\u80f0\u81df\u982d\u90e8\u816b\u7624\u5207\u7247\u4e4b\u75c5\u7406\u70ba\u817a\u764c(adenocarcinoma)\u3002\u4e0b\u5217\u4f55\u9805\u8655\u7f6e\u5c0d\u75c5\u60a3\u6700\u6070\u7576\uff1f\nA. \u809d\u81df\u5207\u7247\nB. \u81bd\u9053\u652f\u67b6\u7f6e\u653e\nC. \u80f0\u81df\u548c\u809d\u81df\u653e\u5c04\u6cbb\u7642\nD. \u624b\u8853\u5207\u9664\u80f0\u81df\u816b\u7624\nE. \u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\n": "(B)", "106-19.\n57\u6b72\u5973\u6027\u56e0\u6025\u6027\u5de6\u4e0b\u8179\u75db\u3001\u8179\u7009\u3001\u5641\u5fc3\u81f3\u6025\u8a3a\uff0c\u9ad4\u6eab38.1\u2103\uff0cBP:115/76mmHg\u3001\u8108\u640f:98/min\uff0c\u5de6\u4e0b\u8179\u6709\u6309\u58d3\u75db\uff0c\u4f46\u7121\u53cd\u5f48\u75db\u4e5f\u7121\u816b\u584a\u3002WBC:14900/\u03bcL\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u4e59\u72c0\u7d50\u8178\u6709diverticula\u4e14\u6709pericolic fatty infiltration\u53cabowel wall thickening\u3002\u4f46\u7121\u81bf\u760d\u3001\u963b\u585e\u6216\u5ed4\u7ba1\u3002\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u8655\u7f6e\u70ba\uff1f\nA. \u4e59\u72c0\u7d50\u8178\u93e1\u6aa2\u67e5\nB. \u5168\u5927\u8178\u93e1\u6aa2\u67e5\nC. \u53e3\u670dcephalexin\u6cbb\u7642\nD. \u53e3\u670dciprofloxacin\u548cmetronidazole\u6cbb\u7642\nE. \u5916\u79d1\u5207\u9664\n": "(D)", "106-20.\n30\u6b72\u7537\u6027\uff0c4\u5e74\u524d\u88ab\u8a3a\u65b7B\u578b\u809d\u708e\uff0c\u6700\u8fd13\u9031\u6709\u75b2\u5026\u3001\u9ec3\u81bd\u73fe\u8c61\u3002\u75c5\u60a3\u5076\u723e\u559d\u4e00\u74f6\u5564\u9152\uff0c\u4e26\u7121\u670d\u7528\u4efb\u4f55\u85e5\u7269\u3002\u8eab\u9ad4\u6aa2\u67e5:\u9ad4\u6eab36.1\u2103\u3001\u8840\u58d3120/65mmHg\u3001\u8108\u640f100/min\u3001\u547c\u543816/min\uff0c\u53f3\u4e0a\u8179\u6709\u8f15\u5ea6\u58d3\u75db\u3002\u8840\u6db2\u6aa2\u67e5:Bilirubin(T)/(D):3.8/1.8mg/dL\u3001AST:1100U/L\u3001ALT:1450U/L\u3001PT INR:1.2\u3001HBsAg(+)\u3001IgG-anti-HBc(+)\u3001IgM-anti-HBc(-)\u3001HBV-DNA<20U/L\u3001anti-HCV(-)\uff0c\u8d85\u97f3\u6ce2\u50c5\u767c\u73fe\u809d\u81df\u5be6\u8cea\u70baheterogeneous echotexture\uff0c\u7121\u5176\u5b83\u7570\u5e38\u3002\u6b64\u75c5\u60a3\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\uff1f\nA. \u6025\u6027\u9152\u7cbe\u6027\u809d\u708e\nB. \u6025\u6027\u81bd\u56ca\u708e\nC. \u809d\u7d30\u80de\u764c\nD. B\u578b\u809d\u708e\u75c5\u6bd2\u518d\u6d3b\u5316(reactivated HBV infection)\nE. D\u578b\u809d\u708e\u75c5\u6bd2superinfection\n": "(E)", "106-21.\n51\u6b72\u7537\u6027\u56e0\u534a\u5e74\u5641\u5fc3\u3001\u8179\u8139\u3001\u548c\u8179\u7009\u5165\u9662\u6aa2\u67e5\u3002\u5641\u5fc3\u548c\u8179\u8139\u5728\u98ef\u5f8c\u4e00\u5c0f\u6642\u767c\u751f\u4e14\u5408\u4f75\u6fc0\u70c8\u8178\u5b50\u8815\u52d5\u53ca\u5fc3\u60b8\u3002\u9ad8\u8102\u98f2\u98df\u4e26\u4e0d\u6703\u52a0\u91cd\u75c7\u72c0\u7522\u751f\uff0c\u4e5f\u6c92\u6709\u8179\u75db\u6216\u9ad4\u91cd\u6e1b\u8f15\u3002\u500b\u68489\u500b\u6708\u524d\u56e0perforated peptic ulcer\u63a5\u53d7distal gastrectomy\u624b\u8853\uff0c\u8853\u5f8c\u4e26\u672a\u670d\u7528\u85e5\u7269\u3002\u8eab\u9ad4\u6aa2\u67e5BMI:24\uff0c\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a\u4e14\u6b63\u5e38\uff0c\u8178\u97f3\u70bahyperactive\u3002\u8840\u6db2\u6aa2\u67e5\u5305\u62ecCBC\u548c\u751f\u5316\u5747\u6b63\u5e38\u3002\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u767c\u73fe\u624b\u8853\u543b\u5408\u8655\u6b63\u5e38\u4e14\u66a2\u901a\uff0c\u5207\u7247\u53ca\u5c0f\u8178\u6db2\u5206\u6790\u4e5f\u6b63\u5e38\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1f\nA. carcinoid syndrome\nB. chronic mesenteric ischemia\nC. dumping syndrome\nD. gastrinoma\nE. irritable bowel syndrome\n": "(C)", "106-22.\n75\u6b72\u5973\u6027\u4e00\u65e9\u8d77\u5e8a\u6709\u8179\u90e8\u7d5e\u75db\u3001\u8179\u7009\u4e8c\u6b21\uff0c\u4e14\u5408\u4f75\u89e3\u51fa\u9bae\u8840\u3002\u75c5\u60a3\u6709\u9ad8\u8840\u58d3\u53ca\u51a0\u72c0\u52d5\u8108\u75be\u75c5\u75c5\u53f2\uff0c\u670d\u7528\u85e5\u7269\u5305\u62ecaspirin, ramipril, metoprolol\u548csimvastatin\u30026\u500b\u6708\u524d\u5927\u8178\u93e1\u6aa2\u67e5\u6b63\u5e38\u3002\u81f3\u6025\u8a3a\u4e4b\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab36.8\u2103\u3001\u8840\u58d3130/80mmHg\u3001\u8108\u640f70/min\u3001\u547c\u543814/min\uff0c\u5de6\u4e0b\u8179\u6709\u58d3\u75db\uff0c\u76f4\u8178\u809b\u8a3a\u6709\u9bae\u8840\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u4e4b\u4e59\u72c0\u7d50\u8178\u6709\u5c40\u90e8\u589e\u539a\u73fe\u8c61\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. Crohn's disease\nB. ulcerative colitis\nC. microscopic colitis\nD. ischemic colitis\nE. CMV colitis\n": "(D)", "107-1.\n\u95dc\u65bc\u6839\u9664\u80c3\u90e8\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u80c3\u90e8\u7684MALT (Mucosa-Associated Lymphoid Tissue) \u6dcb\u5df4\u7624\uff0c\u65bc\u6839\u9664\u80c3\u90e8\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u5f8c\uff0c\u6709\u6a5f\u6703\u6d88\u5931\nB. \u9006\u6d41\u6027\u98df\u9053\u708e\u4e4b\u75c5\u4eba\uff0c\u8981\u7a4d\u6975\u6839\u9664\u5176\u80c3\u90e8\u4e4b\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\uff0c\u4ee5\u514d\u884d\u751f\u98df\u9053\u764c\nC. Probiotics\uff0c\u5982\uff1aLactobacillus spp \u53ca Saccharomyces spp\uff0c \u4e4b\u670d\u7528\u53ef\u589e\u52a0\u80c3\u90e8\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u6839\u6cbb\u4e4b\u6a5f\u7387\nD. \u7d50\u675f\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u6839\u9664\u6cbb\u7642\u5f8c\uff0c\u81f3\u5c11\u8981\u7b49 2 \u9031\u5f8c\u624d\u80fd\u63a5\u53d7 urea breath test \u4f86\u78ba\u8a8d\u662f\u5426\u5df2\u6839\u9664\nE. \u80c3\u90e8\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u6839\u9664\u5f8c\uff0c\u518d\u611f\u67d3\u7387\u7d04\u670940%\n": "(A)", "107-2.\n\u6709\u95dc\u80c3\u5167Helicobacter pylori (H. pylori) \u4e4b\u5075\u6e2c\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u670d\u7528\u6297\u751f\u7d20\u6703\u5f71\u97ff rapid urease test (CLO test) \u4e4b\u6e96\u78ba\u5ea6\nB. \u670d\u7528 PPI (Proton Pump Inhibitors) \u6703\u5f71\u97ff urea breath test \u4e4b\u6e96\u78ba\u5ea6\nC. \u8840\u6e05 H. pylori \u4e4b IgG antibody test \u6709\u5f88\u597d\u7684 negative predictive value\nD. urea breath test \u53ef\u8fa8\u8a8d\u80c3\u5167 H. pylori \u4e4b\u5b58\u5728 (active infection)\uff0cfecal antigen test \u5247\u5426\nE. \u8840\u6e05 H. pylori \u4e4bIgG antibody test \u4e0d\u9069\u5408\u7528\u4f86\u5224\u65b7 H. pylori \u6839\u9664\u6cbb\u7642\u4e4b\u6548\u679c\n": "(D)", "107-3.\n\u76ee\u524d\u5c0d\u6162\u6027\uff23\u578b\u809d\u708e\u60a3\u8005\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4ee5\u5e72\u64fe\u7d20\uff08interferon)\u70ba\u57fa\u790e\u4e4b\u6cbb\u7642\u5df2\u975e\u512a\u5148\u65b9\u5f0f\nB. \u53e3\u670d\u4e0d\u542b\u5e72\u64fe\u7d20\u4e4b\u65b0\u85e5\uff08direct acting antiviral agents, DAA\uff09\u4e4b\u6cbb\u7652\u7387\u5927\u591a\u53ef\u9054\u4e5d\u6210\u4ee5\u4e0a\nC. DAA\u4e4b\u7642\u7a0b\u591a\u572812-24\u9031\nD. DAA\u4e4b\u526f\u4f5c\u7528\u8f03\u5c11\u4e14\u8f15\u5fae\uff0c\u75c5\u4eba\u4e4b\u9806\u5f9e\u6027\u9ad8\nE. DAA\u8207\u5176\u5b83\u85e5\u7269\u5f88\u5c11\u6709drug interaction\n": "(E)", "107-4.\n\u4e0b\u5217\u5404\u9805\u4f55\u8005\u975e\u80c3\u817a\u764c(gastric adenocarcinoma)\u4e4b\u5371\u96aa\u56e0\u5b50(risk factors)\uff1f(1). Peutz-Jeghers syndrome (2). hereditary hemorrhagic telangiectasia (3). Helicobacter pylori infection (4). subtotal gastrectomy (5). drinking\nA. (1)+(4)+(5)\nB. (2)+(5)\nC. (3)+(4)\nD. (4)+(5)\nE. (2)+(3)\n": "(B)", "107-5.\n\u6162\u6027B\u578b\u809d\u708e\u73fe\u5728\u5df2\u6709\u8a31\u591a\u5177\u7279\u7570\u7642\u6548\u4e4b\u85e5\u7269\u53ef\u7528\u4f86\u63a7\u5236\u75c5\u60c5\uff0c\u4e0b\u5217\u76f8\u95dc\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f (1). PEG IFN \u6709\u76f8\u7576\u4e0d\u932f\u7684\u7642\u6548(\u8840\u6e05 e \u6297\u539f\u8f49\u63db\u6210 e \u6297\u9ad4\uff0c\u4e14 ALT\u503c\u6062\u5fa9\u6b63\u5e38)\uff0c\u4f46\u5fa9\u767c\u7387\u905440% (2). PEG IFN \u4e0d\u80fd\u7528\u65bc decompensated patients (3). \u53e3\u670d\u6297B\u809d\u75c5\u6bd2\u85e5\u7269 (nucleot(s)ide analogues) \u526f\u4f5c\u7528\u5c11\u4e14\u5c0f\uff0c\u4f46\u7642\u7a0b\u9577\u77ed\u4e0d\u80fd\u4e8b\u524d\u78ba\u5b9a (4). \u8840\u6e05 HBeAg (-)\u3001HBV DNA < 1,000 IU/mL\u3001ALT\u503c\u6b63\u5e38\u4e14\u7121\u809d\u786c\u5316\u4e4b\u75c5\u4eba\uff0c\u4e0d\u5efa\u8b70\u63a5\u53d7\u6cbb\u7642 (5). \u5df2\u6709\u809d\u786c\u5316\u4e4bB\u809d\u75c5\u4eba\u7686\u61c9\u63a5\u53d7\u7279\u7570\u6027\u6cbb\u7642 (6). cytotoxic chemotherapy\r\u53ef\u80fd\u5c0e\u81f4\u672c\u4f86\u4e0d\u6d3b\u52d5\u7684\u6162\u6027B\u578b\u809d\u708e\u51fa\u73fe\u6025\u6027\u767c\u4f5c\uff0c\u76ee\u524d\u5efa\u8b70\u65bc\u6cbb\u7642\u671f\u9593\u5bc6\u5207\u8ffd\u8e64B\u809d\u75c5\u60c5\uff0c\u4e00\u65e6\u767c\u751f\u6025\u6027\u767c\u4f5c\u518d\u958b\u59cb\u4f7f\u7528\u53e3\u670d\u6297B\u809d\u75c5\u6bd2\u85e5\u7269\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)+(6)\nE. (1)+(4)+(5)+(6)\n": "(C)", "107-6.\n\u95dc\u65bc\u81bd\u56ca\u75be\u75c5\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f (1). porcelain gallbladder \u4e00\u822c\u5efa\u8b70\u63a5\u53d7 cholecystectomy (2). gallbladder polyp > 10 mm \u4f75\u6709 gallstones\uff0c\u5373\u4f7f\u6c92\u6709\u75c7\u72c0\uff0c\u4ecd\u61c9\u8003\u616e\u63a5\u53d7 cholecystectomy (3). pure cholesterol gallstones \u7686\u53ef\u7528UDCA (ursodeoxycholic acid) \u5c07\u4e4b\u5b8c\u5168\u6d88\u9664 (4). \u76f4\u5f91\u5927\u65bc3\u516c\u5206\u4e4b gallstones\uff0c\u7947\u8981\u6c92\u6709\u75c7\u72c0\uff0c\u4e0d\u5fc5\u63a5\u53d7 cholecystectomy (5). 60 \u6b72\u4ee5\u5f8c\u624d\u767c\u751f gallstone\uff0c\u8f03\u6703\u51fa\u73fe\u75c7\u72c0\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(3)+(4)\n": "(A)", "107-7.\n\u4e0b\u5217\u5404\u9805\u95dc\u65bc\u98df\u9053\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. esophageal diverticulum \u901a\u5e38\u56e0\u4f75\u6709\u5176\u5b83\u98df\u9053\u72c0\u6cc1(\u5982\uff1aachalasia) \u624d\u6703\u51fa\u73fe\u75c7\u72c0\uff0c\u8207\u5176\u5927\u5c0f\u7121\u95dc\nB. \u7a4d\u6975\u4f7f\u7528PPI therapy \u53ef\u660e\u986f\u6e1b\u5c11 Barrett's esophagus \u884d\u751f adenocarcinoma \u4e4b\u6a5f\u7387\nC. Barrett's esophagus with high-grade dysplasia \u61c9\u8003\u616e\u4ee5endoscopic mucosal resection\u3001radiofrequency ablation \u6216 photodynamic therapy \u9664\u53bb\u4e4b\nD. \u98df\u9053\u7684 motor disorders \u53ca diverticula \u53ef\u80fd\u6703\u5c0e\u81f4 Candida esophagitis\nE. \u98df\u9053\u7684 hypotensive disorders \u53ef\u80fd\u6703\u52a0\u91cd gastroesophageal reflux disease\n": "(B)", "107-8.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u809d\u529f\u80fd\u7570\u5e38\u6c42\u91ab\uff0c\u5176\u62bd\u8840\u6578\u503c\u5982\u4e0b\uff1aAST (GOT) = 80 (< 31) U/L\uff0cALT (GPT) = 70 (< 41) U/L\uff0cALP = 450 (< 104) U/L\uff0cGGT = 400 (< 64) U/L\uff0cBil(T) = 0.9 (< 1.0) mg/dL\uff0cBil(D) = 0.2 (< 0.18) mg/dL\u3002\u6700\u8fd13\u500b\u6708\u4ed6\u611f\u5230\u5026\u6020\uff0c\u4f46\u81ea1\u5e74\u524d\u958b\u59cb\u5373\u4e0d\u5b9a\u6642\u6709\u8179\u7009\uff0c\u6709\u6642\u6df7\u6709\u8840\u4fbf\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u7121\u7570\u5e38\u767c\u73fe\uff1b\u96fb\u8166\u65b7\u5c64\u4ea6\u672a\u767c\u73fe\u809d\u3001\u81bd\u3001\u80f0\u816b\u7624\uff0c\u4ea6\u7121\u809d\u5167\u81bd\u7ba1\u53ca\u809d\u5916\u81bd\u7ba1\u7570\u5e38\u64f4\u5927\u73fe\u8c61\uff1b\u4f46\u78c1\u632f\u9020\u5f71 (MRI + MRCP)\u5247\u986f\u793a\u7b26\u5408\u539f\u767c\u6027\u786c\u5316\u6027\u81bd\u7ba1\u708e\u4e4b\u8868\u73fe (primary sclerosing cholangitis)\u3002\r\u5c0d\u9019\u4f4d\u75c5\u4eba\uff0c\u76ee\u524d\u6700\u8feb\u5207\u9700\u8981\u5b89\u6392\u7684\u6aa2\u67e5\u70ba\u4e0b\u5217\u4f55\u8005\uff1f\nA. Liver biopsy\nB. Endoscopic ultrasound (EUS)\nC. Endoscopic retrograde cholangiopancreatography (ERCP)\nD. Colonoscopy\nE. Serum IgG4 measurement\n": "(D)", "107-9.\n\u4e00\u4f4d40\u6b72\u5973\u6027\u75c5\u4eba\u70ba\u6162\u6027B\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u8005\uff0c\u5728\u9580\u8a3a\u8ffd\u8e64\u4e2d\u88ab\u767c\u73fe\u6709\u8179\u6c34\uff0c\u4e14\u9010\u6f38\u8b8a\u591a\uff0c\u6162\u6162\u7684\u5169\u908a\u5c0f\u817f\u53ca\u8173\u80cc\u4e5f\u51fa\u73fe\u6c34\u816b\uff0c\u76ee\u524d\u6c92\u6709exertional dyspnea\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u5169\u908a\u9838\u975c\u8108\u660e\u986f\u8139\u5927\uff0c\u5fc3\u81df\u7121\u96dc\u97f3\u3002\u8179\u90e8\u5fae\u8139\uff0c\u6572\u4e4b\u6709shifting dullness\u3002\u5169\u908a\u4e0b\u80a2\u6709pitting edema\u3002\u8840\u6db2\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aAlbumin = 3.5 ( > 3.5) g/dL\uff0cAST = 25 (< 31) U/L\uff0c ALT = 30 (< 41) U/L\uff0cBil(T) = 0.9 (< 1.0) mg/dL\uff0cProthrombin time = 10.0\" (INR = 0.99)\uff0cPlatelet = 175 (> 150) K/ul\u3002\u8179\u6c34\u62bd\u53d6\u9001\u9a57\u4e4b\u7d50\u679c\u70ba Albumin = 2.3 g/dL\uff0cTotal protein = 3.5 g/dL\uff0c WBC =\r120/uL\uff0cneutrophil 30%\u3002\r\u9019\u4f4d\u75c5\u4eba\u8179\u6c34\u6700\u53ef\u80fd\u7684\u75c5\u56e0\u70ba\u4e0b\u5217\u4f55\u8005\uff1f\nA. Postnecrotic cirrhosis\nB. Alcoholic cirrhosis\nC. Tuberculous peritonitis\nD. Constrictive pericarditis\nE. Congestive heart failure\n": "(D)", "107-10.\n\u4e00\u4f4d\u6162\u6027C\u578b\u809d\u708e\u4f75\u6709\u809d\u786c\u5316\u7684\u60a3\u8005\u56e0\u610f\u8b58\u4e0d\u6e05\u800c\u5165\u9662\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8179\u90e8\u8139\u5927\u4e14\u6709shifting dullness\uff0c\u53f3\u80f8\u4e0b\u534a\u547c\u5438\u97f3\u807d\u4e0d\u898b\uff0c\u5169\u5074\u4e0b\u80a2\u6709pitting edema\u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aAmmonia N (NH3) = 130 (< 37) umol/L\uff0cAlbumin = 2.4 (> 3.5) g/dL\uff0cAST = 50 ( < 31) U/L\uff0cALT = 35 (<41) U/L\uff0cBil(T) = 1.5 (< 1.0) mg/dL\uff0cBil(D) = 0.8 (<0.18) mg/dL\uff0cNa = 125 (> 135) mmol/L\uff0c Cr = 1.6 (<1.3) mg/dL (\u672c\u75c5\u4eba\u904e\u53bb\u2266 1.2 mg/dL)\uff0cBUN = 40 (< 25) mg/dL\uff0cPT = 13.0\" (INR = 1.25)\u3002\u62bd\u53d6\u8179\u6c34\u9001\u7d50\u679c\u5982\u4e0b\uff1aAlb = 1.0 g/dL\uff0cWBC = 900\r/ul\uff0cneutrophil\u4f5470%\u3002\u4e0b\u5217\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u5408\u5b9c\u7684\uff1f (1). intravenous cefotaxime (2). 3% saline solution (3). albumin infusion (4). lactulose (5). anticholinergic agent\nA. (1)+(3)+(4)\nB. (1)+(4)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (2)+(4)+(5)\n": "(A)", "107-11.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u7a81\u767c\u53f3\u4e0a\u8179\u75db\u53ca\u767c\u71d2\u800c\u9001\u81f3\u6025\u8a3a\u5ba4\uff0c\u904e\u53bb\u5076\u800c\u6703\u6709\u53f3\u4e0a\u8179\u75db\u4e4b\u75c5\u60c5\u3002\u5176\u9ad4\u6eab\u9ad8\u905439.0C\uff0c\u8108\u640f\u6578\u70ba105\u4e0b/\u5206\u9418\uff0c\u8840\u58d3120/80 mmHg\uff0c\u978f\u819c\u53ca\u76ae\u819a\u6cdb\u9ec3\uff0c\u53f3\u4e0a\u8179\u90e8\u6709\u58d3\u75db\uff0c\u7121shifting dullness\u3002\u62bd\u8840\u6aa2\u9a57\u4e4b\u7d50\u679c\u5982\u4e0b\uff1aWBC = 15,000/ ul\uff0cSeg. 85%\uff0cAST = 250 (<31) U/L\uff0cALT = 220 (<41) U/L\uff0cALP = 220 (<104) U/L\uff0cGGT = 300 (< 64) U/L\uff0cBil(T) = 5.0 (< 1.0) mg/dL\uff0cBil(D) = 3.4 (< 0.18)\rmg/dL\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u809d\u5167\u81bd\u7ba1\u53ca\u8fd1\u7aef\u7e3d\u81bd\u7ba1\u8139\u5927\uff0c\u4f46\u9060\u7aef\u7e3d\u81bd\u7ba1\u88ab\u8178\u6c23\u906e\u4f4f\u800c\u770b\u4e0d\u5230\uff0c\u4e3b\u80f0\u7ba1\u76f4\u5f91\u6b63\u5e38\u3002\u81bd\u56ca\u5167\u6709\u7d50\u77f3\uff0c\u4f46\u81bd\u56ca\u58c1\u6b63\u5e38\u4e14\u81bd\u56ca\u5468\u570d\u6c92\u6709\u7570\u5e38\u6db2\u9ad4\u3002\u91dd\u5c0d\u75c5\u4eba\u76ee\u524d\u75c5\u60c5\uff0c\u4e0b\u5217\u5404\u9805\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u8feb\u5207\u4e14\u5408\u5b9c\u7684\uff1f (1). Endoscopic retrograde cholangiopancreatography (ERCP) (2). Percutaneous cholecystostomy (3). Cholecystectomy (4). Percutaneous transhepatic cholangiography & drainage (PTCD) (5). Intravenous broad-spectrum antibiotics\nA. (1)+(2)\nB. (2)+(4)\nC. (1)+(5)\nD. (3)+(4)\nE. (3)+(5)\n": "(C)", "107-12.\n22\u6b72\u7537\u6027\u670910\u5e74\u80f8\u9aa8\u5f8c\u707c\u71b1\u611f(retrosternal burning)\u75c5\u53f2\uff0c\u61f7\u7591\u80c3\u98df\u9053\u9006\u6d41\u75be\u75c5\uff0c\u96d6\u7136\u65e9\u9910\u524d30\u5206\u9418\u7d66\u4e88omeprazole 20mg\uff0c\u4e5f\u907f\u514d\u523a\u6fc0\u6027\u98df\u7269\uff0c\u4e14\u7761\u89ba\u6642\u6795\u982d\u588a\u9ad8\uff0c\u4f46\u662f\u707c\u71b1\u611f\u53ca\u9006\u6d41\u4ecd\u6301\u7e8c\u3002\u6700\u8fd12\u5e74\u56fa\u9ad4\u98df\u7269\u6709\u541e\u56a5\u56f0\u96e3(dysphagia)\u73fe\u8c61\uff0c\u4f46\u4e26\u7121\u9ad4\u91cd\u6e1b\u8f15\u3002\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\u98df\u9053\u5207\u7247\u6b63\u5e38\uff0c\u56e0\u75c7\u72c0\u6301\u7e8c\u63a5\u53d7\u98df\u9053high-resolution manometry\u6aa2\u67e5\u7d50\u679c\u5982\u9644\u8868\u6240\u793a\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u5408\u9069\u4e4b\u6cbb\u7642\uff1f\nA. 360\u5ea6Nissen fundoplication\nB. Heller myotomy & partial fundoplication\nC. omeprazole\u6539\u621020mg bid\nD. omeprazole\u63db\u6210esomeprazole\nE. omeprazole\u63db\u6210nortriptyline\n": "(B)", "107-13.\n60\u6b72\u80a5\u80d6\u7537\u6027\u6709\u9577\u671f\u80f8\u53e3\u707c\u71b1\u75c5\u53f2\uff0c\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u5176\u98df\u9053\u4e0b\u7aef\u4e4b\u8b8a\u5316\u5982\u5716\u6240\u793a\uff0c\u6b64\u75c5\u4eba\u6bcf\u5e74\u767c\u751f\u98df\u9053\u764c\u4e4b\u6a5f\u6703\u70ba\uff1f\nA. 0.01~0.03%\nB. 0.1~0.3%\nC. 0.6~1%\nD. 1~3%\nE. 3~5%\n": "(B)", "107-14.\n\u80c3\u58c1\u7d30\u80de(gastric parietal cell)\u975c\u614b\u53ca\u523a\u6fc0\u72c0\u614b\u5982\u5716\u793a\uff0c\u6839\u64da\u6b64\u5716\uff0c\u4e0b\u5217\u90a3\u9805\u85e5\u7269\u70ba\u6700\u5f37\u80c3\u9178\u6291\u5236\u5291\uff1f\nA. famotidine\nB. hyoscine butylbromide\nC. lansoprazole\nD. dexlansoprazole\nE. vonoprazan\n": "(E)", "107-15.\n\u4e0b\u5217\u6709\u95dc\u81bd\u9178(bile acid)\u53ca\u5176\u8178\u809d\u5faa\u74b0(enterohepatic circulation)\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u662f\uff1f (1). \u81bd\u9178\u4e3b\u8981\u7531\u98f2\u98df\u800c\u4f86 (2). chenodoxycholic acid\u70ba\u6b21\u7d1a\u81bd\u9178 (3). \u81bd\u9178\u5206\u6ccc\u5f8c\u4e3b\u8981\u65bc\u8ff4\u8178(ileum)\u5438\u6536 (4). \u963b\u65b7\u81bd\u9178\u4e4b\u8178\u809d\u5faa\u74b0\u53ef\u6e1b\u5c11\u8840\u4e2d\u81bd\u56fa\u9187\u503c (5).\u81bd\u9178\u6392\u6cc4\u7570\u5e38\u53ef\u9020\u6210\u8102\u80aa\u4fbf(steatorrhea)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(3)+(5)\n": "(C)", "107-16.\n\u4e0b\u5217\u6709\u95dc\u767c\u708e\u6027\u8178\u9053\u75be\u75c5(inflammatory bowel disease)\u4e4b\u6d41\u884c\u75c5\u5b78\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\uff1f (1). \u767d\u4eba\u8f03\u4e9e\u6d32\u4eba\u767c\u751f\u7387\u70ba\u9ad8 (2). \u62bd\u7159\u53ef\u9810\u9632\u514b\u9686\u6c0f(Crohn's disease) (3). \u76f2\u8178\u5207\u9664(appendectomy)\u53ef\u589e\u52a0\u6f70\u760d\u6027\u8178\u708e(ulcerative colitis)\u767c\u751f\u7387 (4). \u65e9\u5e74\u4f7f\u7528\u6297\u751f\u7d20\u53ef\u589e\u52a0\u6f70\u760d\u6027\u8178\u708e\u767c\u751f\u7387 (5). \u7336\u592a\u4eba\u7684\u767c\u751f\u7387\u5168\u7403\u6700\u9ad8\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (2)+(4)\n": "(B)", "107-17.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u767c\u708e\u6027\u8178\u9053\u75be\u75c5\u5e38\u898b\u7684\u8178\u9053\u5916\u8868\u73fe(extraintestinal manifestation)\uff1f\nA. erythema nodosum\nB. ankylosing spondylitis\nC. uveitis\nD. primary biliary cirrhosis\nE. metabolic bone disorders\n": "(D)", "107-18.\n\u6709\u95dc\u5927\u8178\u61a9\u5ba4\u75c7(Diverticulosis)\u4e4b\u6558\u8ff0\u4f55\u8005\u70ba\u662f\uff1f (1). \u4e9e\u6d32\u4eba70%\u7684\u61a9\u5ba4\u767c\u751f\u65bc\u53f3\u5074\u5927\u8178 (2). 60\u6b72\u4ee5\u4e0a\u7684\u75c5\u4eba\u4e0b\u6d88\u5316\u9053\u51fa\u8840(hematochezia\u8868\u73fe\u70ba\u4e3b)\u6700\u5e38\u898b\u7684\u75c5\u56e0\u70ba\u61a9\u5ba4\u51fa\u8840 (3). \u61a9\u5ba4\u708e\u7684\u8a3a\u65b7\u4ee5\u5927\u8178\u93e1\u70ba\u4e3b (4). \u61a9\u5ba4\u708e\u7684\u6cbb\u7642\u4ee5\u624b\u8853\u70ba\u4e3b (5). \u542bLactobacillus acidophilus\u548cbifidobacterium strains\u4e4bprobiotics\u53ef\u6709\u6548\u9810\u9632\u61a9\u5ba4\u708e\u7684\u5fa9\u767c\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(2)+(5)\nE. (2)+(4)+(5)\n": "(D)", "107-19.\n\u6709\u95dc\u5927\u8178\u764c\u5728\u53f0\u7063\u7684\u73fe\u6cc1\uff0c\u4f55\u8005\u70ba\u932f\uff1f\nA. \u6574\u9ad4\u767c\u751f\u7387\u9ad8\u5c45\u764c\u75c7\u7b2c\u4e00\u4f4d\nB. \u6574\u9ad4\u6b7b\u4ea1\u7387\u9ad8\u5c45\u764c\u75c7\u7b2c\u4e00\u4f4d\nC. \u5168\u570b\u6027\u7be9\u6aa2\u70ba50\u6b72\u4ee5\u4e0a\u6bcf\u4e8c\u5e74\u4e00\u6b21\u7cde\u4fbf\u6aa2\u67e5\nD. \u7cde\u4fbf\u6aa2\u67e5\u4ee5\u514d\u75ab\u6cd5\u70ba\u4e3b\nE. \u7be9\u6aa2\u5df2\u6709\u6548\u964d\u4f4e\u6b7b\u4ea1\u7387\n": "(B)", "107-20.\n\u6709\u95dcGilbert's syndrome\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f?\nA. \u4ee5\u8f15\u5ea6conjugated hyperbilirubinemia\u70ba\u4e3b\u8981\u8868\u73fe\nB. \u5927\u90e8\u5206\u500b\u6848\u4e4bbilirubin< 3mg/dL\nC. \u53ef\u56e0\u58d3\u529b\u3001\u559d\u9152\u7b49\u56e0\u7d20\u800c\u8b93bilirubin\u66f4\u9ad8\nD. \u4e3b\u56e0\u70baUGT1A1\u6d3b\u6027\u6e1b\u5c11\nE. \u6b64\u7a2e\u500b\u6848\u4f7f\u7528irinotecan\u8f03\u6613\u767c\u751fintractable diarrhea\u53camyelosuppression\u7684\u526f\u4f5c\u7528\n": "(A)", "107-21.\n\u6709\u95dc\u75c5\u6bd2\u6027\u809d\u708e\u7684\u809d\u5916\u8868\u73fe(extrahepatic manifestation),\u4f55\u8005\u932f\u8aa4\uff1f\nA. serum sickness-like syndrome\u597d\u767c\u65bc\u6162\u6027B\u578b\u809d\u708e\nB. immune-complex glomerulonephritis\u53ef\u898b\u65bc\u6162\u6027C\u578b\u809d\u708e\nC. mixed cryoglobulinemia\u53ef\u898b\u65bc\u6162\u6027B\u578b\u809d\u708e\nD. C\u578b\u809d\u708e\u8840\u4e2d\u7684immune complex\u5167\u542bHCV-RNA\nE. polyarteritis nodosa\u53ef\u898b\u65bc\u6162\u6027B\u578b\u809d\u708e\n": "(A)", "107-22.\n\u4e0b\u5217B\u578b\u809d\u708e\u7684\u6cbb\u7642\u85e5\u7269\uff0c\u4f55\u8005\u7522\u751f\u75c5\u6bd2\u6297\u85e5\u6027\u7684\u6a5f\u6703\u6700\u9ad8\uff1f\nA. PEG IFN\nB. lamivudine\nC. adefovir\nD. entecavir\nE. telbivudine\n": "(B)", "108-1.\n\u95dc\u65bcacute intestinal obstruction\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1)Hyperparathyroidism\u53ef\u80fd\u9020\u6210ilues (pseudo-obstruction)\uff1b(2)Hypokalemia \u53cahypomagnesemia\u53ef\u80fd\u9020\u6210ilues\uff1b(3)\u8179\u8154\u93e1\u624b\u8853\u4e0d\u53ef\u80fd\u9020\u6210obstructive adhesion\uff1b(4)Bezoars\u53ef\u80fd\u9020\u6210acute intestinal obstruction\uff1b(5)Ileus\u767c\u751f\u6642\uff0c\u75c5\u4eba\u901a\u5e38\u6703\u6709\u8179\u8139\u3001\u7d5e\u75db\u53ca\u53b2\u5bb3\u7684\u5614\u5410\uff1b(6)\u9060\u7aef\u5927\u8178\u767c\u751f\u6025\u6027\u963b\u585e\u6642\uff0c\u7ad9\u7acb\u7684plain films of the abdomen\u6703\u986f\u793aair-fluid levels\u65bc\u5927\u8178\u548c\u5c0f\u8178\u4e2d\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (2)+(4)+(5)\nD. (3)+(5)+(6)\nE. (4)+(5)+(6)\n": "(B)", "108-2.\n\u4e0b\u5217\u4f55\u8005\u662f\u80c3\u817a\u764c(gastric adenocarcinoma)\u4e4b\u5371\u96aa\u56e0\u5b50\uff1f(1)Alcoholism\uff1b(2)Helicobacter pylori infection\uff1b(3)Diet high in salted and preserved food\uff1b(4)Subtotal gastrectomy\uff1b(5) Hereditary hemorrhagic telangiectasia\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (2)+(3)+(5)\nE. (3)+(4)+(5)\n": "(C)", "108-3.\n\u4e00\u4f4d20\u6b72B\u578b\u809d\u708e\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\uff0c\u5176\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1a\rHBsAg (+), HBeAg (+), ALT: 48 (\u226641), AST: 31 (\u226631), Bilirubin (T)/(D)=1.8/0.3 mg/dL, Albumin: 4.1 g/dL (\u22673.5), Prothrombin time (PT) INR= 1.0 (0.8~1.2) \u3002\u4e0b\u5217\u4f55\u8005\u662f\u76ee\u524d\u6700\u5408\u5b9c\u7684\u8655\u7f6e\uff1f\nA. \u61c9\u7acb\u5373\u5b89\u6392\u809d\u5207\u7247 (liver biopsy)\u4ee5\u77ad\u89e3\u75c5\u60c5\nB. \u6bcf2~3\u500b\u6708\u5b9a\u671f\u8ffd\u8e64\u8840\u6e05ALT \u53ca AST\u5373\u53ef\nC. \u82e5\u8840\u6e05HBV viral load \u90541,000,000 IU/mL, \u61c9\u958b\u59cb\u4ee5\u5e72\u64fe\u7d20\u6ce8\u5c04\u6cbb\u7642\nD. \u82e5\u8840\u6e05HBV viral load \u9054100,000 IU/mL, \u61c9\u958b\u59cb\u4ee5\u53e3\u670d\u6291\u5236B\u809d\u75c5\u6bd2\u4e4b\u85e5\u7269\u6cbb\u7642\nE. \u61c9\u5118\u5feb\u5b89\u6392\u6aa2\u67e5\u4ee5\u91d0\u6e05\u963b\u585e\u6027\u9ec3\u75b8\u4e4b\u539f\u56e0\n": "(B)", "108-4.\n\u4e0b\u5217\u6709\u95dc\u809d\u786c\u5316\u53ca\u5176\u4f75\u767c\u75c7\u4e4b\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u809d\u786c\u5316\u75c5\u4eba\u5df2\u5728\u53e3\u670dLactulose\uff0c\u4ecd\u4e00\u518d\u767c\u751f\u809d\u8166\u75c5\u8b8a (hepatic encephalopathy)\uff0c\u4f46\u627e\u4e0d\u5230\u4efb\u4f55\u8a98\u767c\u56e0\u7d20\uff0c\u6b64\u6642\u7d66\u4e88\u670d\u7528Rifaximin\u53ef\u6e1b\u5c11\u767c\u4f5c\u6a5f\u7387\nB. \u809d\u786c\u5316\u4f75\u809d\u9580\u8108\u9ad8\u58d3\u75c5\u4eba\u53ef\u80fd\u51fa\u73feplatypnea \u53ca orthodeoxia \u4e4b\u75c7\u72c0\nC. \u809d\u786c\u5316\u4f75\u809d\u9580\u8108\u9ad8\u58d3\u75c5\u4eba\u53ef\u80fd\u4f75\u767c\u80ba\u52d5\u8108\u9ad8\u58d3\uff0c\u61c9\u5148\u5617\u8a66\u4ee5prostacyclin analogues\u6216endothelin antagonists\u6cbb\u7642\u4e4b\nD. \u8179\u6c34\u75c5\u56e0\u4e4b\u9451\u5225\u8a3a\u65b7\u6709\u8cf4\u62bd\u53d6\u8179\u6c34\u9001\u53bb\u6aa2\u9a57Albumin\u6578\u503c\uff0c\u4e26\u8207\u8840\u6e05Albumin\u6578\u503c\u505a\u6bd4\u8f03\uff0c\u82e5\u8840\u6e05Albumin < 2.5 g/dL\uff0c\u4e14Serum-Ascites Albumin Gradient (SAAG) < 1.1 g/dL\uff0c\u61c9\u8003\u616e\u764c\u75c7\u8f49\u79fb\u81f3\u8179\u819c\u9020\u6210\u4e4b\u8179\u6c34\nE. Type I hepatorenal syndrome\u61c9\u4ee5vasoconstrictor\u4f75Albumin\u6cbb\u7642\n": "(D)", "108-5.\nC\u578b\u809d\u708e\u4e4b\u6cbb\u7642\u5df2\u6709\u7a81\u7834\u6027\u9032\u5c55\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u53f0\u7063\u5065\u4fdd\u5df2\u6709\u7d66\u4ed8Direct Acting Anti-virals (DAAs)\u7528\u65bc\u6cbb\u7642\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\nB. \u53f0\u7063\u4f7f\u7528DAAs\u6cbb\u7642\u6162\u6027C\u578b\u809d\u708e\u75c5\u4eba\u4e4bC\u809d\u75c5\u6bd2\u6839\u9664\u7387(SVR12: Sustained Virologic Response 12 weeks after end of treatment)\u9ad8\u9054\u4e5d\u6210\u4e94\u4ee5\u4e0a\nC. \u73fe\u5728\u7947\u8981\u8840\u4e2d\u6e2c\u5f97\u5230C\u578b\u809d\u708e\u75c5\u6bd2\uff0c\u5373\u53ef\u670d\u7528\u5065\u4fdd\u7d66\u4ed8\u4e4bDAAs\nD. DAAs\u4e4b\u7642\u7a0b\uff0c\u4e00\u822c\u7947\u89818\u9031~12\u9031\nE. \u76ee\u524d\u5065\u4fdd\u6709\u7d66\u4ed8\u4e4bHarvoni (Sofosbuvir+Ledipasvir) \u53ca Epclusa (Sofosbuvir+Velpatasvir)\u5169\u7a2eDAAs\uff0c\u4e0d\u5b9c\u7528\u65bc\u5931\u4ee3\u511f\u6027\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\n": "(E)", "108-6.\n\u6703\u4fc3\u4f7f\u55ae\u7d14\u8102\u80aa\u809d\u4e4b\u75c5\u60c5\u60e1\u5316\uff0c\u671d\u975e\u9152\u7cbe\u6027\u8102\u80aa\u809d\u708e (Non-Alcoholic Steatohepatitis, NASH)\u9032\u884c\u4e4b\u5371\u96aa\u56e0\u5b50\uff0c\u5305\u62ec\u4e0b\u5217\u5404\u9805\uff0c\u4f55\u8005\u4e0d\u662f\uff1f\nA. \u80a5\u80d6\nB. \u80f0\u5cf6\u7d20\u6297\u6027 (insulin resistance)\nC. \u65b0\u9673\u4ee3\u8b1d\u75c7\u5019\u7fa4 (metabolic syndrome)\nD. \u8840\u8102\u7570\u5e38 (dyslipidemia)\nE. \u9ad8\u8840\u58d3\n": "(E)", "108-7.\n\u95dc\u65bcUlcerative Colitis (UC) \u548cCrohn's Disease (CD) \u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u5404\u9805\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8f03\u5e38\u898b\u5230gross blood in stool \u7684\u662fUC\nB. \u6703\u5f62\u6210 enterocutaneous fistula \u7684\u662f CD\nC. \u53ef\u80fd\u6478\u5230\u53f3\u4e0b\u8179\u90e8\u6709 mass formation \u7684\u662f UC\nD. \u6703\u9020\u6210 small bowel obstruction \u7684\u662f CD\nE. \u6703\u9020\u6210 colon obstruction \u7684\u662f CD\n": "(C)", "108-8.\n\u95dc\u65bcCrohn's Disease \u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7d04\u6709 10% \u6703\u9020\u6210 colon stricture\uff0c\u4f46\u5728\u5927\u8178\u93e1\u6aa2\u67e5\u78b0\u5230\u72f9\u7a84\u800c\u904e\u4e0d\u53bb\u6642\uff0c\u4ecd\u9700\u6392\u9664\u5927\u8178\u764c\u4e4b\u53ef\u80fd\u6027\nB. \u6700\u5e38\u4fb5\u72af\u4e4b\u90e8\u4f4d\u662f terminal ileum\nC. \u670910~20% \u6703\u6709\u9ad4\u91cd\u6e1b\u8f15\u7684\u60c5\u6cc1\nD. \u53ef\u80fd\u9020\u6210 fistula (\u5982\uff1aenterocutaneous \u3001enterovesical)\nE. \u5e38\u6703\u9020\u6210 perforation of intestine\u5c0e\u81f4\u8179\u8154\u5167\u6709\u660e\u986f\u4e4b\u6e38\u96e2\u7a7a\u6c23\n": "(E)", "108-9.\n\u4e0b\u5217\u6709\u95dc\u80f0\u81df\u708e\u4e4b\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6162\u6027\u80f0\u81df\u708e\u75c5\u4eba\uff0c\u8840\u6e05 amylase \u53ca lipase \u6578\u503c\u901a\u5e38\u4e0d\u6703\u7570\u5e38\u5347\u9ad8\nB. \u521d\u671f\u6162\u6027\u80f0\u81df\u708e\uff0c\u53ef\u80fd\u9023\u5f71\u50cf\u6aa2\u67e5\u90fd\u770b\u4e0d\u51fa\u4f86\uff0c\u6b64\u6642\u53ef\u7528 fecal elastase test \u5354\u52a9\u5224\u65b7\nC. \u660e\u986f\u4e0a\u8179\u75db\u7591\u4f3c\u6025\u6027\u80f0\u81df\u708e\uff0c\u4f46\u8840\u6e05amylase \u6578\u503c\u6b63\u5e38\uff0c\u53ef\u80fd\u662fhypertriglyceridemia\u4e4b\u5e72\u64fe\nD. \u6162\u6027\u814e\u81df\u75c5\u60a3\u8005\u82e5\u88ab\u61f7\u7591\u6709\u6025\u6027\u80f0\u81df\u708e\uff0c\u61c9\u76f4\u63a5\u62bd\u8840\u6aa2\u9a57lipase\u4f86\u52a0\u4ee5\u5224\u65b7\nE. \u808b\u819c\u7a4d\u6c34\u88ab\u9a57\u51fa\u7570\u5e38\u5347\u9ad8\u4e4b amylase \u6578\u503c\uff0c\u6709\u53ef\u80fd\u662f\u80ba\u764c\u6240\u9020\u6210\n": "(B)", "108-10.\n\u6709\u95dc Hyperbilirubinemia \u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f(1)\u6eb6\u8840 (hemolysis) \u5c0e\u81f4\u7684 hyperbilirubinemia \u901a\u5e38 Bilirubin (total) \u2266 4 mg/dL, Bilirubin (direct) < 15%\uff1b(2)\u5927\u578b\u7684 hematoma \u53ef\u80fd\u5c0e\u81f4\u4ee5 direct (conjugated) bilirubin \u70ba\u4e3b\u7684 hyperbilirubinemia\uff1b(3)Megaloblastic anemia \u53ef\u80fd\u5c0e\u81f4 indirect (unconjugated) bilirubin \u70ba\u4e3b\u7684 hyperbilirubinemia\uff1b(4)Rotor syndrome \u75c5\u4eba\u6703\u51fa\u73fe tea-colored urine\uff1b(5)Dubin-Johnson syndrome \u75c5\u4eba\u4e4b hyperbilirubinemia \u901a\u5e38 \u2267 20 mg/dL\uff0c\u4e14\u4ee5 direct bilirubin \u70ba\u4e3b\uff1b(6)Gilbert's\rsyndrome\u5c0e\u81f4\u4e4bhyperbilirubinemia \u4ee5 indirect bilirubin \u70ba\u4e3b\uff0ctotal bilirubin \u901a\u5e38\u2266 4 mg/dL\uff0c\u670d\u7528 phenobarbital \u6703\u8b93 total bilirubin\uff0c\u964d\u81f3\u6b63\u5e38\u7bc4\u570d\nA. (2)+(3)+(4)\nB. (1)+(3)+(5)\nC. (4)+(5)+6)\nD. (3)+(6)\nE. (2)+(5)\n": "(E)", "108-11.\n\u95dc\u65bc\u5927\u8178\u76f4\u8178\u764c\u53ca\u5927\u8178\u606f\u8089\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\r(1) \u7d55\u5927\u591a\u6578\u5927\u8178\u76f4\u8178\u764c\u6e90\u81ea\u5927\u8178 adenomatous polyps\r(2) \u7d0430% adenomatous polyps \u6703\u884d\u751f\u5927\u8178\u76f4\u8178\u764c\r(3) tubular adenoma \u6bd4villous adenoma\u8f03\u6613\u8f49\u8b8a\u6210\u5927\u8178\u76f4\u8178\u764c\r(4) \u6709 adenomatous polyp \u7684\u75c5\u4eba\uff0c < 5%\u4e4b\u7cde\u4fbf\u6703\u51fa\u73fe\u6f5b\u8840\u4e4b\u967d\u6027\u53cd\u61c9\r(5) > 2.5 \u516c\u5206\u7684\u5927\u8178\u606f\u8089\uff0c\u6709 30% \u6703\u4f75\u6709 invasive cancer\r(6) \u5927\u8178\u606f\u8089\u7d93\u5207\u9664\u5f8c\uff0c\u5927\u591a\u6578\u4eba\u7d93\u904e 3 \u5e74\u5f8c\u518d\u63a5\u53d7\u8ffd\u8e64\u6027\u5927\u8178\u93e1\u6aa2\u67e5\u5373\u53ef\nA. (1)+(2)+(3)\nB. (2)+(4)+(5)\nC. (3)+(4)+(6)\nD. (2)+(3)+(5)\nE. (4)+(5)+(6)\n": "(D)", "108-12.\n55\u6b72\u5973\u60278\u5e74\u524d\u63a5\u53d7\u6e1b\u91cd\u7684\u7e5e\u9053\u624b\u8853\uff0c\u8853\u5f8c\u9ad4\u91cd\u6e1b\u5c1168kg\uff0c\u6700\u8fd1\u5e7e\u5e74\u4f86\u9ad4\u91cd\u7a69\u5b9a\uff0c\u4f46\u662f\u8853\u5f8c\u6709\u6162\u6027\u975e\u51fa\u8840\u6027\u8179\u7009\uff0c\u5bb9\u6613\u75b2\u5026\u3001\u53cd\u819a\u4e7e\u71e5\u3001\u773c\u775b\u4e7e\u7662\uff0c\u665a\u4e0a\u958b\u8eca\u770b\u4e0d\u6e05\u695a\u8def\u6a19\u7b49\u60c5\u5f62\u3002\u53e6\u5916\u56e0\u7cd6\u5c3f\u75c5\u548c\u9ad8\u8840\u58d3\u670d\u7528metformin\u53calisinopril\uff0c\u4e5f\u81ea\u884c\u670d\u7528\u591a\u7a2e\u7dad\u4ed6\u547d\u548c\u9435\u5291\uff0c5\u5e74\u524d\u7684\u5927\u8178\u93e1\u6aa2\u67e5\u6b63\u5e38\u3002\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3\u70ba140/79 mmHg\uff0c\u8108\u640f63/min\uff0cBMI:25\u3002\u8840\u6db2\u6aa2\u67e5Hb:10.5g/dL\uff0cMCV:95fL\u3002\u4e0b\u5217\u4f55\u7a2e\u71df\u990a\u7d20\u7f3a\u4e4f\u662f\u5c0e\u81f4\u6b64\u75c5\u60a3\u81e8\u5e8a\u8868\u73fe\u7684\u539f\u56e0?\nA. Copper\nB. Iron\nC. Vitamin A\nD. Vitamin B12\nE. Vitamin B1\n": "(C)", "108-13.\n57\u6b72\u5973\u6027\u63a5\u53d7\u7be9\u6aa2\u6027\u5927\u8178\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u5728\u5347\u7d50\u8178\u767c\u73fe\u4e00\u984612mm\u606f\u8089\uff0c\u5207\u9664\u5f8c\u75c5\u7406\u5831\u544a\u70baserrated polyp\u3002\u5979\u4e0b\u6b21\u5927\u8178\u93e1\u6aa2\u67e5\u7684\u6700\u9069\u7576\u6642\u9593\u70ba\u4f55?\nA. 1\u5e74\nB. 2\u5e74\nC. 3\u5e74\nD. 5\u5e74\nE. 10\u5e74\n": "(C)", "108-14.\n28\u6b72\u7537\u6027\u8179\u7009\u5df23\u5e74\uff0c\u6700\u8fd13\u500b\u6708\u611f\u5230\u75b2\u5026\uff0c\u7406\u5b78\u6aa2\u67e5\u986f\u793aBMI:24\uff0c\u6709\u809d\u81df\u816b\u5927\u4f46\u813e\u81df\u6c92\u6709\u816b\u5927\uff0c\u4e5f\u7121\u8179\u6c34\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5AST:87 U/L\uff0cALT:75 U/L\uff0cALP:456 U/L\uff0cBilirubin (T/D):1.2/0.4 mg/dL\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u809d\u5916\u81bd\u7ba1\u58c1\u589e\u539a\u4f46\u7121\u809d\u5167\u81bd\u7ba1\u64f4\u5f35\uff0cMRCP\u6aa2\u67e5\u7591\u4f3c\u539f\u767c\u786c\u5316\u6027\u81bd\u7ba1\u708e(primary sclerosing cholangitis)\uff0c\u8a66\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6aa2\u67e5\u5c0d\u75c5\u60c5\u91d0\u6e05\u6700\u6070\u7576?\nA. colonoscopy\nB. ERCP\nC. Liver biopsy\nD. Serum IgG4\nE. ANA\n": "(A)", "108-15.\n55\u6b72\u7537\u6027\u67098\u5e74\u5fc3\u707c\u71b1(heartburn)\u53ca\u80c3\u9178\u9006\u6d41(acid reflux)\uff0c\u6bcf\u65e5\u670d\u7528\u4e00\u9846pantoprazole\uff0c\u75c7\u72c0\u63a7\u5236\u826f\u597d\uff0c10\u9031\u524d\u56e0\u591c\u9593\u5fc3\u707c\u71b1\u800c\u63d0\u9ad8\u5291\u91cf\u81f3\u4e00\u65e5\u4e8c\u6b21\u3002\u75c5\u4eba\u78ba\u8a8d\u5728\u98ef\u524d30\u5206\u9418\u670d\u85e5\uff0c\u4f46\u75c7\u72c0\u4ecd\u53ea\u6709\u4e9b\u5fae\u6539\u5584\uff0c\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u7d50\u679c\u6b63\u5e38\uff0c\u63a5\u4e0b\u4f86\u61c9\u5b89\u6392\u4f55\u9805\u8655\u7f6e?\nA. Ambulatory pH impedance monitoring\nB. Barium esophagogram\nC. Esophageal manometry\nD. Abdominal computed tomography\nE. Fundoplication\n": "(A)", "108-16.\n63\u6b72\u7537\u6027\u6709\u4e09\u500b\u6708\u7f3a\u9ad4\u6027\u8ca7\u8840\u75c5\u53f2\uff0c\u63a5\u53d7\u904e\u4e8c\u6b21\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u53ca\u4e00\u6b21\u4e0b\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\u5747\u7121\u767c\u73fe\u80c3\u8178\u51fa\u8840\u75c5\u7076\uff0c\u75c5\u4eba\u56e0\u6162\u6027\u5fc3\u623f\u986b\u52d5\u670d\u7528diltiazem\u53cawarfarin\uff0c\u53e6\u5916\u4e5f\u53e3\u670d\u9435\u5291\uff0c\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3130/78 mmHg\uff0c\u8108\u640f80/min\uff0c\u547c\u543818/min\uff0c\u8840\u6db2\u6aa2\u67e5Hb:9.2 g/dL\uff0cINR:2.5\uff0c\u7cde\u4fbf\u6f5b\u8840\u53cd\u61c9\u5448\u73fe\u967d\u6027\uff0c\u61c9\u5b89\u6392\u4e0b\u5217\u4f55\u9805\u6aa2\u67e5\u4ee5\u9032\u4e00\u6b65\u8655\u7f6e?\nA. Angiography\nB. Capsule endoscopy\nC. Intraoperative endoscopy\nD. Technetium-labeled nuclear scan\nE. Abdominal computed tomogrphy\n": "(B)", "108-17.\n68\u6b72\u7537\u6027\u56e0\u4e0b\u80a2\u6c34\u816b\u53ca\u65b0\u767c\u751f\u7684\u8179\u6c34\u63a5\u53d7\u6aa2\u67e5\uff0c\u75c7\u72c0\u5728\u904e\u53bb4\u9031\u9010\u6f38\u52a0\u91cd\uff0c\u4ed6\u6709\u559d\u9152\u75c5\u53f2\uff0c8\u500b\u6708\u524d\u63a5\u53d7\u51a0\u72c0\u52d5\u8108\u7e5e\u9053\u624b\u8853\uff0c\u670d\u7528\u4f4e\u5291\u91cfaspirin\uff0catorvastatin\u53cametoprolol\u3002\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab36.8\u2103\uff0c\u8840\u58d3122/84 mmHg\uff0c\u8108\u640f64/min\uff0c\u547c\u543816/min\u3002\u5fc3\u81df\u6aa2\u67e5jugular venous presscure\u589e\u52a0\uff0c\u6709\u6b63\u5e38\u7684S1\u53caS2\u5fc3\u97f3\uff0c\u4e26\u7121\u5fc3\u96dc\u97f3\u3002\u80f8\u8154\u6aa2\u67e5\u6b63\u5e38\u8179\u90e8\u6aa2\u67e5\u6709\u809d\u816b\u5927\uff0cfluid wave\u5448\u73fe\u967d\u6027\uff0c\u4e0b\u80a2\u67092+\u7684pitting edema\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5albumin:3.5 g/dL\uff0cAST/ALT\u6b63\u5e38\u3002\u8179\u6c34\u6aa2\u67e5\u5982\u4e0b\uff1aWBC:120/ L\uff0c30%\u70baPMN\uff0calbumin:2.3g/dL\uff0c\u86cb\u767d\u7e3d\u91cf3.5g/dL\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba?\nA. Alcoholic cirrhosis\nB. Constrictive pericarditis\nC. Nonalcoholic cirrhosis\nD. Tuberculous peritonitis\nE. Spontaneous bacterial peritonitis\n": "(B)", "108-18.\n\u6709\u95dc\u80c3\u8178\u9593\u8cea\u7624(gastrointestinal stromal tumor-GIST)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u662f? (1)\u80c3\u6700\u5e38\u767c\u751f\uff0c\u7d04\u536070% (2)\u80c3\u7684\u9593\u8cea\u7624\u751f\u9577\u5feb\u901f (3)\u5e38\u6709K-ras\u57fa\u56e0\u7a81\u8b8a (4)\u816b\u7624\u5927\u5c0f\u548c\u9810\u5f8c\u7121\u95dc (5)\u9664\u624b\u8853\u5916\uff0c\u76ee\u524d\u6709tyrosine kinase inhititor\u53ef\u7528\u65bc\u6cbb\u7642\u8f49\u79fb\u6027GIST\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (1)+(5)\nE. (2)+(5)\n": "(D)", "108-19.\n\u6709\u95dcmultiple endocrine neoplasia(MEN)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e? (1)\u53ef\u5408\u4f75Zollinger-Ellison syndrome\u4e4b\u767c\u751f (2)parathyroid, pituitary\u548cpancreas\u662f\u816b\u7624\u5e38\u767c\u751f\u8655 (3)\u5c6cautosomal recessive\u907a\u50b3 (4)\u81e8\u5e8a\u8868\u73fe\u9664\u6d88\u5316\u6027\u6f70\u760d\u5916\uff0c\u53ef\u4ee5\u6709\u814e\u7d50\u77f3\u548c\u9ad8\u8840\u7cd6 (5)\u80c3\u548c\u5341\u4e8c\u6307\u8178\u6613\u767c\u751fneuroendocrine tumors\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (3)+(5)\nE. (2)+(5)\n": "(C)", "108-20.\n\u4e0b\u5217\u4f55\u7a2e\u80c3\u764c\u8f03\u4e0d\u9069\u5408\u505a\u5167\u8996\u93e1\u9ecf\u819c\u5207\u9664\u8853(endoscopic mucosal resection)?\nA. \u8178\u9053\u578b(intestinal type)\nB. \u5167\u8996\u93e1\u8d85\u97f3\u6ce2\u986f\u793a\u70bamucosal cancer\u4e14\u7121\u6dcb\u5df4\u7d50\u8f49\u79fb\nC. \u55ae\u4e00\u816b\u7624\nD. \u7a81\u8d77\u578b\u816b\u76242\u516c\u5206\nE. \u6f70\u760d\u7d50\u75a4\u4e4b\u51f9\u9650\u578b1.5\u516c\u5206\n": "(E)", "108-21.\n\u6709\u95dc\u5927\u8178\u61a9\u5ba4\u75c7\u4e4b\u6558\u8ff0\uff0c\u4ee5\u4e0b\u4f55\u8005\u70ba\u6b63\u78ba? (1)\u4f75\u767c\u75c7\u5305\u62ecAbscess\uff0cFistula\u53caPerforation (2)\u5728\u53f0\u7063\u5e38\u898b\u65bcsigmoid colon\u53caascending colon (3)\u4e00\u822cDiverticula\u767c\u751f\u65bcMesenteric\u53caAntimesenteric taeniae\u4e4b\u9593 (4)\u5927\u8178\u5167\u8996\u93e1\u70ba\u6700\u4f73\u4e4b\u8a3a\u65b7\u5de5\u5177 (5)\u5927\u8178\u764c\u4e4b\u81e8\u5e8a\u75c7\u72c0\uff0c\u8207\u6b64\u75c5\u6700\u4e0d\u50cf\uff0c\u4f46\u548c\u7f3a\u8840\u6027\u5927\u8178\u708e\u6700\u50cf\nA. (1)+(3)+(4)\nB. (1)+(2)+(3)\nC. (2)+(4)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(B)", "108-22.\n\u4e00\u4f4d60\u6b72\u5a66\u5973\uff0c\u4e3b\u8a34\u53f3\u4e0a\u8179\u75bc\u75db\u3001\u5641\u5fc3\u3001\u5614\u5410\u3001\u767c\u71d2\uff0c\u9019\u4e9b\u75c7\u72c0\u6301\u7e8c8\u5c0f\u6642\u3002\u8eab\u9ad4\u6aa2\u67e5\uff0c\u9ad4\u6eab39\u2103\uff0c\u8108\u640f105\u4e0b\uff0c\u8840\u58d3120/76\uff0c\u8179\u90e8\u6aa2\u67e5\u53f3\u4e0a\u8179\u6709\u58d3\u75db\uff0c\u53ef\u81f4\u547c\u5438\u505c\u6b62\uff0c\u5979\u6c92\u6709\u9ec3\u75b8\u3002\u4e0b\u5217\u5f71\u50cf\u5b78\u6aa2\u67e5\u7d50\u679c\uff0c\u4e0d\u50cf\u662f\u5979\u7684?\nA. \u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u81bd\u56ca\u58c1\u539a\uff0c\u5468\u570d\u6709\u6db2\u9ad4\u6eef\u7559\nB. \u96fb\u8166\u65b7\u5c64\u651d\u5f71\u986f\u793a\u81bd\u56ca\u816b\u8139\nC. \u6838\u91ab\u9020\u5f71(hepatobiliary scintigraphy)\u770b\u4e0d\u5230\u81bd\u56ca\nD. \u8179\u90e8X\u5149(KUB)\u53ef\u4ee5\u770b\u5230\u81bd\u56ca\u5167\u6709\u7a7a\u6c23\nE. \u8d85\u97f3\u6ce2\u4e0a\u770b\u5230\u809d\u5167\u53ca\u809d\u5916\u81bd\u7ba1\u816b\u8139\uff0c\u81bd\u56ca\u5167\u6709\u8a31\u591a\u5c0f\u77f3\u982d\n": "(E)", "109-45.\u75c5\u4eba\u56e0\u611f\u5230\u5026\u6020\u800c\u5c31\u91ab \uff0c\u5176\u62bd\u8840\u6aa2\u9a57\u5982\u4e0b \uff1aAST=70 (<31) U/L\uff0cALT=35 (<41) U/L\uff0cALP (Alkaline \nphosphatase)=105 (<104) U/L\u3002\u4e0b\u5217\u75c5\u6cc1\u4f55\u8005\u4e0d\u80fd\u89e3\u91cb\u5176\u7d50\u679c \uff1f   \nA.\u6eb6\u8840 (hemolysis)\nB.\u5fc3\u808c\u6897\u585e (myocardial infarction)\nC.\u91cd\u8a13 (heavy muscle exercise)\nD.\u9157\u9152 (alcoholism)\nE.\u5065\u5eb7\u7684B\u578b\u809d\u708e\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\uff08\u5065\u5eb7\u5e36\u539f\u8005\uff09\n": "[E]", "109-46.\u75c5\u4eba\u56e0\u4e0a\u8179\u75bc\u75db\u4e00\u5929\u88ab\u9001\u81f3\u6025\u8a3a\u5ba4 \uff0c\u62bd\u8840\u6aa2\u9a57 Amylase\u4e0a\u5347\u81f31000 U/L\u3002\u4f4f\u9662\u7b2c\u4e09\u5929 \uff0c\u8840\u6e05 amylase \u964d\n\u81f3\u6b63\u5e38\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u6aa2\u6e2c\u8840\u6e05 triglyceride \u6fc3\u5ea6\u53ef\u80fd >1000 mg /dL\n(2) \u8981\u91d0\u6e05\u6709\u7121\u81bd\u7d50\u77f3\n(3) \u8eab\u9ad4\u8a3a\u5bdf\u53ef\u80fd\u6709Obturator sign\n(4) \u4f4f\u9662\u5f8c24\u5c0f\u6642\u9700\u6ce8\u610f serum Creatinie level\n(5) \u9700\u6392\u9664 perforated peptic ulcer\n(6) \u9700\u6392\u9664 mesenteric vascular occlusion\n(7) \u6bcf\u5929\u505a\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u662f\u6700\u4f73\u5224\u65b7 severity \u4e4b\u65b9\u5f0f   \nA.(2)+(3)+(4)+(7)\nB.(3)+(4)+(5)+(6)\nC.(1)+(2)+(4)+(5)+(7)\nD.(1)+(3)+(5)+(6)\nE.(1)+(2)+(4)+(5)+(6)\n": "[E]", "109-47.\u75c5\u4eba\u6700\u8fd1\u56e0\u95dc\u7bc0\u708e\u800c\u9700\u670d\u7528NSAID (Non-steroidal Anti -inflammatory Drug )\u3002\u67d0\u5929\u534a\u591c\u7a81\u7136\u611f\u5230\u5287\u70c8\u7684\u80f8\n\u9aa8\u5f8c\u75bc\u75db\u800c\u9192\u4f86 \u3002\u95dc\u65bc\u9019\u500b\u75c5\u4eba\u7684\u75c5\u60c5 \uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.Anti-secretory drugs \u5e38\u88ab\u7528\u4f86\u52a0\u901f\u75c5\u60c5\u4e4b\u6539\u5584\nB.\u670d\u85e5\u5f8c\u8981\u559d\u8db3\u5920\u7684\u6c34\u4e14\u907f\u514d\u65bc 30 \u5206\u9418\u5167\u8eba\u5e73\u7761\u89ba\nC.\u6700\u5bb9\u6613\u767c\u751f\u65bc\u98df\u9053\u4e2d\u6bb5\nD.\u670d\u7528 potassium chloride \u53ca quinidine \u4ea6\u53ef\u80fd\u9020\u6210\u985e\u4f3c\u75c5\u60c5\nE.\u6b64\u7a2e\u75c5\u60c5\u50c5\u6703\u6301\u7e8c\u5e7e\u5929\uff0c\u4e14\u4e0d\u6703\u6709\u5f8c\u907a\u75c7\n": "[E]", "109-48.\u4e00\u500b\u75c5\u4eba\u88ab\u8a3a\u65b7\u809d\u786c\u5316\u5df2\u6709\u4e09\u5e74 \uff0c\u6700\u8fd1\u809a\u5b50\u9010\u6f38\u9f13\u6f32 \uff0c\u5c31\u91ab\u6642\u91ab\u5e2b\u5728\u8eab\u9ad4\u8a3a\u5bdf\u5176\u8179\u90e8\u6642\u767c\u73fe\u6709shifting \ndullness\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u61c9\u5118\u53ef\u80fd\u5b89\u6392\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\nB.\u8840\u6db2\u6aa2\u9a57\u5f88\u53ef\u80fd\u767c\u73fe thrombocytosis\nC.\u75c5\u4eba\u6bcf\u65e5\u6240\u98df\u7528\u7684\u9209\u61c9\u4f4e\u65bc 2 gm\nD.\u5fc5\u8981\u6642\u9700\u958b\u7acb spironolactone +/- furosemide\nE.\u8981\u6aa2\u6e2c\u5176\u8840\u6e05 Albumin \u6fc3\u5ea6\n": "[B]", "109-49.\u6709\u95dcC\u578b\u809d\u708e\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f       \nA.\u809d\u529f\u80fd\u5931\u4ee3\u511f\u4e4b\u60a3\u8005\uff0c\u4e0d\u80fd\u670d\u7528\u542b Protease Inhibitor (PI) \u985e\u4e4b\u85e5\u7269\nB.eGFR < 15 \u4e4b\u672b\u671f\u814e\u75c5\u60a3\u8005\uff0c\u4e0d\u5b9c\u670d\u7528\u542bNS5B \u6291\u5236\u5291\u4e4b\u85e5\u7269\nC.\u76ee\u524d\u53f0\u7063\u5065\u4fdd\u7d66\u4ed8\u898f\u7bc4 \uff0c\u7947\u8981\u75c5\u4eba\u8840\u4e2d\u6e2c\u5230 C\u809d\u75c5\u6bd2\uff0c\u5373\u53ef\u63a5\u53d7 Direct Acting Antivirals (DAAs) \u4e4b\u6cbb\n\u7642\nD.\u76ee\u524d DAAs \u4e4b\u7642\u7a0b\uff0c\u591a\u572812~24\u9031\nE.\u53f0\u7063\u904e\u53bb\u5169\u5e74\u4f7f\u7528 DAAs \u6cbb\u7642 C\u809d\u75c5\u4eba\uff0c\u53ea\u8981\u75c5\u60c5\u5c1a\u4f73 \uff08\u7121\u809d\u786c\u5316\u6216\u50c5\u6709\u4ee3\u511f\u6027\u809d\u786c\u5316\uff09\uff0c \u5176 \nSVR12 ( sustained virologic response at 12 weeks after end of treatment) \u6a5f\u7387\u9ad8\u9054 98 %\u3002\n": "[D]", "109-50.\u95dc\u65bc\u809d\u7d30\u80de\u764c (hepatocellular carcinoma, HCC) \u4e4b\u4e0b\u5217\u5404\u9805\u6558\u8ff0 \uff0c\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u5728\u53f0\u7063\uff0cB\u578b\u809d\u708e\u75c5\u6bd2\u548c C\u578b\u809d\u708e\u75c5\u6bd2\u662f\u5f15\u767c HCC \u7684\u4e3b\u8981\u5371\u96aa\u56e0\u5b50\n(2) \u65b0\u751f\u5152\u5168\u9762 B\u578b\u809d\u708e\u75ab\u82d7\u63a5\u7a2e \uff0c\u5df2\u660e\u986f\u964d\u4f4e HCC \u4e4b\u767c\u751f\u7387\n(3) \u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\u9ad4\u5167\u4e4b C\u809d\u75c5\u6bd2\u88ab\u53e3\u670d\u6297 C\u809d\u75c5\u6bd2\u85e5\u7269 (Direct Acting Antirivrals) \u6839\u9664\u4e4b\u5f8c \uff0cHCC \u4e4b\n\u767c\u751f\u7387\u5df2\u660e\u986f\u964d\u4f4e\n(4) Statins \u53ca Metformin \u5df2\u88ab\u8b49\u5be6\u53ef\u964d\u4f4e HCC \u4e4b\u767c\u751f\u7387\n(5) \u76f4\u5f91\u5927\u65bc 2 \u516c\u5206\u4e4b HCC \uff0c\u5728 contrast -enhanced computed tomography (CECT) \u4e2d\u5448\u73fe\u5178\u578b\u7684\u8868\n\u73fe\uff0c\u5373\u53ef\u78ba\u8a3a \uff0c\u4e0d\u9700\u505a\u5207\u7247\u6aa2\u67e5\n(6) BCLC (Barcelona -Clinic-Liver-Cancer) staging system 0\u671f\u8005\uff0c\u4ee5 RFA ( Radiofrequency Ablation) \u6cbb\n\u7642\u7684\u6210\u529f\u7387\u8207\u958b\u5200\u5207\u9664\u5dee\u4e0d\u591a   \nA.(1)+(2)+(3)+(4)\nB.(1)+(2)+(4)+(5)\nC.(2)+(4)+(5)+(6)\nD.(3)+(4)+(5)+(6)\nE.(1)+(2)+(5)+(6)\n": "[E]", "109-51.\u95dc\u65bc\u5927\u8178\u764c\u8207\u5927\u8178\u606f\u8089\u4e4b\u6558\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u8001\u5e74\u4eba\u7d04 50% \u6709 adenomatous polyp \u65bc\u5176\u5927\u8178\u4e2d \uff0c\u5176\u4e2d < 1% \u6703\u6f14\u8b8a\u6210\u5927\u8178\u764c\n(2) \u6709\u5927\u8178\u606f\u8089\u8005 \uff0c\u7d04 20% \u6703\u9a57\u51fa\u7cde\u4fbf\u6709\u6f5b\u8840\u53cd\u61c9\n(3) Sessile villous adenomas \u884d\u751f\u764c\u8b8a\u4e4b\u6a5f\u7387\u7d04\u70ba tubular adenoma \u4e4b 3 \u500d\n(4) \u767c\u708e\u6027\u8178\u9053\u75be\u75c5 (Inflammatory Bowel Disease) \u60a3\u8005\u767c\u75c5\u5f8c \uff0c\u524d10\u5e74\u767c\u751f\u5927\u8178\u76f4\u8178\u764c\u4e4b\u6a5f\u7387\u76f8\u7576\u4f4e\n(5) \u7f79\u60a3\u5927\u8178\u76f4\u8178\u764c\u4e4b\u60a3\u8005 \uff0c\u7d04 50% \u5176\u7cde\u4fbf\u6f5b\u8840\u70ba\u9670\u6027\u53cd\u61c9\n(6) < 1 cm \u4e4b sessile serrated polyp \u88ab\u5207\u9664\u5f8c \uff0c\u5176\u5f8c\u61c9\u6bcf\u5e74\u6aa2\u67e5\u4e00\u6b21\u5927\u8178\u93e1   \nA.(1)+(2)+(3)+(4)\nB.(1)+(3)+(4)+(5)\nC.(2)+(3)+(4)+(5)\nD.(2)+(4)+(5)+(6)\nE.(3)+(4)+(5)+(6)\n": "[B]", "109-52.\u4e0b\u5217\u95dc\u65bc\u80c3\u8178\u9053\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f    \nA.Hypocalcemia \u53ef\u80fd\u9020\u6210 constipation\nB.\u6cbb\u7642\u6025\u6027\u5927\u8178\u61a9\u5ba4\u708e (diverticulitis) \u76ee\u524d\u6700\u5e38\u4f7f\u7528\u5c0d\u6297 aerobic gram -negative rods \u53ca anaerobic \nbacteria \u4e4b\u6297\u751f\u7d20 \uff0c\u5305\u62ec\u7b2c\u4e09\u4ee3 cephalosporin \u53ca metronidazole\nC.\u6025\u6027\u80c3\u8178\u9053\u51fa\u8840\u75c5\u4eba\u6709\u5fc3\u640f\u904e\u901f\u73fe\u8c61 (tachycardia) \u6642\uff0c\u61c9\u4f7f\u7528 \u03b2 blockers \u63a7\u5236\u4e4b\nD.Secretory diarrhea \u75c5\u4eba\u4e4b\u5927\u4fbf\u91cf\u901a\u5e38\u5c0f\u65bc 1L/\u5929\uff0c\u7981\u98df\u5373\u6703\u505c\u6b62\u8179\u7009\nE.Chronic mesenteric ischemia (intestinal angina) \u75c5\u4eba\u4e4b\u8179\u75db\u901a\u5e38\u8207\u9032\u98df\u7121\u95dc   \n": "[B]", "109-53.\u95dc\u65bc\u5e7d\u9580\u87ba\u65cb\u687f\u83cc (H. pylori) \u4e4b\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f    \nA.Eradication of H. pylori \u6e1b\u5c11\u5341\u4e8c\u6307\u8178\u6f70\u760d\u5fa9\u767c\u9054 80% \u4ee5\u4e0a\nB.\u8840\u6e05 H. pylori \u4e4b IgG antibody test \u53ef\u7528\u4f86\u5224\u65b7 H. pylori eradication \u4e4b\u6548\u679c\nC.\u80c3\u90e8 H. pylori \u88ab\u6839\u9664\u5f8c\uff0c\u518d\u611f\u67d3\u7387\u751a\u4f4e\nD.NSAID (Nonsteroidal Anti-inflammatory Drugs)- induced \u80c3\u6f70\u760d\u8207 H. pylori \u6709\u95dc\nE.H. pylori eradication \u9700\u4f7f\u7528\u7d44\u5408\u7642\u6cd5 \uff0c\u6297\u751f\u7d20\u70ba\u5176\u4e2d\u91cd\u8981\u9805\u76ee \uff0c\u5e38\u7528\u8005\u5305\u62ec \nclarithromycin \u3001amoxicillin\n": "[B]", "109-54.\u75c5\u4eba\u904e\u53bb\u6709\u6162\u6027\u809d\u708e\u75c5\u53f2 \uff0c\u4f46\u4e00\u76f4\u6c92\u6709\u7372\u5f97\u660e\u78ba\u8a3a\u65b7 \u3002\u6b64\u6b21\u5c31\u91ab\u62bd\u8840\u6aa2\u9a57\u6240\u5f97\u7d50\u679c\u5982\u4e0b \uff1aAST=100 (<31) \nU/L\uff0cALT=100 (<41) U/L\uff0cALP=500 (<104) U/L\uff0cGGT=450 (<50) U/L\uff0cBil (T)/(D)=4.0/3.1 mg/dL\uff0cPT \nINR=1.05\u3002\u8acb\u554f\u5176\u8a3a\u65b7\u6700\u4e0d\u53ef\u80fd\u70ba\u4e0b\u5217\u4f55\u8005 \uff1f   \nA.Primary Biliary Cholangitis\nB.Primary Sclerosing Cholangitits\nC.Drug-induced liver injury\nD.Hepatic failure\nE.Stone impaction at common bile duct\n": "[D]", "109-55.\u75c5\u4eba\u81ea\u8a34\u5026\u6020 \u3001\u5641\u5fc3\u3001\u98df\u617e\u4e0d\u632f\u5df2\u6709\u4e94\u5929 \uff0c\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u767c\u73fe \uff1aALT=300 (<41) U/L\uff0cAST=210 (< 31) \nU/L\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u82e5\u62bd\u8840\u6aa2\u9a57 IgM Anti-HAV \u5448\u9670\u6027\uff0c\u5c31\u4e0d\u662f\u6025\u6027 A\u578b\u809d\u708e\nB.\u82e5\u62bd\u8840\u6aa2\u9a57 HBsAg \u5448\u967d\u6027\uff0c\u5c31\u53ef\u78ba\u5b9a\u662f\u6025\u6027 B\u578b\u809d\u708e\u6216 B\u809d\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\u4f75\u6025\u6027\u809d\u708e\u767c\u4f5c\nC.\u82e5\u62bd\u8840\u6aa2\u9a57 Anti-HCV \u5448\u967d\u6027\uff0c\u4e0d\u4e00\u5b9a\u662f\u6025\u6027 C\u578b\u809d\u708e\nD.\u82e5\u6700\u8fd1\u6709\u56e0\u7070\u6307\u7532\u670d\u7528 Ketoconazole\uff0c\u61c9\u7acb\u5373\u505c\u85e5\uff0c\u901a\u5e38\u505c\u85e5\u5f8c 1~2 \u9031\uff0cALT\u503c\u53ef\u80fd\u6703\u660e\u986f\u4e0b\u964d\nE.\u82e5\u6700\u8fd1\u6709\u53f3\u4e0a\u8179\u75db\uff0c\u9700\u6ce8\u610f\u81bd\u7d50\u77f3\u662f\u5426\u6389\u81f3\u7e3d\u81bd\u7ba1\u4e2d\n": "[B]", "109-56.60\u6b72\u5973\u6027\u56e0\u541e\u56a5\u75bc\u75db (odynophagia )\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5 \uff0c\u7d50\u679c\u5982\u9644\u5716 \uff0c\u5efa\u8b70\u7528\u4e0b\u5217\u4f55\u7a2e\u85e5\u53e3\u670d\u6cbb\n\u7642\uff1f   \nA.Acyclovir\nB.Valganciclovir\nC.Fluconazole\nD.Ganciclovir\nE.Dexlansoprazole\n": "[C]", "109-57.50\u6b72\u4e2d\u5e74\u7537\u6027\u6709\u80f8\u75db\u75c7\u72c0 \uff0c\u5fc3\u81df\u6aa2\u67e5\u7121\u7570\u5e38 \uff0c\u56e0\u70ba\u541e\u56a5\u56f0\u96e3\u63a5\u53d7\u92c7\u5291\u98df\u9053\u651d\u5f71 \uff0c\u7d50\u679c\u5982\u9644\u5716 \u3002\u4e0b\u5217\u6558\u8ff0\u4f55\n\u8005\u6b63\u78ba\uff1f\n(1) \u98df\u9053\u58d3\u529b (esophageal manometry )\u53ef\u5448\u73fehypotense lower esophageal sphincter \u53capoor peristaltic \nactivity\n(2) \u53ef\u4ee5\u5408\u4f75\u9006\u6d41 (reflux)\u75c7\u72c0\n(3) \u53ef\u4ee5\u9032\u5c55\u6210\u98df\u9053\u5f1b\u7de9\u4e0d\u80fd (achalasia )\n(4) \u53ef\u4ee5\u7528calcium channel blockers\u6cbb\u7642\n(5) \u4e0d\u80fd\u7528botulinum toxin injections\u6cbb\u7642   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(3)+(4)+(5)   \nD.(1)+(3)+(4)\nE.(2)+(3)+(5)\n": "[B]", "109-58.55\u6b72\u7537\u6027 \uff0c\u9577\u671f\u6709\u80c3\u9178\u9006\u6d41\u53ca\u80f8\u53e3\u707c\u71b1\u75c7\u72c0 \uff0cBMI:30\uff0c\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5 \uff0c\u7d50\u679c(\u5982\u9644\u5716)\u3002\u4e0b\u5217\u6558\n\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u62bd\u7159\u589e\u52a0\u7f79\u75c5\u98a8\u96aa\nB.\u591a\u5403\u852c\u679c\u53ef\u6e1b\u5c11\u7f79\u75c5\u98a8\u96aa\nC.\u6bcf\u5e74\u67090.12~0.5%\u7f79\u764c\u98a8\u96aa\nD.\u589e\u52a0\u98df\u9053\u4e0a\u76ae\u7d30\u80de\u764c(esophageal squamous cell carcinoma)\u98a8\u96aa\nE.\u6297\u9006\u6d41\u624b\u8853(antireflux surgery)\u7121\u6cd5\u9810\u9632\u5176\u9032\u5c55\u6210\u764c\u75c7\n": "[D]", "109-59.\u6709\u95dc\u5e7d\u9580\u87ba\u65cb\u687f\u83cc (Helicobacter pylori )\u611f\u67d3\u7684\u6558\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4 \uff1f\n(1) \u4e16\u754c\u885b\u751f\u7d44\u7e54\u5b9a\u5176\u70badefinite carcinogen\n(2) \u8207\u80c3\u9ecf\u819c\u76f8\u95dc\u6dcb\u5df4\u7d44\u7e54 (gastric mucosa -associated lymphoid tissue -MALT)\u6dcb\u5df4\u764c\u7684\u767c\u751f\u6709\u95dc\n(3) \u8207\u80c3\u98df\u9053\u9006\u6d41\u6027\u75be\u75c5\u7684\u767c\u751f\u6709\u95dc\n(4) \u8207\u4e0d\u660e\u539f\u56e0\u8840\u5c0f\u677f\u6e1b\u5c11\u7d2b\u6591\u75c7 (idiopathic thrombocytopenic purpura )\u7684\u767c\u751f\u6709\u95dc\n(5) \u7b2c\u4e00\u7dda\u6cbb\u7642\u61c9\u7528\u6a19\u6e96\u5291\u91cfproton pump inhibitor twice daily\u52a0\u4e0alevoflaxacin 500mg /d\u53caamoxicilliin \n1000mg twice daily   \nA.(1)+(2)\nB.(3)+(4)\nC.(1)+(5)\nD.(3)+(5)\nE.(2)+(3)\n": "[D]", "109-60.\u4e0b\u5217\u6709\u95dc\u80c3\u606f\u8089(gastric polyp)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f    \nA.Sporadic fundic gland polyp (FGP)\u8207proton pump inhibitor\u4f7f\u7528\u6709\u95dc \uff0c\u606f\u8089\u6578\u76ee\u5c0f\u65bc10 \uff0c\u5927\u5c0f\n\u57281-5mm\uff0c\u6bcb\u9700\u5207\u9664\nB.\u907a\u50b3\u6027FGPs\u606f\u8089\u6578\u76ee\u5e38\u5927\u65bc30 \uff0c\u8207familial adenomatous polyposis (FAP)\u6216MYH-associated \npolyposis\u6709\u95dc \uff0c\u6613\u6709\u4e0d\u826f\u5316\u751f (dysplasia )\nC.\u61f7\u7591FAP \u6216MYH-associated polyposis\u5fc5\u9808\u9032\u884c\u5927\u8178\u93e1\u6aa2\u67e5\nD.Hyperplastic polyps\u4e0d\u6703\u6709\u4e0d\u826f\u5316\u751f(dysplasia)\nE.Adenomatous polyps\u8207\u840e\u7e2e\u6027\u80c3\u708e (atrophic gastritis )\u3001\u8178\u5316\u751f(intestinal metaplasia )\u3001\u53ca\u5e7d\u9580\u87ba\u65cb\u687f\n\u83cc\u611f\u67d3\u6709\u95dc\n": "[D]", "109-61.55\u6b72\u7537\u6027\u56e0\u6025\u6027\u8179\u75db \u3001\u5641\u5fc3\u548c\u5614\u5410\u81f3\u6025\u8a3a\u8655\u5c31\u91ab \uff0c6\u9031\u5167\u4ed6\u6709\u5169\u6b21\u98ef\u5f8c\u7684\u53f3\u4e0a\u8179\u75db \uff0c\u9664\u6b64\u5916\u4ed6\u904e\u53bb\u4e26\u7121\u4efb\n\u4f55\u91ab\u85e5\u53f2 \u3002\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab36 .8\u2103\u3001\u8840\u58d3130/75 mmHg \u3001\u8108\u640f89/min\u3001\u547c\u5438\u901f\u738717 /min\u3001BMI:29\uff0c\u978f\u819c\u6709\n\u9ec3\u75b8\uff0c\u8179\u90e8\u6aa2\u67e5\u6709tenderness \uff0c\u4f46\u4e26\u7121guarding \u6216rebound pain \uff0c\u8178\u97f3\u5448\u73fehypoactive \u3002\u4f4f\u9662\u5f8c\uff0c\u7d66\n\u4e88fluid resuscitation \u5f8c\uff0c\u5be6\u9a57\u5ba4\u6578\u64da (\u5982\u9644\u8868)\uff1a\u8179\u90e8\u8d85\u97f3\u6ce2\u6709\u81bd\u7d50\u77f3\u4f46\u4e26\u7121\u81bd\u56ca\u58c1\u589e\u5f8c\u6216\u7a4d\u6c34\u73fe\u8c61 \uff0c\u7e3d\u81bd\n\u7ba1\u4e26\u7121\u64f4\u5f35 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u9069\u7576\u8655\u7f6e \uff1f   \nA.\u51fa\u9662\u524d\u9032\u884cCholecystectony\nB.\u9032\u884ccholecystokin hepatobiliary (CCK-HIDA)scintigraphy\nC.\u9032\u884cendoscopic retrograde cholangiopancreaticography with bitiary sphincterotomy\nD.Intravenous imipenem\nE.Total parenteral nutirition   \n": "[A]", "109-62.43\u6b72\u5973\u6027\u56e0\u70ba 4\u5929\u7684\u8179\u75db\u81f3\u6025\u8a3a\u8655 \uff0c\u4e00\u9031\u524d\u5979\u63a5\u53d7\u8179\u8154\u93e1\u81bd\u56ca\u5207\u9664\u8853 (laparoscopic cholecystectomy )\uff0c\u624b\n\u8853\u5f88\u9806\u5229 \uff0c\u4e26\u7121\u660e\u986f\u4f75\u767c\u75c7 \uff0c\u5979\u65bc\u540c\u65e5\u51fa\u9662 \u3002\u624b\u8853\u5f8c3\u5929\u958b\u59cb\u6709\u6301\u7e8c30\u5206\u9418\u81f3 2\u5c0f\u6642\u7684\u4e0a\u8179\u75db \uff0c\u5408\u4f75\u5641\n\u5fc3\u3002\u8eab\u9ad4\u6aa2\u67e5 \uff1a\u9ad4\u6eab:36.8\u2103\uff0c\u8840\u58d3106/60 mmHg \u3001\u8108\u640f82/min\u3001\u547c\u5438\u901f\u738716 /min\uff0c\u8179\u90e8\u6aa2\u67e5\u4e26\u7121\u7570\u5e38\n\u73fe\uff0c\u624b\u8853\u50b7\u53e3\u5fa9\u539f\u826f\u597d \uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5ALT: 84 U/L\u3001AST: 62U/L\u3001CBC\u3001ALP\u548camylase\u6578\u503c\u5747\u65bc\u6b63\u5e38\u7bc4\n\u570d\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u4e26\u7121\u8179\u6c34 \uff0c\u809d\u5167\u53ca\u809d\u5916\u81bd\u7ba1\u6709\u64f4\u5f35\u73fe\u8c61 \u300224\u5c0f\u6642\u5f8cAST \u53caALT\u6062\u5fa9\u6b63\u5e38 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\n\u6700\u53ef\u80fd\u7684\u8a3a\u65b7 \uff1f   \nA.Acute pancreatitis\nB.Bile leak\nC.Cholangitis\nD.Choledocholitihiasis\nE.Sphincter of Oddi dysfunction\n": "[D]", "109-63.80\u6b72\u7537\u6027\u904e\u53bb 3\u500b\u6708\u6709\u9593\u6b47\u6027\u89e3\u9ed1\u4fbf (intermittent melena )\uff0c\u5165\u9662\u6642\u8eab\u9ad4\u6aa2\u67e5 \uff1a\u9ad4\u6eab:37\u2103\uff0c\u8840\u58d3135/80 \nmmHg\u3001\u8108\u640f80/min\u3001\u547c\u5438\u901f\u738718 /min\uff0cHb: 8.2 g/dL\u3002\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u53ca\u5168\u5927\u8178\u93e1\u6aa2\u67e5\u4e26\u7121\u7570\u5e38\u767c\n\u73fe\u3002\u81a0\u56ca\u5167\u8996\u93e1 (Capsule endoscopy )\u6aa2\u67e5\u767c\u73feproximal jejunum\u6709\u9bae\u8840 \uff0c\u4e26\u6709\u4e00\u4e9bangiodysplasia \u3002\u4e0b\u4e00\n\u6b65\u6700\u9069\u7576\u7684\u8655\u7f6e\u70ba\u4f55 \uff1f   \nA.Intraoperative endoscopy\nB.Push enteroscopy\nC.Repeat upper endoscopy\nD.Repeat colonoscopy\nE.Technetium labeled nuclean scan\n": "[B]", "109-64.38\u6b72\u7537\u6027\u6f70\u760d\u6027\u8178\u708e\u60a3\u800510\u5929\u524d\u958b\u59cb\u6bcf\u65e5\u670d\u7528prednisolone 60mg \uff0c\u4f46\u662f\u4ecd\u6bcf\u65e5\u6709 6\u81f39\u6b21\u7684\u8840\u4fbf\u5408\u4f75\u8179\n\u75db\uff0c\u56e0\u70ba\u9032\u98df\u52a0\u91cd\u75bc\u75db\u548c\u8179\u7009 \uff0c\u4ed6\u4e3b\u52d5\u6e1b\u5c11\u7d93\u53e3\u9032\u98df \u3002\u8eab\u9ad4\u6aa2\u67e5 \uff1a\u9ad4\u6eab:37\u2103\uff0c\u8840\u58d3110/56 mmHg \u3001\u8108\n\u640f96/min\uff0c\u8179\u90e8\u6709diffuse tenderness\u4f46\u4e26\u7121guarding \u6216rebound pain\u73fe\u8c61 \u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u986f\u793aHb: 9.7 \ng/dL\u3001WBC: 6300 /\u03bcL\uff0c\u7cde\u4fbf\u57f9\u990a\u548cClostridium difficile\u6aa2\u67e5\u7686\u70ba\u9670\u6027 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6b64\u60a3\u8005\u76ee\u524d\u6700\u9069\u7576\u7684\u6cbb\n\u7642\uff1f   \nA.\u589e\u52a0prednisolone\u81f3\u6bcf\u65e580mg\nB.\u4f7f\u7528adalimumab\nC.\u4f7f\u7528ciprofloxacin \u548cmetronidazole\nD.\u4f7f\u7528mesalamine\nE.\u4f7f\u7528sulfasalazine\n": "[B]", "109-65.28\u6b72\u5973\u6027\u56e0 8\u9031\u7684\u4e0b\u8179\u7d5e\u75db\u5408\u4f75\u8179\u7009\u75c5\u53f2 \uff0c\u63a5\u53d7\u9032\u4e00\u6b65\u8a55\u4f30 \uff0c\u5979\u6bcf\u5929\u6392\u4fbf 6\u81f310\u6b21\uff0c\u5176\u4e2d\u6709\u4e00\u81f3\u4e8c\u6b21\u5728\u534a\n\u591c\uff0c\u5927\u4fbf\u7279\u5fb5\u70baloose to watery with intermittent blood streaking \u3002\u53e6\u5916\u5979\u6709\u5641\u5fc3\u53ca\u98df\u617e\u8b8a\u5dee\u73fe\u8c61 \uff0c\u4f46\u7121\u5614\n\u5410\u3001\u767c\u71d2\uff0c\u4e5f\u7121\u670d\u7528\u85e5\u7269\u75c5\u53f2 \u3002\u8eab\u9ad4\u6aa2\u67e5 \uff1a\u9ad4\u6eab:37.8\u2103\uff0c\u8840\u58d3100/54 mmHg \u3001\u8108\u640f96/min\uff0c\u8179\u90e8\u5448\n\u73fediffuse tenderness\u4f46\u7121rigidity, guarding \u6216rebound pain \u3002\u5927\u8178\u93e1\u6aa2\u67e5\u5728\u5347\u7d50\u8178 \u3001\u6a6b\u7d50\u8178\u53ca\u964d\u7d50\u8178\u6709\u5982\n\u9644\u5716\u4e4b\u767c\u708e\u75c5\u7076 \uff0c\u4f46\u662fterminal ileum \u53carectum\u4e26\u7121\u767c\u708e\u73fe\u8c61 \uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7 \uff1f   \nA.Collagenous colitis\nB.Crohn colitis\nC.Ischemic colitis\nD.Ulcerative colitis\nE.Tuberculous colitis   \n": "[B]", "109-66.\u6709\u95dcCOVID -19\u7684\u80c3\u8178\u8207\u809d\u81df\u7570\u5e38\u8868\u73fe\u6558\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u5641\u5fc3(nausea)\u6bd4\u98df\u617e\u4e0d\u632f (anorexia )\u5e38\u898b\n(2) \u8179\u7009\u662f\u6700\u5e38\u898b\u7684\u80c3\u8178\u8868\u73fe\n(3) \u4ee5\u55c5\u89ba\u6216\u5473\u89ba\u505a\u70ba\u9810\u6e2cCOVID -19\u8868\u73fe\uff0c\u654f\u611f\u5ea6\u6bd4\u7279\u7570\u5ea6\u9ad8\n(4) \u8f15\u5ea6AST /ALT\u4e0a\u6607\u70ba\u6700\u5e38\u898b\u4e4b\u809d\u81df\u7570\u5e38\n(5) \u80c3\u8178\u7570\u5e38\u8f03\u809d\u81df\u7570\u5e38\u66f4\u5e38\u898b   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(3)+(4)+(5)\nD.(1)+(3)+(5)\nE.(2)+(4)+(5)\n": "[E]", "110-37.\u75c5\u4eba\u56e0\u8179\u75db\u5c31\u91ab \uff0c\u5176\u75c5\u53f2\u5df2\u6709 6-7\u500b\u6708\uff0c\u8179\u75db\u6c92\u6709\u56fa\u5b9a\u90e8\u4f4d \uff0c\u672c\u4f86\u6bcf\u9031\u4e00\u6b21 \uff0c\u8fd1\u4f86\u983b\u7387\u589e\u52a0\u81f3\u6bcf\n\u90312-3\u6b21\uff0c \u6bcf\u6b21\u8179\u75db\u6301\u7e8c\u6642\u9593\u9577\u77ed\u4e0d\u4e00 \u3002\u5728\u9019\u6bb5\u671f\u9593 \uff0c\u5927\u4fbf\u6b21\u6578\u81ea\u904e\u53bb\u7684\u6bcf\u5929\u4e00\u6b21\u589e\u81f3\u6bcf\u5929 3-4\u6b21\uff0c\u91cf\u4e0d\n\u591a\uff0c\u4e14\u591a\u4e0d\u6210\u5f62 \u3002\u75c5\u4eba\u64d4\u5fc3\u662f\u5426\u5df2\u7f79\u60a3\u5927\u8178\u764c \u3002\u95dc\u65bc\u9019\u500b\u75c5\u4eba\u7684\u75c5\u60c5 \uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u82e5\u6b64\u75c5\u4eba\u6709\u8ca7\u8840\u73fe\u8c61 \uff0c\u61c9\u5b89\u6392\u5927\u8178\u93e1\u6aa2\u67e5\n(2) \u6b64\u7a2e\u75c5\u4eba\u4e00\u822c\u4e0d\u6703\u6709\u9ad4\u91cd\u6e1b\u8f15\u60c5\u6cc1\n(3) \u6b64\u7a2e\u75c5\u4eba\u665a\u4e0a\u5e38\u6703\u88ab\u8179\u75db\u5435\u9192\n(4) \u6b64\u7a2e\u75c5\u4eba\u9700\u5b89\u6392\u98df\u7269\u904e\u654f\u539f\u6aa2\u6e2c\n(5) \u6b64\u7a2e\u75c5\u4eba\u6709\u6642\u6703\u6392\u51fa\u7c98\u6db2 \uff0c\u4f46\u4e00\u822c\u4e0d\u6703\u89e3\u51fa\u9bae\u8840\n(6) \u6b64\u7a2e\u75c5\u4eba\u5e38\u5408\u4f75\u6709dyspepsia \u3001heartburn \u6216 nausea   \nA.(1) + (2) + (3) + (4)\u3002\nB.(1) + (3) + (5) + (6)\u3002\nC.(2) + (3) + (4) + (6)\u3002\nD.(3) + (4) + (5) + (6)\u3002\nE.(1) + (2) + (5) + (6)\u3002\n": "[E]", "110-38.70\u6b73\u5973\u6027\u75c5\u4eba\u56e0\u7a81\u767c\u5de6\u4e0b\u8179\u75db\u53ca\u767c\u71d2\u81f338 .5\u2070C\u800c\u5c31\u91ab\uff0c\u62bd\u8840\u6aa2\u9a57\u6709\u767d\u8840\u7403\u7570\u5e38\u5347\u9ad8\u73fe\u8c61 \uff0c\u5de6\u4e0b\u8179\u89f8\u6478\u6703\u75db \n(tenderness) \u4f46\u6c92\u6709\u53cd\u5f48\u75db (rebound pain )\uff0c\u96b1\u7d04\u6478\u5230\u4e00\u5718\u5c0f\u5c0f\u7684\u816b\u584a \uff0c\u75c5\u4eba\u8840\u58d3\u6b63\u5e38 \u3002\u91dd\u5c0d\u9019\u500b\u75c5\u4eba\u4e4b\n\u75c5\u60c5\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u61c9\u5118\u5feb\u5b89\u6392\u5927\u8178\u93e1\u6aa2\u67e5\n(2) \u61c9\u5b89\u6392contrast -enhanced computed tomography (CECT)\n(3) \u61c9\u99ac\u4e0a\u7167\u6703\u5916\u79d1\u6e96\u5099emergent operation\n(4) \u61c9\u7167\u6703\u5a66\u7522\u79d1\u4ee5\u6392\u9664\u5375\u5de2\u56ca\u816b\u76f8\u95dc\u75be\u75c5\n(5) \u5148\u7981\u98df\uff0c\u4e26\u7d66\u4e88\u6297\u751f\u7d20 \uff0c\u5305\u62ec\u7b2c\u4e09\u4ee3cephalosporin \u6216 ciprofloxacin \u4f75 metronidzole\n(6) \u75c5\u4eba\u53ef\u80fd\u6709 abscess   \nA.(1) + (2) + (3) + (4)\u3002\nB.(1) + (3) + (5) + (6)\u3002\nC.(2) + (4) + (5) + (6)\u3002\nD.(2) + (3) + (5) + (6)\u3002\nE.(3) + (4) + (5) + (6)\u3002\n": "[C]", "110-39.\u75c5\u4eba\u56e0\u8336\u8272\u5c3f\u4e09\u5929\u53ca\u53f3\u4e0a\u8179\u75db\u800c\u4f86\u5c31\u91ab \uff0c\u6c92\u6709\u767c\u71d2 \u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b \uff1aAST=300 U/L (<31)\uff0cALT=345 \nU/L (<41)\uff0cALP=430 U/L (<104)\uff0c\u03b3-GT=450 U/L (<50)\uff0cBil (T)/(D)=4.5/3.5 mg/dL \n(<1.1/<0.4)\uff0c Albumin=4.0 g/dL (>3.5)\uff0cProthrombin time =10.1\"\uff0cINR=1.01\n\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u61c9\u5118\u5feb\u5b89\u6392\u8d85\u97f3\u6ce2\u6aa2\u67e5\u3002\nB.\u5f71\u50cf\u6aa2\u67e5\u5f88\u53ef\u80fd\u767c\u73fe\u5169\u5074\u809d\u5167\u81bd\u7ba1\u64f4\u5f35\u3002\nC.\u5f71\u50cf\u6aa2\u67e5\u5f88\u53ef\u80fd\u767c\u73fe\u7e3d\u81bd\u7ba1\u64f4\u5f35\u3002\nD.\u5f8c\u7e8c\u53ef\u80fd\u9700\u5b89\u6392\u5167\u8996\u93e1\u9006\u884c\u6027\u81bd\u80f0\u7ba1\u651d\u5f71\u53ca\u76f8\u95dc\u4ecb\u5165\u8655\u7f6e\u3002\nE.\u75c5\u4eba\u7f79\u60a3\u539f\u767c\u6027\u81bd\u6c41\u6eef\u7559\u6027\u809d\u75c5 (primary biliary cirrhosis)\u3002\n": "[E]", "110-40.\u75c5\u4eba\u56e0\u5026\u6020\u53ca\u98df\u617e\u4e0d\u632f\u800c\u4f86\u5c31\u91ab \uff0c\u62bd\u8840\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b \uff1aFree T4=1.00ng/dL (0.7-1.48)\uff0cTSH=1.85mU/L \n(0.35-4.94)\uff0cBUN=15mg/dL (<25)\uff0cCr=0.6mg/dL (<1.2)\uff0cALT=450 U/L (<41)\uff0cAST=350 U/L \n(<31)\uff0cALP=650 U/L (<104)\uff0c\u03b3-GT=790 U/L (<50)\uff0cBil(T)/(D)=2.5/1.85 mg/dL \n(<1.1/<0.4)\uff0c Albumin=3.9 g/dL (>3.5)\uff0cProthrombin time INR =1.05\uff0cAnti-HCV (+)\uff0cHCV RNA: Not \ndetected \uff0cHBsAg (+) \uff0cHBV DNA =500 IU/mL\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u75c5\u4eba\u6709hypothyroidism\u3002   \nB.\u75c5\u4eba\u6709\u6025\u6027\u809d\u708e\u767c\u4f5c\uff0c\u61c9\u8207 B\u578b\u809d\u708e\u75c5\u6bd2\u6709\u95dc\u3002\nC.\u75c5\u4eba\u6709\u6025\u6027\u809d\u708e\u767c\u4f5c\uff0c\u61c9\u8207 C\u578b\u809d\u708e\u75c5\u6bd2\u6709\u95dc\u3002\nD.\u75c5\u4eba\u6709\u6025\u6027\u809d\u708e\u767c\u4f5c\uff0c\u5176\u75c5\u56e0\u5f88\u53ef\u80fd\u70ba\u81bd\u6c41\u6eef\u7559\u6027\u809d\u75c5 (cholestatic liver disease)\u3002\nE.\u75c5\u4eba\u5df2\u6709\u809d\u81df\u5931\u4ee3\u511f\u73fe\u8c61 (liver decompensation)\u3002\n": "[D]", "110-41.\u6709\u95dc\u53f0\u7063 C\u578b\u809d\u708e\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u76ee\u524d\u53f0\u7063\u5065\u4fdd\u7d66\u4ed8 Direct Acting Antivirals (DAAs) \u4e4b\u6cbb\u7642\u50c5\u9650\u7528\u65bc\u6162\u6027 C\u578b\u809d\u708e\u75c5\u4eba\u3002\nB.\u76ee\u524dDAAs\u4e4b\u7642\u7a0b\uff0c\u591a\u57288-12\u9031\u3002\nC.\u670d\u7528\u542bNS 3/4A Protease Inhibitors\u985e\u4e4bDAAs \u6642\uff0c\u4e00\u65e6\u767c\u73fe prothrombin time \u660e\u986f\u5ef6\u9577 \uff0c\u61c9\u7acb\u5373\u505c\u6b62\n\u670d\u85e5\u3002\nD.\u76ee\u524d\u53f0\u7063\u4f7f\u7528\u4e4bDAAs \u85e5\u7269\u4e3b\u8981\u662f pangenotypic drugs\u3002\nE.\u53f0\u7063\u8981\u57282025\u5e74\u6839\u9664 C\u809d\uff0c\u5176\u4e3b\u8981\u95dc\u9375\u5728\u65bc\u5f37\u5316\u7be9\u6aa2\u627e\u51fa\u6f5b\u5728\u7684 C\u809d\u75c5\u4eba\u3002\n": "[A]", "110-42.\u95dc\u65bc\u53f0\u7063\u5065\u4fdd\u5c0d B\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u7d66\u4ed8\u898f\u7bc4\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u76ee\u524d\u7684\u5171\u8b58\u662f \uff1a\u7947\u8981\u8840\u4e2d B\u809d\u75c5\u6bd2\u91cf (viral load) \u5927\u65bc 1,000,000 IU/mL\uff0c\u5c31\u61c9\u8a72\u958b\u59cb\u4ee5\u53e3\u670d\u6297 B\u809d\u75c5\n\u6bd2\u85e5\u7269\u6cbb\u7642 \u3002\nB.\u521d\u6b21\u88ab\u767c\u73fe\u8840\u4e2d HBsAg \u967d\u6027\uff0c IgM Anti -HBc \u4ea6\u967d\u6027\u4e14\u6578\u503c\u76f8\u7576\u9ad8 \uff0cALT=400 U/L (<41)\uff0cBil (T)\n=0.9 mg/dL (<1.1)\uff0cProthrombin time =11.0\"\uff0cINR=1.1\uff0c\u4e0d\u5fc5\u6025\u8457\u958b\u59cb\u7d66\u4e88\u53e3\u670d\u6297 B\u809d\u75c5\u6bd2\u85e5\u7269 \u3002\nC.30\u6b72\u7684\u6162\u6027 B\u578b\u809d\u708e\u60a3\u8005\uff0c\u6cbb\u7642\u7684\u512a\u5148\u8003\u91cf\u85e5\u7269\u662f pegylated interferon\u3002\nD.\u7f79\u60a3\u809d\u7d30\u80de\u764c\u4e4b B\u809d\u60a3\u8005\uff0c\u7947\u8981\u8840\u4e2d\u6e2c\u5f97\u5230 B\u809d\u75c5\u6bd2\uff0c\u5c31\u53ef\u4ee5\u9577\u671f\u670d\u7528\u6297 B\u809d\u75c5\u6bd2\u85e5\u7269\u3002\nE.\u4f7f\u7528\u53e3\u670d\u6297 B\u809d\u75c5\u6bd2\u85e5\u7269\u6642\uff0c\u61c9\u96a8\u6642\u6ce8\u610f\u75c5\u4eba\u4e4b\u814e\u529f\u80fd\u3002\n": "[A]", "110-43.\u8179\u90e8\u8d85\u97f3\u6ce2\u4e4b\u4f7f\u7528\u6108\u4f86\u6108\u983b\u7e41 \uff0c\u56e0\u6b64\u816b\u7624\u610f\u5916\u88ab\u767c\u73fe\u7684\u6a5f\u7387\u4e5f\u6108\u4f86\u6108\u9ad8 \u3002\u95dc\u65bc\u809d\u816b\u7624\u7684\u8a3a\u65b7\u8207\u6cbb\u7642 \uff0c\u4e0b\u5217\n\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u8840\u7ba1\u7624 (hemangioma) \u662f\u6700\u5e38\u898b\u7684\u826f\u6027\u809d\u816b\u7624\uff0c\u901a\u5e38\u7947\u8981\u5b9a\u671f\u8ffd\u8e64\u5373\u53ef\u3002\nB.\u809d\u81df\u817a\u7624 (hepatic adenoma) \u76f8\u7576\u5c11\u898b \uff0c\u5176\u5f62\u6210\u8207 oral contraceptives \u6216 anabolic androgenic \nsteroids \u5bc6\u5207\u76f8\u95dc \u3002\nC.B\u809d\u75c5\u6bd2\u53ca C\u809d\u75c5\u6bd2\u5c0e\u81f4\u7684\u809d\u786c\u5316\u75c5\u4eba\uff0c\u662f\u7f79\u60a3\u809d\u7d30\u80de\u764c\u7684\u6700\u9ad8\u5371\u96aa\u7fa4\u3002\nD.\u809d\u786c\u5316\u7684\u809d\u81df\u5167\u6709\u4e00\u9846\u76f4\u5f91 2\u516c\u5206\u7684\u7d50\u7bc0 \uff0c\u60a3\u8005\u8840\u4e2dAFP (Alpha-fetoprotein) \u53ca PIVKA -II (Protein \ninduced by Vitamin K absence or antagonists -II) \u6578\u503c\u7686\u5728\u6b63\u5e38\u7bc4\u570d\u5167 \uff0c\u4e14\u8207\u904e\u53bb\u5dee\u4e0d\u591a \uff0c\u6545\u4e0d\u53ef\u80fd\n\u70ba\u809d\u7d30\u80de\u764c \u3002\nE.\u81bd\u7ba1\u7d30\u80de\u764c (cholangiocarcinoma) \u4e4b\u9810\u5f8c\uff0c\u4e00\u822c\u6bd4\u809d\u7d30\u80de\u764c\u5dee\u3002\n": "[D]", "110-44.\u975e\u9152\u7cbe\u6027\u8102\u80aa\u809d\u75c5 (Non-alcoholic fatty liver disease, NAFLD) \u6108\u4f86\u6108\u666e\u904d \uff0c\u5df2\u6210\u70ba\u6162\u6027 B\u809d\u53caC\u809d\u4ee5\u5916\u6700\n\u5e38\u898b\u7684\u809d\u75c5 \u3002\u4e0b\u5217\u6709\u95dc NAFLD \u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u7f8e\u570b\u98df\u85e5\u5c40 (FDA) \u5df2\u901a\u904e Thiazolidinedions \u985e\u85e5\u7269\u53ef\u7528\u4f86\u6cbb\u7642 NAFLD\u3002\nB.\u7f8e\u570b\u7684\u8cc7\u6599\u986f\u793a\uff0cNAFLD \u75c5\u4eba\u4e2d\u7d04 20-25% \u5df2\u6709 NASH (non-alcoholic steatohepatitis)\u3002\nC.Metformin \u96d6\u80fd\u6539\u5584 hepatic insulin resistance\uff0c\u4f46\u4ecd\u7121\u6cd5\u6539\u5584 NASH\u3002\nD.Transient elastography (Fibroscan) \u53ef\u7528\u4f86\u9577\u671f\u8ffd\u8e64 NAFLD \u75c5\u4eba\u4e4b\u809d\u5167\u8102\u80aa\u91cf\u53ca\u7e96\u7dad\u5316\u72c0\u614b\u3002\nE.\u8102\u80aa\u809d\u4f75\u6709\u7cd6\u5c3f\u75c5\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u4e4b\u75c5\u4eba\u4e5f\u662f\u7f79\u60a3\u809d\u7d30\u80de\u764c\u7684\u5371\u96aa\u7fa4\u3002\n": "[A]", "110-45.Acute intestinal obstruction \u53ef\u5206 mechanical blockage \u53ca functional dysmotility (ileus) \u5169\u7a2e\u75c5\u60c5 \u3002\u4e0b\u5217\u6709\n\u95dc acute intestinal obstruction \u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.Upright plain films of the abdomen \u5c0d\u8a3a\u65b7\u5f88\u6709\u5e6b\u52a9\uff0c\u5fc5\u8981\u6642\u518d\u5b89\u6392\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002   \nB.\u82e5 Upright plain films of the abdomen \u986f\u793a\u5927\u8178\u53ca\u5c0f\u8178\u7686\u6f32\u5927\u4e14\u5145\u6eff\u6c23\u9ad4 \uff0c\u5373\u53ef\u8a3a\u65b7\u70ba colon \nobstruction \u3002\nC.ileus \u7684\u75c5\u4eba\u901a\u5e38\u4e0d\u6703\u5614\u5410\u3002\nD.\u6108\u9060\u7aef\u7684\u8178\u5b50\u767c\u751f mechanical blockage\uff0c\u809a\u5b50\u8139\u5f97\u6108\u53b2\u5bb3\u3002\nE.Mechanical blockage \u767c\u751f\u521d\u671f \uff0c\u75c5\u4eba\u6613\u6709 colicky abdominal pain \uff0cbowel sound \u8f03 \nhyperactive \uff0c\u5176\u5f8c colicky pain \u53ef\u80fd\u6162\u6162\u6e1b\u8f15\uff0c bowel sound \u53ef\u80fd\u8b8a\u6210 hypoactive \u3002\n": "[B]", "110-46.\u60a3\u8005\u4ee5\u541e\u56a5\u56f0\u96e3 (dysphagia )\u4e3b\u8a34\u4f86\u8a3a \uff0c\u4e4b\u524d\u6709\u8072\u97f3\u6c99\u555e (hoarseness )\u73fe\u8c61\uff0c\u76ee\u524d\u5408\u4f75\u6709\u9f3b\u8fd4\u6d41 (nasal \nregurgitation )\u53ca\u5bb9\u6613\u55c6\u5230 (aspiration )\uff0c\u4e0b\u5217\u4f55\u9805\u8a3a\u65b7\u6700\u4e0d\u53ef\u80fd\u662f\u6b64\u4f4d\u60a3\u8005\u7684\u75c5\u56e0 \uff1f   \nA.Pakinson\u2019s disease\u3002\nB.Schatzki ring\u3002\nC.Zenker\u2019s diverticulum\u3002\nD.Guillain-Barre syndrome\u3002\nE.Post head and neck surgery\u3002\n": "[B]", "110-47.\u8179\u6c34\u75c5\u60a3 \uff0c\u8840\u6db2\u767d\u86cb\u767d (albumin) 3.0g/dL\uff0c\u8179\u6c34\u4e2d\u86cb\u767d\u7e3d\u91cf 2.0g/dL\uff0c\u767d\u86cb\u767d1.2g/dL\uff0c\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\n\u4e0b\u5217\u4f55\u8005 \uff1f   \nA.nephrotic syndrome\u3002\nB.pancreatitis\u3002\nC.constrictive pericarditis\u3002\nD.tuberculosis\u3002\nE.liver cirrhosis\u3002\n": "[E]", "110-48.\u60a3\u8005\u56e0\u9577\u671f\u80f8\u53e3\u707c\u71b1 (heartburn )\u53ca\u80f8\u75db\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5 \uff0c\u7d50\u679c\u5982\u5716 \uff0c\u4e0b\u5217\u4f55\u8005\u548c\u6b64\u75c5\u7076\u7684\u767c\u751f\u7121\n\u95dc\uff1f   \nA.Lower esophageal sphincter hypotension\u3002\nB.Hiatal hernia\u3002\nC.Helicobacter pylori infection\u3002\nD.Pepsin\u3002\nE.Bile\u3002\n": "[C]", "110-49.\u6709\u95dc\u6162\u6027\u840e\u7e2e\u6027\u80c3\u708e (chronic atrophic gastritis )\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4 \uff1f(1)\u5206\u6210A\u578b\u53caB\u578b\uff0c\u5e7d\u9580\u687f\u83cc\u611f\u67d3\n\u548cB\u578b\u6709\u95dc (2)pepsinogen I \u548cpepsinogen II\u7684\u6578\u503c\u7686\u6e1b\u5c11 (3)\u548c\u60e1\u6027\u8ca7\u8840 (pernicious anemia )\u7121\u95dc \n(4)gastrin\u6578\u503c\u964d\u4f4e (5)\u6709\u4e9b\u60a3\u8005\u53ef\u6e2c\u5230\u91dd\u5c0dthyroid antigen\u4e4b\u6297\u9ad4   \nA.(1)+(2)+(3)\u3002\nB.(1)+(2)+(4)\u3002\nC.(2)+(3)+(4)\u3002\nD.(2)+(3)+(5)\u3002\nE.(3)+(4)+(5)\u3002\n": "[C]", "110-50.23\u6b72\u7537\u6027\u56e0\u89e3\u9ecf\u6db2\u4fbf \u3001\u8179\u90e8\u7d5e\u75db\u5408\u4f75\u76f4\u8178\u51fa\u8840 \uff0c\u63a5\u53d7\u5168\u5927\u8178\u93e1\u6aa2\u67e5 (\u7d50\u679c\u5982\u5716\u4e00 )\uff0c\u5207\u7247\u6aa2\u67e5\u75c5\u7406\u5716\u50cf (\u5716\n\u4e8c)\uff0c\u4e0b\u5217\u6709\u95dc\u6b64\u75c5\u7684\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u975e \uff1f(1)\u897f\u73ed\u7259\u88d4\u7f8e\u570b\u4eba\u767c\u751f\u7387\u8f03\u767d\u4eba\u70ba\u9ad8 (2)\u62bd\u7159\u53ef\u964d\u4f4e\u6b64\u75c5\u7684\u767c\u751f\u7387 \n(3)\u53e3\u670d\u907f\u5b55\u85e5\u6703\u589e\u52a0\u98a8\u96aa (4)\u5207\u9664\u76f2\u8178 (appendectomy )\u6703\u589e\u52a0\u98a8\u96aa (5)\u51fa\u751f\u4e00\u5e74\u5167\u4f7f\u7528\u6297\u751f\u7d20\u6703\u589e\u52a0\u98a8\u96aa   \nA.(1)+(2)+(3)\u3002   \nB.(1)+(3)+(4)\u3002\nC.(2)+(3)+(4)\u3002\nD.(2)+(3)+(5)\u3002\nE.(3)+(4)+(5)\u3002\n": "[B]", "110-51.\u60a3\u8005\u56e0\u770b\u7259\u91ab\u767c\u73fe\u65bc\u5634\u5507 \u3001\u53e3\u8154\u6709\u6df1\u68d5\u8272\u8272\u7d20\u6c88\u7a4d \uff0c\u800c\u8f49\u8a3a\u6d88\u5316\u5167\u79d1 \uff0c\u7d93\u4e0a\u3001\u4e0b\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5 \uff0c\u767c\u73fe\n\u65bc\u80c3\u53ca\u5927\u8178\u6709\u606f\u8089 \uff0c\u6709\u95dc\u6b64\u75c5\u75c7\u7684\u6558\u8ff0\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u606f\u8089\u75c5\u7406\u70bahamartoma\u3002\nB.\u6bd4\u8d77familial adenomatous polyposis\uff0c\u6b64\u7a2e\u606f\u8089\u8f49\u6210\u60e1\u6027\u6a5f\u6703\u8f03\u4f4e\u3002\nC.\u8207\u5375\u5de2\u816b\u7624\u767c\u751f\u6709\u95dc\u3002\nD.\u8207\u80f0\u81df\u816b\u7624\u767c\u751f\u6709\u95dc\u3002\nE.\u8207\u53e3\u8154\u816b\u7624\u767c\u751f\u6709\u95dc\u3002\n": "[E]", "110-52.\u6709\u95dc\u5927\u8178\u61a9\u5ba4\u75c7(diverticulosis)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u901a\u5e38\u5728\u4e59\u72c0\u7d50\u8178(sigmoid colon)\uff0c\u4f46\u5728\u4e9e\u6d32\u65cf\u7fa4\uff0c\u670970%\u767c\u751f\u5728\u53f3\u5074\u7d50\u8178\u3002\nB.\u662f60\u6b72\u4ee5\u4e0a\u75c5\u60a3\u767c\u751f\u4e0b\u6d88\u5316\u9053\u51fa\u8840\u6700\u5e38\u898b\u65f3\u539f\u56e0\u3002\nC.aspirin\u53caNSAID\u4e0d\u6703\u589e\u52a0\u6b64\u985e\u60a3\u8005\u4e0b\u6d88\u5316\u9053\u51fa\u8840\u7684\u98a8\u96aa\u3002\nD.\u4ee5\u8179\u75db\u3001\u767c\u71d2\u3001\u767d\u8840\u7403\u589e\u52a0\u70ba\u8868\u73fe\u7684\u61a9\u5ba4\u708e\u53ef\u4ee5\u5148\u7528\u6297\u751f\u7d20\u6cbb\u7642\u3002\nE.\u61a9\u5ba4\u708e\u53ef\u9032\u5c55\u6210\u7a7f\u5b54\u53ca\u8179\u819c\u708e\u3002\n": "[C]", "110-53.\u60a3\u8005\u56e0\u8179\u75db \u3001\u5641\u5fc3\u3001\u5614\u5410\u53ca\u767c\u71d2\u5230\u6025\u8a3a \uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u5982\u5716 \uff0c\u6309\u58d3\u6b64\u75c5\u60a3\u5de6\u4e0b\u8179\u6642\u9020\u6210\u53f3\u4e0b\u8179\u660e\u986f\u75bc\n\u75db\uff0c\u6b64\u73fe\u8c61\u7a31\u70ba ?   \nA.Rovsing\u2019s sign\u3002\nB.Obturator sign\u3002\nC.Iliopsoas sign\u3002\nD.Murphy\u2019s sign\u3002\nE.Cullen\u2019s sign\u3002\n": "[A]", "110-54.\u60a3\u8005\u56e0\u4e0a\u8179\u75db\u53cd\u5c04\u81f3\u80cc\u90e8 \uff0c\u5408\u4f75\u5641\u5fc3 \u3001\u5614\u5410\u81f3\u6025\u8a3a \uff0c\u8840\u6db2\u6aa2\u67e5amylase \u548clipase\u503c\u5747\u6709 3\u500d\u4ee5\u4e0a\u7684\u589e\u52a0 \uff0c\u4e0b\n\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u5224\u65b7\u6b64\u75c5\u56b4\u91cd\u5ea6\u7684BISAP score \uff1f   \nA.BUN>25mg/dL\u3002\nB.Impaired mental status\u3002\nC.SIRS:2 \u2267 of 4 present\u3002\nD.Amylase>2000 IU/L\u3002\nE.Pleural effusion\u3002\n": "[D]", "111-37.\u809d\u751f\u6aa2(liver biopsy )\u4e4b\u76f8\u95dc\u6558\u8ff0 \uff0c\u4e0b\u5217\u5404\u9805\u90a3\u4e9b\u6b63\u78ba \uff1f\n(1) Cholestasis\u75c5\u4eba\u8a3a\u65b7\u4e4b\u9996\u9078\u6aa2\u67e5\u662f\u809d\u751f\u6aa2\n(2) Budd-Chiari syndrome\u75c5\u4eba\u8a3a\u65b7\u4e4b\u9996\u9078\u6aa2\u67e5\u662f\u809d\u751f\u6aa2\n(3) \u809d\u751f\u6aa2\u6709\u52a9\u65bc\u809d\u7e96\u7dad\u5316\u7a0b\u5ea6\u4e4b\u5224\u65b7\n(4) \u73fe\u5728\u6709\u6578\u7a2e\u975e\u4fb5\u8972\u6027\u65b9\u5f0f (non-invasive tests )\u53ef\u7cbe\u6e96\u5224\u65b7\u809d\u7e96\u7dad\u5316\u7a0b\u5ea6 \uff0c\u5df2\u53ef\u53d6\u4ee3\u809d\u751f\u6aa2\n(5) \u809d\u751f\u6aa2\u6709\u52a9\u65bc\u4e0d\u660e\u539f\u56e0\u809d\u708e\u4e4b\u8a3a\u65b7\n(6) \u6709\u660e\u986f\u8179\u6c34\u4e4b\u75c5\u4eba \uff0c\u61f7\u7591\u6709\u809d\u5167\u7030\u6f2b\u6027\u816b\u7624 \uff0c\u7947\u80fd\u4ee5\u7d93\u76ae\u809d\u751f\u6aa2\u8a3a\u65b7\n(7) \u809d\u751f\u6aa2\u6709\u52a9\u65bc\u81ea\u9ad4\u514d\u75ab\u809d\u708e\u4e4b\u78ba\u8a3a   \nA.(1) + (3) + (5)\u3002\nB.(2) + (4) + (6)\u3002\nC.(3) + (4) + (5)\u3002\nD.(3) + (5) + (7)\u3002\nE.(4) + (5) + (6)\u3002\n": "[D]", "111-38.\u53f0\u7063\u73fe\u884c\u5065\u4fdd\u7d66\u4ed8\u6709\u95dc\u6162\u6027 B\u578b\u809d\u708e\u53e3\u670d\u6297\u75c5\u6bd2\u85e5\u7269\u7684\u4f7f\u7528\u898f\u7bc4\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.HBeAg\u967d\u6027\u60a3\u8005\u61c9\u63a5\u53d7\u6cbb\u7642\u81f3HBeAg\u6d88\u5931\u5f8c\uff0c\u518d\u7e7c\u7e8c\u670d\u7528\u4e00\u5e74\u3002\nB.HBeAg\u9670\u6027\u60a3\u8005\u61c9\u63a5\u53d7\u6cbb\u7642\u81f3\u8840\u4e2dHBV DNA\u6e2c\u4e0d\u5230 \uff08\u6bcf\u534a\u5e74\u6e2c\u4e00\u6b21 \uff0c\u9023\u7e8c\u4e09\u6b21\u6e2c\u4e0d\u5230\uff09\uff0c \u7642\u7a0b\u81f3\u5c11\n\u5169\u5e74\uff0c\u81f3\u591a\u4e09\u5e74 \u3002\nC.\u8b49\u5be6\u6709\u809d\u786c\u5316\u7684\u60a3\u8005\uff0c\u7947\u8981\u8840\u4e2d\u6e2c\u5f97\u5230 B\u809d\u75c5\u6bd2\uff0c\u5f97\u9577\u671f\u670d\u7528\u6297\u75c5\u6bd2\u85e5\u7269\u3002\nD.\u809d\u7d30\u80de\u764c\u60a3\u8005\uff0c\u7947\u8981\u8840\u4e2d\u6e2c\u5f97\u5230 B\u809d\u75c5\u6bd2\uff0c\u5f97\u7d42\u751f\u670d\u7528\u6297\u75c5\u6bd2\u85e5\u7269\u3002\nE.\u6e96\u5099\u63a5\u53d7\u5316\u5b78\u7642\u6cd5\u7684\u6162\u6027 B\u809d\u60a3\u8005\uff0c\u53ef\u65bc\u5316\u7642\u555f\u52d5\u524d\u4e00\u5468\u958b\u59cb\u9810\u9632\u6027\u7528\u85e5 \uff0c\u76f4\u81f3\u5316\u7642\u7d50\u675f\u518d\u670d\u7528\u534a\n\u5e74\u3002\n": "[D]", "111-39.\u95dc\u65bc\u53f0\u7063 C\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u5065\u4fdd\u7d66\u4ed8\u898f\u7bc4 \uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f\n(1) \u73fe\u5728\u662f\u4ee5\u5168\u53e3\u670d\u85e5\u7269 \uff08Direct-Acting Antivirals, DAAs \uff09\u70ba\u6cbb\u7642\u4e3b\u6d41\n(2) C\u809d\u75c5\u4eba\u8981\u7b49 6\u500b\u6708\u624d\u80fd\u63a5\u53d7DAAs\u6cbb\u7642\n(3) \u73fe\u5728\u53f0\u7063\u7684\u57f7\u696d\u897f\u91ab\u5e2b\u7686\u53ef\u958b\u7acbDAAs\u6cbb\u7642 C\u809d\u75c5\u4eba\n(4) \u6709\u809d\u529f\u80fd\u5931\u4ee3\u511f\u7684\u60a3\u8005 \uff0c\u7947\u80fd\u7528Maviret \uff08Glecaprevir + Pibrentasvir \uff0c\u542bNS3/4A protease \ninhibitor\uff09\u6cbb\u7642\n(5) \u7d76\u5927\u591a\u6578 C\u809d\u75c5\u4eba\uff08\u542b\u4ee3\u511f\u6027\u809d\u786c\u5316 )\u63a5\u53d7\u73fe\u5728\u6240\u7528\u7684DAAs\u6cbb\u7642 \uff0cC\u809d\u75c5\u6bd2\u6839\u9664\u7387\u53ef\u905498 %\n(6) \u88ab\u5075\u6e2c\u51fa\u6709\u4e00\u500b\u76f4\u5f91 3\u516c\u5206\u809d\u764c\u7684\u75c5\u4eba \uff0c\u540c\u6642\u88ab\u767c\u73fe\u70ba C\u809d\u60a3\u8005\uff0c\u4ed6\u61c9\u8a72\u5148\u63a5\u53d7DAAs\u6cbb\u7642\n(7) \u5408\u4f75\u6709B\u809d\u548cC\u809d\u4e4b\u60a3\u8005 \uff0c\u65bc\u63a5\u53d7DAAs\u6cbb\u7642\u4e2d \uff0c\u5176\u4e26\u5b58\u4e4b B\u809d\u75c5\u6bd2\u53ef\u80fd\u6703\u88ab\u6fc0\u6d3b   \nA.(1)+(3) + (5)\u3002\nB.(2) + (4) + (6)\u3002\nC.(3) + (6) + (7)\u3002\nD.(2) + (5) + (7)\u3002\nE.(3) + (4) + (5)\u3002\n": "[B]", "111-40.\u95dc\u65bc\u81bd\u56ca\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u82e5\u7121\u4f75\u767c\u75c7\uff0c\u6025\u6027\u81bd\u56ca\u708e\u4e00\u822c\u5efa\u8b70\u5728\u78ba\u7acb\u8a3a\u65b7\u5f8c48-72\u5c0f\u6642\u5167\u65bd\u884c\u81bd\u56ca\u5207\u9664\u8853\u3002\nB.\u7cd6\u5c3f\u75c5\u4eba\u6709\u81bd\u56ca\u7d50\u77f3\uff0c\u82e5\u7121\u4efb\u4f55\u75c7\u72c0\uff0c\u4e0d\u5fc5\u5efa\u8b70\u63a5\u53d7\u9810\u9632\u6027\u81bd\u56ca\u5207\u9664\u8853\u3002\nC.\u81bd\u56ca\u5167\u7684radiolucent cholesterol stones\u4e0d\u8ad6\u5927\u5c0f \uff0c\u7686\u670950%\u6a5f\u6703\u80fd\u4ee5Ursodeoxycholic acid (UDCA) \n\u5c07\u4e4b\u5b8c\u5168\u6eb6\u5316 \u3002\nD.\u5728\u8d85\u97f3\u6ce2\u6aa2\u67e5\u610f\u5916\u767c\u73fe\u7684\u81bd\u56ca\u7d50\u77f3 \uff0c\u82e5\u53d7\u6aa2\u8005\u904e\u53bb\u5f9e\u7121\u76f8\u95dc\u75c7\u72c0 \uff0c\u9577\u671f\u8ffd\u8e64\u5f8c \uff0c60-80%\u4e0d\u6703\u7522\u751f\u75c7\n\u72c0\u3002   \nE.50\u6b72\u4ee5\u4e0a\u82e5\u7d93\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u6709\u5927\u65bc1 cm\u7684\u81bd\u56ca\u606f\u8089\uff0c\u4e00\u822c\u6703\u5efa\u8b70\u63a5\u53d7\u81bd\u56ca\u5207\u9664\u8853\u3002\n": "[C]", "111-41.\u5716A\u53ca\u5716B\u6240\u793a\u92c7\u5291\u986f\u5f71\u4e0b\u4e4b\u98df\u9053\u5f62\u50cf\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u5169\u8005\u7686\u53ef\u80fd\u4ee5\u80f8\u75db\u53ca\u541e\u56a5\u7570\u5e38\u70ba\u75c5\u4eba\u7684\u75c7\u72c0\u3002\nB.\u5728Manometry\u6aa2\u67e5\u6642\uff0c\u6703\u6709\u4e0d\u540c\u7684esophageal pressure topography\u5448\u73fe\u3002\nC.\u91dd\u5c0d\u5716A\u4e4b\u75c5\u6cc1\uff0c\u901a\u5e38\u6703\u5148\u5617\u8a66\u4ee5\u85e5\u7269\u6cbb\u7642\uff0c\u6709\u76f8\u7576\u9ad8\u7684\u6a5f\u6703\u80fd\u9577\u671f\u6539\u5584\u75c5\u4eba\u4e4b\u75c7\u72c0\u3002\nD.\u91dd\u5c0d\u5716B\u4e4b\u75c5\u6cc1\uff0c\u96d6\u7136manometry\u4e4b\u7d50\u679c\u662f\u4e3b\u8981\u7684\u8a3a\u65b7\u4f9d\u64da \uff0c\u4f46\u4ecd\u9700\u4ee5\u5167\u8996\u93e1\u6aa2\u67e5\u6392\u9664\u5176\u5b83\u53ef\u80fd\u7522\u751f\n\u985e\u4f3c\u75c7\u72c0\u4e4b\u75be\u75c5 \u3002\nE.\u7f79\u60a3\u5716A\u4e4b\u75c5\u4eba\uff0c\u82e5\u672a\u52a0\u4ee5\u8655\u7406\uff0c\u8d85\u904e\u5341\u5e74\u4ee5\u4e0a\uff0c\u6709\u8f03\u9ad8\u6a5f\u7387\u6703\u7522\u751fsquamous cell carcinoma\u3002\n": "[C]", "111-42.Barrett's metaplasia \u662fgastroesophageal reflux disease\u7684\u4f75\u767c\u75c7\u4e4b\u4e00\uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u73fe\u5728\u5167\u8996\u93e1\u8a3a\u65b7\u53ca\u5f37\u800c\u6709\u6548\u4e4b\u6291\u5236\u80c3\u9178\u5206\u6ccc\u85e5\u7269\u7686\u6709\u5f88\u5927\u7684\u9032\u5c55 \uff0c\u56e0\u6b64 Barrett 's metaplasia\u4e4b\u767c\u751f\n\u7387\u9010\u6f38\u6e1b\u5c11 \u3002\nB.\u9157\u9152\u4e0d\u662fBarrett's metaplasia\u4e4b\u98a8\u96aa\u56e0\u5b50\u3002\nC.Long-segment Barrett's metaplasia \u662fesophageal adenocarcinoma \u4e4bprecursor lesion\u3002\nD.Barrett's metaplasia\u672a\u4f75\u6709dysplasia\u8005\uff0c\u7d04\u6bcf3-5\u5e74\u63a5\u53d7\u4e00\u6b21\u5167\u8996\u93e1\u6aa2\u67e5\u5373\u53ef\u3002\nE.Barrett's metaplasia\u4f75\u6709high-grade dysplasia\u8005\uff0c\u61c9\u63a5\u53d7endoscopic eradication therapy\u3002\n": "[A]", "111-43.\u95dc\u65bcpeptic ulcer disease (PUD) \u4e4b\u6cbb\u7642 \uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\u90a3\u4e9b\u932f\u8aa4 \uff1f\n(1) Refractory PUD\u63a5\u53d7\u8f03\u9ad8\u5291\u91cfproton pump inhibitors (PPIs) \u6cbb\u7642 8\u9031\u6709 90% \u4ee5\u4e0a\u6703\u7652\u5408\n(2) \u9577\u671f\u670d\u7528PPIs \u53ef\u80fd\u589e\u52a0 community -acquired pneumonia\u767c\u751f\u6a5f\u7387\n(3) \u65b0\u958b\u767c\u7684 K-competitive acid pump antagonist (P-CAPs) \u4e4b\u7642\u6548\u5c1a\u4e0d\u660e\u78ba\n(4) Gastric maltoma (MALT) lymphoma \u61c9\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\n(5) Helicobacter pylori (HP) \u5b58\u5728\u80c3\u4e2d\u4e4b\u5075\u6e2c\u65b9\u6cd5\u5305\u62ec \uff1astool antigen\u6aa2\u6e2c, urea breath test (UBT) \n\u53caserological testing\n(6) \u6b32\u8b49\u5be6 HP eradication therapy \u5df2\u6210\u529f \uff0c\u9700\u5728eradication therapy \u7d50\u675f 4\u9031\u5f8c\u70ba\u4e4b   \nA.(1) + (2) + (3)\u3002\nB.(2) + (4) + (5)\u3002\nC.(3) + (4) + (5)\u3002\nD.(4) + (5) + (6)\u3002\nE.(3) + (4) + (6)\u3002\n": "[C]", "111-44.\u5728\u53f0\u7063\uff0c\u5927\u8178\u76f4\u8178\u764c\u4e4b\u6bcf\u5e74\u767c\u751f\u4eba\u6578\u76ee\u524d\u9ad8\u5c45\u9996\u4f4d \uff0c\u5982\u4f55\u65e9\u671f\u767c\u73fe\u53ca\u9810\u9632\u5f88\u91cd\u8981 \uff0c\u4e0b\u5217\u5404\u9805\u76f8\u95dc\u6558\u8ff0 \uff0c\u4f55\n\u8005\u932f\u8aa4\uff1f   \nA.\u7cde\u4fbf\u6f5b\u8840\u6aa2\u6e2c\u8207\u5167\u8996\u93e1\u6aa2\u67e5\u5df2\u6210\u7be9\u6aa2\u4e4b\u4e3b\u8981\u5de5\u5177\u3002\nB.Air contrast\u92c7\u5291\u986f\u5f71\u53cavirtual colonoscopy\uff08\u96fb\u8166\u65b7\u5c64\uff09\u5df2\u5c11\u7528\u4e86\u3002\nC.\u7f8e\u570bMulti -Society Task Force\u91dd\u5c0d\u4e00\u822c\u98a8\u96aa\u6210\u5e74\u4eba \uff0c\u5efa\u8b7050\u6b72 (\u6700\u8fd1\u6539\u621045 \u6b72) \u4ee5\u4e0a\u4e4b\u5927\u8178\u76f4\u8178\u764c\u7be9\n\u6aa2\u65b9\u5f0f\u70ba\u6bcf\u5e74\u7cde\u4fbf\u6f5b\u8840\u6aa2\u6e2c+ \u6bcf\u4e94\u5e74\u4e00\u6b21flexible sigmoidoscopy\u6216\u6bcf\u5341\u5e74\u4e00\u6b21total colon \ncolonoscopy \u3002\nD.\u7f8e\u570bMulti -Society Task Force\u5c0d\u65bc\u521d\u6b21\u5927\u8178\u93e1\u6aa2\u67e5\u767c\u73fe\u6709\u4e0d\u542b\u60e1\u6027\u6210\u5206\u4e4bpolyp (s) \u4e14\u5df2\u4e88\u4ee5\u5b8c\u5168\u5207\u9664\n\u8005\u4e4b\u5f8c\u7e8c\u8ffd\u8e64 \uff0c\u9664\u4e86adenomas\u8d85\u904e10\u9846\u4ee5\u4e0a\u8005 \uff0c\u82e5\u5f8c\u7e8c\u7cde\u4fbf\u6f5b\u8840\u6aa2\u6e2c\u5448\u9670\u6027\u6642 \uff0c\u4e00\u822c\u5efa\u8b70 3\u5e74\u5f8c\u518d\n\u4ee5\u5927\u8178\u93e1\u8ffd\u8e64 \u3002\nE.Peutz-Jeghers syndrome\u60a3\u8005\u4e4b\u8178\u9053\u606f\u8089\u8f49\u70ba\u60e1\u6027\u4e4b\u6a5f\u7387\u6975\u9ad8\uff0c\u61c9\u5bc6\u96c6\u8ffd\u8e64\u7be9\u6aa2\u3002   \n": "[E]", "111-45.\u4e00\u4f4d70\u6b72\u7537\u6027\u75c5\u4eba\u4e3b\u8a34\u6700\u8fd1\u4e00\u5e74\u8001\u662f\u89ba\u5f97\u98ef\u5f8c\u6703\u6709\u5fc3\u7aa9\u8655\u75bc\u75db \uff0c\u8b93\u4ed6\u5c0d\u9032\u98df\u5fc3\u751f\u6050\u61fc \uff0c\u9ad4\u91cd\u5df2\u6e1b\u8f15\u4e86 6\u516c\n\u65a4\u3002\u5c31\u91ab\u6642\u8eab\u9ad4\u8a3a\u5bdf\u986f\u793a\u8f03\u6d88\u7626 \uff0c\u8179\u90e8\u6aa2\u67e5\u7121\u660e\u986f\u7570\u5e38 \u3002\u5b89\u6392\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\u4e26\u672a\u767c\u73fe\u6d88\u5316\u6027\u6f70\n\u760d\u3001\u80c3\u764c\u6216\u9006\u6d41\u6027\u98df\u9053\u708e \u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u672a\u767c\u73fe\u81bd\u7d50\u77f3 \u3002\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u4e5f\u78ba\u8a8d\u6c92\u6709\u80f0\u81df\u764c \u3002\u5fc3\u96fb\u5716\u986f\u793a\n\u6709\u5fc3\u623f\u632f\u986b \uff08atrial fibrillation\uff09\u3002 \u6709\u95dc\u9019\u4f4d\u75c5\u4eba\u4e4b\u6558\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u5176\u75c5\u60c5\u6709\u6642\u6703\u6709\u6025\u6027\u75c5\u6cc1\uff0c\u6b7b\u4ea1\u7387\u53ef\u80fd\u9ad8\u9054 50% \u4ee5\u4e0a\u3002\nB.Duplex ultrasound \u5728\u6025\u8a3a\u5ba4\u5e38\u88ab\u62ff\u4f86\u505a\u70ba\u9019\u7a2e\u75c5\u4eba\u4e4b\u521d\u6b65\u7be9\u6aa2\u5de5\u5177 \uff0c\u5176\u8a3a\u65b7\u4e4b\u654f\u611f\u5ea6\u53ca\u7279\u7570\u6027\u76f8\u7576\n\u4e0d\u932f\u3002\nC.Duplex ultrasound \u6aa2\u67e5\u8981\u5728\u98ef\u5f8c\u70ba\u4e4b\u6548\u679c\u6700\u4f73\u3002\nD.\u82e5\u8a3a\u65b7\u5df2\u5927\u81f4\u78ba\u7acb\uff0c\u9032\u4e00\u6b65\u8655\u7f6e\u524d\u52d9\u5fc5\u8981\u6709 CT angiogram\u3002\nE.\u5176\u8655\u7f6e\u5305\u62ec endovascular or open surgical revascularization\u3002\n": "[C]", "111-46.30\u6b72\u7537\u6027\u60a3\u8005\u6709\u591a\u5e74\u7684\u55c6\u54b3\u53ca\u541e\u56a5\u56f0\u96e3 \uff0c\u63a5\u53d7\u98df\u9053\u651d\u5f71\u53ca\u6aa2\u58d3\u8853 (manometry )\uff0c\u7d50\u679c\u5982\u5716 1\u3001\u57162\uff0c \u4e0b\u5217\u6558\n\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f(1)\u6b64\u75c5\u53ef\u4ee5\u9810\u9632 (2)\u8d77\u56e0\u70ba\u4e0b\u98df\u9053\u62ec\u7d04\u808c\u58d3\u529b\u592a\u4f4e (3)\u53ef\u4ee5\u7528nitrate \u6216calcium channel \nblocker\u6cbb\u7642 \uff0c\u4f46\u6548\u679c\u6709\u9650 (4)\u53ef\u4ee5\u7528\u5167\u8996\u93e1\u64f4\u5f35\u8853 (pneumatic dilation )\u6cbb\u7642\uff0c\u4f46\u4e0d\u540c\u4e2d\u5fc3\u6709\u6548\u7d50\u679c\u5831\u544a\n\u5f9e30~90% (5)per oral esophageal myotomy (POES)\u6548\u679c\u4e0d\u932f \uff0c\u4e14\u8f03\u50b3\u7d71\u5916\u79d1\u624b\u8853\u6062\u5fa9\u5feb   \nA.(1)+(2)\u3002\nB.(2)+(3)\u3002\nC.(3)+(4)\u3002\nD.(4)+(5)\u3002\nE.(1)+(5)\u3002\n": "[A]", "111-47.\u4e0b\u5217\u4e0d\u9069\u7528\u65bc\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(Helicobacter pylori)\u4e4b\u6551\u63f4\u6cbb\u7642(salvage therapy)\u7684\u8655\u65b9(regimen)?    \nA.bismuth quadruple regimen\u3002\nB.clarithromycin triple regimen\u3002\nC.concomitant regimen\u3002\nD.levofloxacin triple regimen\u3002\nE.rifabutin triple regimen\u3002\n": "[B]", "111-48.\u6709\u95dc\u81bd\u9178 (bile acid)\u548c\u8178\u809d\u5faa\u74b0 (enterohepatic circulation )\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba (1)\u81bd\u9178\u7531\u81bd\u56fa\u9187 (cholesterol )\u5728\n\u809d\u81df\u5408\u6210 \uff0c\u6bcf\u59295\u516c\u514b (2)\u5f9e\u809d\u81df\u5408\u6210\u7684\u521d\u7d1a (primary)\u81bd\u9178\u6709cholic acid \u548clithocholic acid (3)\u81bd\u9178\u5408\u6210\n\u75317\u03b1-hydrxylase\u81ea\u4e3b\u8abf\u63a7 (autoregulated) ( 4)\u6b21\u7d1a(secondary )\u81bd\u9178\u7684\u5f62\u6210\u9808\u8981\u5927\u8178\u5167\u7684\u7d30\u83cc\u5354\u52a9 (5)\u81bd\u9178\n\u900f\u904e\u9580\u975c\u8108\u56de\u5230\u809d\u81df \uff0c\u7136\u5f8c\u518d\u5ea6\u5206\u6ccc\u5230\u5c0f\u8178   \nA.(1)+(2)+(3)\u3002\nB.(2)+(3)+(4)\u3002\nC.(3)+(4)+(5)\u3002\nD.(1)+(3)+(5)\u3002\nE.(2)+(4)+(5)\u3002\n": "[C]", "111-49.25\u6b72\u7537\u6027\u56e0\u9577\u671f\u8840\u4fbf \u3001\u9ad4\u91cd\u6e1b\u8f15 \uff0c\u7d93\u91ab\u5e2b\u8a3a\u65b7\u70ba\u514b\u9686\u6c0f\u75c5 (Crohn\u2019s disease )\uff0c\u4e0b\u5217\u56db\u5f35\u92c7\u5291\u8178\u9053\u651d\u5f71\u7d50\n\u679c\uff0c\u4f55\u8005\u7279\u5fb5\u7b26\u5408\u6b64\u75c5 ?   \nA.\u5716A\u3002\nB.\u5716B\u3002\nC.\u5716C\u3002   \nD.\u5716D\u3002\nE.\u4ee5\u4e0a\u7686\u975e\u3002\n": "[D]", "111-50.\u4e00\u4f4d\u6025\u6027\u8179\u75db\u60a3\u8005\uff0c\u5728\u6025\u8a3a\u8655\u63a5\u53d7\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\uff0c\u7d50\u679c\u5982\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f    \nA.\u6b64\u75c5\u767c\u751f\u7387\u5448\u589e\u52a0\u8da8\u52e2\u3002\nB.\u8d85\u904e\u516b\u6210\u7684\u60a3\u8005\u53ef\u767c\u73fe\u7cde\u77f3(fecalith)\u3002\nC.\u4e00\u534a\u4ee5\u4e0a\u60a3\u8005\u8eab\u9ad4\u6aa2\u67e5\u51fa\u73fepsoas sign\u3002\nD.\u5e74\u8001\u60a3\u8005\u6613\u6709\u975e\u5178\u578b\u8868\u73fe\u3002\nE.\u6cbb\u7642\u4ee5\u5167\u79d1\u4fdd\u5b88\u6027\u65b9\u5f0f\u70ba\u4e3b\u3002\n": "[D]", "111-51.74\u6b72\u5973\u6027\u56e0\u76ae\u819a\u9ec3 \u3001\u8336\u8272\u5c3f\u548c\u7070\u767d\u4fbf\u5341\u5929\u81f3\u6025\u8a3a\u8655 \uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u9ec3\u75b8 \u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b \uff1aALP: \n175 U/L\uff0cALT: 57 U/L\uff0cAST: 49 U/L\uff0cBil(T/D): 6.0/4.6 mg/dL\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u6709\u5f8c\u8179\u8154\u7e96\u7dad\n\u5316(retroperitoneal fibrosis )\u53ca\u80f0\u81df\u816b\u5927\u5982\u9999\u8178\u72c0 (sausage-shaped)\u4f75\u80f0\u7ba1\u72f9\u7a84 \uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u4f75\u7d30\u91dd\u62bd\u53d6\u7d30\n\u80de\u5b78\u6aa2\u67e5\u5728\u9ad8\u500d\u4e0b\u767c\u73fe10\u500b\u4ee5\u4e0a\u7684IgG 4-positive\u7d30\u80de \uff0c\u4e14\u6c92\u6709\u60e1\u6027\u7d30\u80de \u3002\u4ee5\u4e0b\u4f55\u8005\u70ba\u6700\u9069\u7576\u6cbb\u7642 ?   \nA.azathioprine\u3002\nB.ERCP with biliary stent placement\u3002\nC.prednisolone\u3002\nD.methotrexate\u3002\nE.totoal pancreatectomy\u3002\n": "[C]", "111-52.45\u6b72\u5973\u6027\u56e0alkaline phosphatase (ALP)\u6301\u7e8c\u7570\u5e38\u8ffd\u8e64\u4e00\u6bb5\u6642\u9593 \uff0c\u75c7\u72c0\u53ea\u6709\u8f15\u5fae\u76ae\u7662 (pruritus)\uff0c\u4e26\u7121\u5bb6\u65cf\n\u53f2\u6216\u5176\u5b83\u7cfb\u7d71\u6027\u75be\u75c5 \uff0c\u8eab\u9ad4\u6aa2\u67e5\u6b63\u5e38 \uff0c\u8840\u6db2\u6aa2\u67e5\u5305\u62ecCBC \uff0cAST/ALT\uff0calbumin\uff0cbilirubin\u548ctotal \nprotein\u5747\u70ba\u6b63\u5e38 \uff0c\u53ea\u6709ALP 212 U/L\u4e0a\u5347\u3002\u4e0b\u5217\u4f55\u9805\u662f\u8a3a\u65b7\u7684\u6700\u9069\u7576\u6aa2\u67e5 ?   \nA.anti-smooth muscle antibody\u3002\nB.antinuclear antibody\u3002\nC.anti-mitochondria antibody\u3002\nD.serum IgG4\u3002\nE.liver biopsy\u3002\n": "[C]", "111-53.60\u6b72\u7537\u6027 \uff0c\u65bc\u9580\u8a3a\u8ffd\u8e64\u6642\u767c\u73feAST /ALT\u503c\u4e0a\u5347 \u3002\u672c\u8eab\u6709\u7cd6\u5c3f\u75c5 \u3001\u9ad8\u8840\u58d3\u53ca\u9ad8\u8840\u8102 \uff0c\u76ee\u524d\u670d\u7528metformin, \nhydrochlorothiazide, losartan \u548catorvastatin \u3002\u4ed6\u6709social drinking \uff0cBP: 143/80 mmHg \uff0cBMI: 37\uff0c\u8179\u90e8\u6aa2\n\u67e5\u6709\u809d\u816b\u5927\u4f46\u7121\u58d3\u75db\u6216\u89f8\u75db \uff0c\u4e5f\u7121\u813e\u816b\u5927 \u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5ALP: 180 U/L\uff0cAST: 42 U/L\uff0cALT: 64 \nU/L\uff0cCBC\u3001albumin\u548cbilirubin\u5747\u6b63\u5e38 \u3002\u8d85\u97f3\u6ce2\u6aa2\u67e5\u53ea\u6709\u81bd\u606f\u8089 \uff0c\u809d\u81df\u816b\u5927 \uff0c\u4e14echogenicity\u589e\u52a0 \uff0c\u4f46\u81bd\u7ba1\n\u6b63\u5e38\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6b64\u75c5\u60a3\u6700\u9069\u7576\u7684\u6cbb\u7642 ?   \nA.\u6212\u9152\u3002\nB.\u505c\u7528atorvastatin\u3002\nC.\u52a0\u7528pioglitazone\u3002\nD.\u6e1b\u91cd\u3002\nE.\u505c\u7528losartan\u3002\n": "[D]", "111-54.40\u6b72\u5973\u6027\u5728\u98ef\u5f8c30 \u81f360\u5206\u9418\u5f8c \uff0c\u6709\u4e0a\u8179\u75db \u3001\u8179\u8139\u3001\u5641\u5fc3\u548c\u8179\u7009 \uff0c\u5df2\u767c\u751f\u4e09\u500b\u6708 \uff0c\u6709\u6642\u5927\u9910\u5f8c\u5408\u4f75\u982d\n\u75db\u3001\u6d41\u6c57\u73fe\u8c61 \uff0c\u4e0a\u8ff0\u75c7\u72c0\u5728\u98ef\u5f8c30\u5206\u9418\u81f3 2\u5c0f\u6642\u6703\u7de9\u89e3 \u3002\u672c\u8eab\u70ba\u80a5\u80d6 \u3001\u9ad8\u8840\u58d3\u548c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u56db\u500b\n\u6708\u524d\u63a5\u53d7\u6e1b\u91cd\u624b\u8853sleeve gastrectomy \u3002\u80c3\u93e1\u6aa2\u67e5\u9664sleeve gastrectomy\u5916\u4e26\u7121\u7570\u5e38 \uff0c\u80c3\u5207\u7247\u7121\u5e7d\u9580\u87ba\u65cb\n\u687f\u83cc\uff0c\u5341\u4e8c\u6307\u8178\u5207\u7247\u53ca\u80c3\u6392\u7a7a\u6aa2\u67e5\u5747\u70ba\u6b63\u5e38 \u3002\u6b64\u4f4d\u60a3\u8005\u6700\u6070\u7576\u7684\u6cbb\u7642\u70ba ?   \nA.acarbose\u3002   \nB.metformin\u3002\nC.metoclopramide\u3002\nD.rifaximin\u3002\nE.\u5c11\u91cf\u591a\u9910\u3002\n": "[E]"}